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INTRODUCTION & OUTLINE 
Chapter 1 
LUNG CANCER 
Lung cancer is one of the leading causes of death in the world. It is the most frequent 
type of cancer among men and ranks third among women. Worldwide, more than 
500,000 new cases are diagnosed each year331 In 1994, in the southeastern part of 
the Netherlands the incidence was 70 per 100,000 person-years in men and 13 per 
100,000 person-years in women207 The prevalence was 219 per 100,000 In men and 
33 per 100,000 in women.84 The major risk factor of lung cancer is smoking. 126 The 
prognosis of patients with locally advanced (stage III) or metastatic (stage IV) non-
small-cell lung cancer remains poor despite the continuing exploration of new 
cytotoxic drugs. The 1- and 5-year survival rates in these patients are 25 to 40%, and 
less than 5%, respectively.153 The high morbidity and mortality are not only due to 
progressive tumor growth but also to the high frequency of the cachexia syndrome in 
this patient population. 94,116,204,440 
CACHEXIA 
Cancer-associated cachexia is characterized by involuntary weight loss, fatigue, 
impaired physical performance, and general malaise. The word cachexia is derived 
from the Greek words kakos and ilexis meaning 'bad condition'. Cachexia is 
associated with extensive wasting of energy stores of fat, skeletal muscle and liver 
tissues;374 with elevated lipolysis,128,391 proteolysis,266,306 and gluconeo-
genesis. 103,267,389 In newly diagnosed non-small-cell lung cancer patients 
approximately 35 % had more then 5 % weight loss, and this was associated with 
decreased mean survival. 116 
Dietary counseling,76,317 use of enteral supplements76 and administration of 
parenteral nutrition282 have failed to reverse cachexia. Corticosteroids56,1l4,336 and 
the anti-seritonergic drug cyproheptadine2t5 induced an increase in appetite without 
positive effects on body weight, The phosphoenolpyruvate-carboxykinase inhibitor 
hydrazine sulfate had no effect on appetite or body weight. 215,259 Anabolic steroids 
also failed to influence weight in non-small-cell lung cancer patients75 Progestagens 
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induced an increase in appetite,55,137 reduction of weight loss137 or weight gain. 396 
However, this was attributed mainly to fat gain.261 ,396 
ADENOSINE 5'-TRIPHOSPHATE 
Adenosine 5'-triphosphate (ATP) is a purine nucleotide found in every cell of the 
human body. In addition to its welt-established intracellular energy-transferring role, 
ATP is involved extracellularly in biological processes including neurotransmission, 
muscle contraction, cardiac function, platelet function, vasodilatation, and liver 
glycogen metabolism. Extracellular ATP has been known to exert its effects through 
P2 receptors on the surface of many cells. In recent years several clinical applications 
of ATP have been reported. [ntravenously administered ATP has been found to have 
potential in cardiOlogy, anesthesia, pulmonology, and also oncology. In oncology, 
preclinical studies showed that administration of ATP induced growth inhibition of 
various human tumor celt lines3)6.92,135,149,224,343,344,405,443 and aninlal-implanted 
tumors. 134,161,239,301,309,327,344,345,347,348 Furthermore, intraperitoneal ATP 
administration resulted in inhibition of weight loss348 and significantly prolonged 
survival in these animals. 134,239,309 
Recently, in the United States in a small uncontrolled phase II study 15 patients 
with advanced non-small-cell lung cancer were treated with one to seven intravenous 
ATP infusions of 96 hours at 4-week intervals. After treatment a mean maintenance 
of weight, quality of life, and performance status togedler with inhibition of tumor 
growth in 10 out of 15 patients was shown. 187 These results supported earlier 
findings from a phase I study in eight patients with lung cancer. 188 
AIMS OF THE THESIS 
Based on these promising preliminary reports, the aim of the present project was to 
assess the effects of intravenous ATP infusions on weight loss, body composition, 
performance score, quality of life, tumor response, and survival in patients Witll 
advanced non-smalt-cell lung cancer (stage lIIB or IV). In addition, we performed 
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supportive studies in order to examine underlying mechanisms contributing to clinical 
effects of ATP. 
OUTLINE OF THE THESIS 
In Chapter 2, established and potential applications of ATP in clinical practice are 
reviewed. 
In Chapter 3, the clinical effects of intravenous ATP infusions in advanced lung 
cancer patients are reported, including quality of life, muscle strength and body 
weight (3.1), body composition and nutritional status (3.2), and tumor response and 
survival (3.3). In addition, we report a pilot study exploring the potential value of 
intravenous adenosine infusion in the pain treatment of advanced cancer patients 
(3.4). 
In Chapter 4, five satellite studies are reported. These studies involve the 
pharmacokinetics of ATP infusion (4.1), effects of ATP on liver energy status (4.2), 
effects of ATP on glucose turnover and gluconeogenesis (4.3), and a cell line study 
on ATP-induced growth inhibition of human lung tumor cells (4.4). Finally, the 
validity of skinfold anthropometry for measuring longitudinal changes in body 
composition in patients with advanced lung cancer is assessed using the deuterium 
dilution technique as a reference (4.5). 
A general discussion and conclusions are presented in Chapter 5. 
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REVIEW 
ADENOSINE TRIPHOSPHATE: ESTABLISHED 
AND POTENTIAL CLINICAL APPLICATIONS 
Drugs 1999; 58 (2): 211-232 
Hendrik J. Agteresch,' Pieter C. Dagnelie, '.2 J .Willem O. van den Berg,' 
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Chapter 2 
ABSTRACT 
Adenosine 5' -triphosphate (ATP) is a purine nucleotide found in every cell of the 
human body. In addition to its well-established role in cellular metabolism, 
extracellular ATP and its breakdown product adenosine, exert pronounced effects in a 
variety of biological processes including neurotransmission, muscle contraction, 
cardiac function, platelet function, vasodilatation, and liver glycogen metabolism. 
These effects are mediated by both PI and P2 receptors. A cascade of 
ectonucleotidases plays a role in the effective regUlation of these processes and may 
also have a protective function by keeping extracellular A TP and adenosine levels 
within physiological limits. In recent years several clinical applications of ATP and 
adenosine have been reported. In anesthesia, low-dose adenosine reduced neuropathic 
pain, hyperalgesia, and ischemic pain to a similar degree as morphine or ketamine. 
Postoperative opioid use was reduced. During surgery, ATP and adenosine have been 
used to induce hypotension. In patients with hemorrhagic shock, increased survival 
was observed after ATP treatment. In cardiology, ATP has been shown to be a well-
tolerated and effective pulmonary vasodilator in patients with pulmonary 
hypertension. Bolus injections of ATP and adenosine are useful in the diagnosis and 
treatment of paroxysmal supraventricular tachycardias. Adenosine also allowed 
highly accurate diagnosis of coronary artery disease. In pulmonology, nucleotides in 
combination with a sodium-chamlel blocker improved mucociliary clearance from the 
airways to near normal in patients with cystic fibrosis. In oncology, there are 
indications that ATP may inhibit weight loss and tumor growth in patients with 
advanced lung cancer. There are also indications of potentiating effects of cytostatics 
and protective effects against radiation tissue damage. Further controlled clinical 
trials are warranted to determine the full beneficial potential of ATP, adenosine and 
uridine 5' -triphosphate. 
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INTR,ODUCTION 
Adenosine 5'-triphosphate (ATP) is a naturally occurring nucleotide which is present in 
every cell. It consists of a purine base (adenine), ribose, and three phosphate groups. 
Nucleotides were first recognized as important substrate molecules in metabolic 
interconversions, and later as the building blocks of DNA and RNA. More recently, 
it was found that nucleotides are also present in the extracellular fluid under physio-
logic circumstances. 152 Extracellular ATP is broken down by a cascade of 
ectoenzymes and xanthine oxidase to form uric acid, which is excreted in urine 
(Figure 2.1). 
I AdenosIne triphosphate I 
Ec/o-ATPase , 
I AdenosIne d~hosphate I 
Ecto-ADPase 
, AdenosIne monophosphate., 
Eclo-5'-nucleo tidase 
Adenosine deaminase 
{ AdenosIne InosIne I 
Purine nucleoside phosphorylase 
Adenine deamlnase Xanthine oxidase 
, AdenIne HypoxanthIne XanthIne I 
Xan thine oxidase 
IUdc acid I 
Figure 2.1. Pathway of adenosine 5'-triphosphate (ATP) breakdown to uric acid 
Extracellular ATP appears to be involved in the regulation of a variety of biological 
processes including neurotransnllssion, muscle contraction, cardiac function, platelet 
function, vasodilatation, and liver glycogen metabolism. ATP can be released from the 
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cytoplasm of several cell types and interacts with specific purinergic receptors on the 
surface of many cells. These receptors playa fundamental role in cell physiology, and 
are divided in two major classes: PI and P2 receptors. In general, the effects of 
adenosine are UlOught to be mediated through PI receptors, whereas ATP binds to P2 
receptors. PI receptors are subdivided into AI, AlA, AlB and A3 receptors 155 which 
activate phopholipase C (AI, AlD, A3) and adenylate cyclase (AlA, A'B), and modulate 
ion channels (AI, AlB, A3)J38 P2 receptors are subclassified in G-protein-coupled 
receptors termed P2Y receptors and intrinsic ion channels termed P2X receptors. t ,t55 
StinlUlation of the various receptors evokes diverse biological responses and has been 
reviewed by Dubyak and el-Moatassinl130 and Conigrave and Jiang,89 
In recent years the possible pharmacological uses of A TP have received attention, 
following reports of its potential benefit in pain, vascular diseases and cancer (Table 
2,1), In this review, current and potential clinical applications, and proposed mecha-
nisms of action of extracellular ATP and its breakdown product adenosine (Figure 
2,2), are discussed together with their pharmacokinetic properties and adverse 
effects, 
2.1 PlIARMACOKlNETIC PROPERTms 
Physiological levels 
The average physiological concentration of ATP within mammalian cells is 
3152±1698 (SD) flM. The ATP content in tissue cells is somewhat higher than in 
blood cells 432 In human erythrocytes ATP concentrations of 1500 to 1900 ftM are 
detected. 112,429,463 Only three authors have reported ATP concentrations in human 
plasma. Forrester and Lind152 described concentrations of 1.2±0,5 ]lM, while 
Harkness et al. 185 measured 3.9±1.5 flM ATP, and Ryan et al.364 reported a range 
of 0.15 to 0,65 ]lM ATP, These concentrations are in the same order of magnitude as 
the physiological concentrations of adenosine in plasma, that is 0.1 to 1 ftM3t4 
Cellular uptake and transport 
Using suspensions of washed intact human erythrocytes and labeled purines, Parker et 
a!. 329 found that ATP is metabolized outside the cell via adenosine diphosphate (ADP) 
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and adenosine monophosphate (AMP) to adenosine. Adenosine rapidly entered the 
erythrocytes where it was incorporated in adenine nucleotides. At extracellular 
adenosine concentrations below 3 flM, most intracellular adenosine was phosphorylated 
to adenine nucleotides. At higher extracellular adenosine concentrations, adenosine was 
degraded in the erythrocytes to inosine and hypoxanthine. 375 Intravenous administration 
of ATP is followed by rapid uptake by erythrocytes 431 In a study using patients with 
cancer infusion of ATP 50 fIg/kg. min induced a 63% increase in whole blood ATP 
levels; a higher rate of ATP infusion of 75 flg/kg.min gave only a slightly greater 
increase (67%).188 
After intraperitoneal bolus injection of adenine nucleotides in mice,348 an increase 
in erythrocyte ATP concentrations (from 600 to 1700 flM) was preceded by an increase 
in liver ATP (from 3000 to 7000 fIM). The intraperitoneal mode of administration of 
adenine nucleotides seems to favor uptake by the liver, presumably because they enter 
tile portal circulation.348 Lerner and Lowy250 showed that rabbit liver perfused with 
['Hladenine released ['Hladenosine. They suggested that adenosine may be released 
from liver cells into the interstitial fluid and then the hepatic sinusoids, where it would 
be rapidly taken up by the circulating erythrocytes and incorporated into adenine 
nucleotides. Within seconds after intraperitoneal administration of unlabelled ATP and 
['H]adenosine, [3H]ATP was found in plasma. 347 Rapaport344.345 suggested that 
following rapid degradation of administered ATP, ATP is resynthesized in the liver, 
and then taken up by erythrocytes from which it is subsequently slowly released into 
plasma resulting in micromolar plasma levels of ATP. 
Metabolism 
Degradation of ATP in whole blood ill vitro is considerably slower than under ill vivo 
conditions. 111 vitro, five minutes after incubation of rabbit whole blood with ATP at 
37'C, 93.2% of the ATP remained. 388 In contrast, in rabbits 40 seconds after an 
intravenous bolus injection of ATP only 1 % of injected ATP was detected in whole 
blood. 388 SimiL1rly, a bolus of ATP is almost completely cleared during a single 
passage through either perfused dog lung35 or perfused guinea-pig heart. 323 Ryan and 
Smith363 showed a half-life of ATP of less than 0.2 seconds in perfused rat lung. At 
physiological concentratiollS, the half-life of ['H]adenosine in human plasma ill vivo is 
0.6 to 1.5 seconds.294 
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Table 2.1. Effects of adenosine 5'-triphosphate (ATP) and adenosine with potential or 
demonstrated clinical implications 
Topic Cells/Organs Animals Patients 
Anesthesia and analgesia 
blood pressure during surgery reduced 
anesthetic requirement reduced reduced 
opioid requirement after surgery reduced 
pain reduced reduced 
Pulmonary hypertension reduced reduced 
Supraventricular tachycardias inhibited 
SA + AV node conduction inhibited inhibited 
Mechanism wide QRS complex diagn. assessment 
Coronary artery disease diagn. assessment 
Shock 
organ function improved improved 
survival rate increased increased 
Airway mucosa function 
surfactant secretion increased 
chloride secretion~ increased increased 
ciliary beat frequency increased 
mucus secretion increased 
water secretion increased 
mucociliary clearancet increased 
Metabolism 
gluconeogenesis reduced/increased 
glycogenolysis increased 
Cancer treatment 
weight loss inhibited inhibited 
tumor growth inhibited inhibited inhibited 
chemotherapy efficacy increased increased 
radiotherapy damage reduced reduced 
radiotherapy efficacy increased Increased 
radiotherapy survival rate increased 
"'Observed in epithelia of healUIY patients and cystic fibrosis patients 
t Epithelia of cystic fibrosis patients 
AV = atrioventricular; SA = sinoatrial 
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A cascade of ectonucleotidases on the endothelial cells is thought to be responsible 
for the hydrolysis of ATP in blood ill vivo. 178 ,333,363,365 There are three types of 
ectonucleotidases: ecto-ATPases, ecto-ADPases and ecto-5'-nucleotidases. 431 These 
enzymes have also been detected on a variety of other cell types including 
erythrocytes,431 leukocytes,83 B-lymphocytes,18 both helper and cytotoxic T-lympho-
cytes,143 and hepatocytes.376 The ectonucleotidase system could be of importance in the 
regulation of neurotransmission, blood-platelet function and vasodilatation. 333 It has 
also been suggested that ectonucleotidases on the surface of cell membranes may have a 
protective function by keeping extracellular ATP and adenosine levels within 
physiological limits .431 
N5=N: N 
II ') OH OH OH 
""'" N I I I 
o II II II 
000 
N Q-P-O-P-O-P-OH 
OH OH 
Figure 2.2. Structural formulae of adenosine 5'-triphosphate (ATP) and adenosine 
2.2 PHYSIOLOGICAL EFFECTS AND MECHANISMS OF ACTION 
Nervous system 
ATP acts as neurotransmitter in both the central and peripheral nervous system and can 
also modulate the release of other neurotransmitters. 177 There is evidence that ATP 
plays a role as sensory neurotransmitter and adenosine as neuromodulator when both 
are released from non-nociceptive large diameter prinJary afferent neurons and cap-
saicin-sensitive small diameter primary afferent nerve terminals in the dorsal horn, and 
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that adenosine in particular inhibits pain transmission. 371 ,372 It also seems likely tllat the 
effects of ATP on pain are dependent on ATP being broken down to adenosine.367,371 
The antinociceptive effects are mediated through activation of Al and A1. 
receptors.371 ,372 These receptors are localized in the substantia gelatinosa of the spinal 
dorsal horn.77,78,170 Based on the observation that the adenosine blockers theophylline 
and caffeine also partly inhibit the analgesic effects of morphine, it has been suggested 
that adenosine may be one of the intermediary substances involved in morphine-induced 
spinal antinociception371 
Respit-atol'Y system 
Several cell types in both the upper and lower respiratory system respond to ATP and 
also to uddine 5' -triphosphate (UTP). In type II alveolar epithelial cells of newborn 
rats, A TP and UTP stimulate P2Y receptor-coupled surfactant secretion. 173,354 In 
airway epithelia of healthy individuals and patients with cystic fibrosis (CF), ATP and 
UTP stimulate transepithelial chloride secretion. Chloride is secreted through the cystic 
fibrosis transmembrane regulator (CFTR)81,82,412 as well as the non_CFTR. 60,350,353 In 
this way, in nasal epithelial cells from CF patients, Knowles et aI. 226 observed an 
increase in transepithelial potential difference. The magnitude of potential difference 
~orrelates with the rate of chloride secretion and sodium absorption. Several studies 
have demonstrated that the effects of ATP and UTP on chloride transport are mediated 
by a separate class of P2 receptors,226,279 named P2Y, receptors.88,269,332 Stimulation 
of these receptors activates inositol phospholipid hydrolysis and calcium mobiliza-
tion.279 
A TP export from the mucosal cell has also been related to the CFTR gene product. 
It has been suggested that the CFTR functions directly as an ATP_channel,2,3,60 but this 
finding was recently rejected: Reddy and Quinton350 and Reddy et al 351 demonstrated 
thatthe CFTR is a regulator of an associated ATP channel. 
ImIllune system 
Lymphokine-activated killer (LAK) cells and cytotoxic T lymphocytes (CTLs) are 
subtypes of effector lymphocytes which play an important role in immune defense 
against tumor cells and virus-infected cells. The mechanism by which LAK cells and 
CTLs lyse their target cells is a subject of intense interest. Since the early 1990s, ATP 
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has been proposed as a possible mediator of cytotoxic cell-dependent lysis. ATP could 
either be secreted via exocytosis, or directly released from the cytoplasm of LAK cells 
and CTLs by a yet unknown process. 119 Zanovello et a\.474 observed an ATP-induced 
calcium influx in classical natural killer target cells (YAC-I), and DNA-fragmentation 
in P815 target cells. Both EL-4 lymphoma cells and multidmg resistant human colon 
carcinoma cells (LoYo-Dx) were sensitive to ATP, as well as to CTLs and LAK 
cells. 15.92,93 Filippini et a\. 143,144 suggested that the lytic effects of ATP on CTL target 
cells may be the result of ATP on purinergic receptor or ectoprotein kinase stimulation. 
CTLs and LAK cells, as putative sources of ATP, have been shown to be resistant to 
the lytic effects of ATP,92,1l7,142,474 possibly because of the absence of purinergic 
receptors92 and a high expression of ecto-ATPases.92,142 These ecto-ATPases would 
effectively elintinate self-generated ATP from the LAK cell membrane. tl7 
Blood vessels 
Both PI and Pl receptors are present in blood vessel walls. Two subtypes of the P2 
receptor have been described: P2X and P2Y receptors.58,200 P2X receptors are located 
on vascular smooUl muscle cells, and mediate vasoconstriction. P2Y and PI receptors 
are located on endothelial cells, and mediate a vasodilator response,39,217 and this 
vasodilatation is probably responsible for a variety of the physiological effects of ATP. 
When given intravenously, low-dose ATP and adenosine have mainly pulmonary 
rather than systemic effects, because they are rapidly metabolized during their passage 
through the lung.436 In the pulmonary circulation, the predominant types of purinergic 
receptors are the P2Y and PI receptors.40,254 ATP binds to the PlY receptor on the 
pUlmonary endothel~al cell and stimulates the formation of nitric oxide (NO). NO 
increases the concentration of the intracellular messenger involved in smooUl muscle 
relaxation, cyclic guanosine monophosphate (cGMP).147.203 Adenosine binds to the PI 
receptor on pulmonary endothelial cells, increasing endothelial-cell adenylate cyclase 
activity and cellular cyclic AMP (cAMP) level and causing vascular smooth muscle 
relaxation. 147,177 
Heart 
In the sinoatrial (SA) and atrioventricular (A Y) nodal cells, extracellular ATP and ade-
nosine stimulate the release of potassium which induces an electric current and results 
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in pepression of the sinoatrial node as well as slowing down the A V node 
conductionn ,23,1l1,157,475 ATP is thought to induce the effects after degradation to 
adenosine,83 Their electrophysiological effects are mediated by activation of extracellu-
lar Al receptors which are coupled with guanosine triphosphate-binding inhibitory pro-
teins, Dipyridamole, an inhibitor of adenosine transport across cell membranes, 
potentiates these effects, while methylxanthines, such as tlleophylline and caffeine 
antagonize the activities of the adenosine receptors, Stimulation of the Al receptor influ-
ences both the potassium channels and cAMP production,233 
Some authors have postulated that the nodal effects of ATP are modulated by 
atropine, suggesting that these effects may partly be mediated through muscarine recep-
tors of the vagal nerve,298,458 Recently, Tai et al,424 demonstrated that during use of 
atropine, patients required a higher dose of adenosine to terminate tachycardia, 
However, in other studies atropine did not influence the cardiac effects of ATP and 
adenosine, 123,136 
Liver 
Extracellular ATP induces phosphatidylinositol hydrolysis and CaH -mobilization and 
influJ( in isolated hepatocytes.48 ,64,311 This has been ascribed to stinlUlation of P2 
receptors. 62,64,124,311 Koike et al. 229 showed that the rise in intracellular calcium plays 
an important role in triggering gluconeogenesis. Depending on the concentration, 
extracellular ATP can either stimulate or inhibit gluconeogenesis in isolated hepato-
cytes. Maximal stimulation of gluconeogenesis was shown at 40 flM366 and 100 flM 
ATP. 62,133,229 Maximal inhibition was shown at 1000 flM ATP13 and 500 flM adeno-
sine.264 
The increase in hepatocyte calcium concentrations is also associated Witil increased 
glycogenolysis.64,97,218,219 Studies in perfused rat livers have been confirmed tile 
stimulating effects of ATP on glycogenolysis.59 
TUlllor 
ATP has cytostatic and cytotoxic effects in many types of transformed and tumor cells. 
Several mechanisms have been proposed: 
1. Exposure of human adenocarcinoma cells to extracellular ATP has been 
reported to cause intracellular accumulation of ATP and arrest of tumor cells in the S-
22 
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phase of cell replication, followed by cell death343 A similar ATP-induced growth 
inhibition, caused by prolonging of the S-phase, is found in rat ureter carcinoma 
cells357 and in human breast cancer cells.405 Weisman et al. 461 showed that extracel-
lular ATP was hydrolyzed to extracellular adenosine which was transported into the 
cells by adenosine translocators. 
2. Intracellular adenosine induced growth inhibition by elevating intracellular 
ATP and ADP and reducing intracellular UTP levels. These changes induced inhibition 
of pyrinlidine nucleotide biosynthesis. Based on this, it was suggested that the inhibition 
of tumor growth after exposure to extracellular ATP is caused by an adenosine-
dependent pyrimidine starvation effect. 134,239,461 
3. ATP-induced tumor growth inhibition is associated with lower rates of protein 
synthesis and lower y-glutamylcysteine synthase activity 239 The latter leads to a 
decrease in glutathione content of the tumor, but not of normaltissues. 134,239,309 
4. Protein phosphorylation catalyzed by a number of cell surface protein kinases 
is known to occupy a key role in transmembrane signal transduction. Friedberg and 
Kuebler 159 and Friedberg et al. t58 showed a positive correlation between the activity 
of ectoprotein kinase and the ability of ATP to induce cell growth inhibition. 
Removal of this enzyme prevented the ATP-induced growth inhibition. A growth 
inhibitor, a protein witl! an apparent molecular mass of 13 kDa, is produced on 
exposure to extracellular ATP. Transformed cells have a higher activity of 
ectoprotein kinase compared with nontransformed cells. 158, 159 
5. After ATP administration, increased membrane permeability has been 
demonstrated in various transformed cells, including fibroblasts,120,159.193,224,361 
ovary cells,223 melanoma cells,224,299 neuroblastoma cells,1I8 hepatoma cells,2l he-
patocytes,300,478 erythroleukemia cells ,63 mastocytoma cells, 143 lymphoma 
cells, 117, 119,474,476 and leukemic lymphocytes.465-467 In contrast, this increase in 
permeability was not observed in untransformed cells. 159,222,224,299,361,466 Although 
in these studie's no systematic search for receptors was undertaken, the evidence 
suggests that increased cell permeability after exposure to extracellular ATP may be 
due to activation of P2X, (formerly P2Z) ~eceptors.154,413 These receptors are llighly 
selective for the tetrabasic ATP" form 404 The tumor cell types that express these 
receptors on their cell surfaces include various leukemia cells36,52,378,404 and 
neuroblastoma cells. 214 Activation of the P2X, receptors causes Opelllng of ion channels 
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which leads to an increase of intracellular Ca2+, loss of K+, entry of Na + and a decre-
ase in the membrane potential. Activation of P2X, receptors also results in formation of 
nonselective pores, which induces an increase in nonselective membrane permeability 
for aqueous solutes that ordinarily do not cross the cell membrane, including nucleoti-
des and small hydrophylic molecules of MW up to 900 Da.73 In transformed 3T6 
mouse fibroblasts, Saribas et al. 369 found that ATP increases the permeability to 
molecules as large as 20 kDa. Opening of tIlese ATP-sensitive channels or ATP-
induced pores will lead to cell death either by cell swelling, which is characteristic for 
necrosis,73.193 or DNA fragmentation, which is characteristic for apoptosis.474.476 
Beyer and Steinberg32 showed that pore formation in macrophages is the result of 
damage to the gap junction protein connexin-43. Loewenstein255 confirmed these 
results and reported that connexin-43 is more exposed in neoplastic cells than in 
normal cells. Neoplastic cells are known to be deficient in intercellular communica-
tion and therefore have gap junction proteins which are exposed to the extracellular 
enviromnent. 32,255 It has been suggested that connexin-43 may has a function as a 
'suicide receptor' .255 However, Alves et a1.9 recently were unable to show an effect 
of extracellular ATP on cOImexin-43 hemigap-junction channels, thus contradicting 
the findings of Beyer and Steinberg. 32 
Tissne protection 
Under conditions of metabolic stress, such as ischemia, a rapid and massive depletion 
of intracellular ATP occurs. As a consequence of ATP breakdown, adenosine, inosine 
and hypoxanthine accumulate in the ischemic tissue.302 ,477 Bouma et al 43 proposed tIlat 
adenosine may exert protective effects during the reperfusion period by binding to A2 
and A3 receptors. In this context, Newby et a1.303 introduced the term 'retaliatory 
metabolite' and Bouma et a1. 46 described adenosine as part of a 'natural defense 
system'. The protective action of adenosine or ATP can be explained by cardiovascular, 
metabolic and anti-inflammatory activities, as studied under ill vitro, in vivo and clinical 
conditions. 
The cardiovascular effects of ATP seem important in improving flow after 
ischemia. In animal models of shock, intravenous ATP-MgCh enhances the rel1al454 
and hepatic microcirculation,11,195.196 portal and total hepatic blood f1ow,452 and 
cardiac output 451 
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ATP-induced metabolic effects, including improved mitochondrial function and 
electrolyte transport, increased intracellular ATP,68,69,310 reduced 0, consumption,470 
enhancement of P2 receptor binding capacity,276 and normalization of impaired second 
messengers cAMP and inositoll,4,5-triphosphate (IpJ)275 
The inhibitory effects of adenosine extends to different processes related to 
inflammation: 
• inhibition of effectors neutrophil superoxide production, neutrophil 
degranulation,43 and anti-oxidants activation;273,340 
• inhibition of mediators - tumor necrosis facot (TNF), interleukin (IL)_6,44,453 
IL-8 44,45 eicosanoids232 and complement·238 , , 
• inhibition adhesion of neutrophils,98 inhibition of adhesion molecule expression.45 
Furthermore, Cronstein et al.99 demonstrated that the antiphlogistic action of the 
potent anti-inflammatory agent methotrexate is caused by increased adenosine release at 
inflamed sites. The increase in extracellular adenosine diminishes both the accumulation 
and function of leukocytes in inflamed sites. 
2.3 CLINICAL APPLICATIONS 
2.3.1 ANESTHESIA 
Pain Reduction 
During the last decade, studies in both animal models and patients have shown that 
ATP and particularly adenosine at low doses may modulate pain. Intravenous ATP in 
mice was found to have a dose-dependent analgesic activity on hot plate and 
phenylquinone-induced stretching assays.175.371.372 In dogs, when adenosine was used 
in combination with halothane, halothane requirement was reduced by 49%.385 
Several double-blind, placebo-controlled, cross-over studies in healthy volunteers 
showed pain-reducing effects of intravenous adenosine infusion 50-70 flg/kg.min. 
Segerdahl et al. 380 observed a reduction in size of the tactile allodynic area by approxi-
mately 50%. They also reported ischemic pain-reducing effects of intravenous adeno-
sine (70 flg/kg.min during 30 min) comparable with morphine (20 j.1g/kg.min during 5 
25 
Chapter 2 
min) or ketamine (20 flg/kg.min during 5 min). Furthermore, adenosine given in 
combination with morphine or ketamine had an additive effect on pain reduction.381 
In two randomized double-blind studies in patients undergoing breast surgery (75 
patients)379 and gynecological abdominal surgery (43 patienls),382 a systemic 
intravenous adenosine infusion (80 fIg/kg. min) significantly reduced perioperative 
isofluorane requirements and postoperative pain. In addition, in both studies the need 
for opioids was reduced by approximately 25% in the adenosine group during the first 
24 postoperative hours 379,382 
Several reports have provided evidence that low dosages of adenosine (50 
flg/kg.min) alleviate neuropathic pain, hyperalgesia and allodynia without inducing 
other pain symptoms.24,400 Intravenous adenosine infusion for 45 to 60 minutes led to 
improvement of spontaneous or evoked pain in six out of seven patients with peripheral 
neuropathic pain, which lasted from six hours to four days,24 This positive fmding was 
unexpected since it is known that adenosine is rapidly eliminated from the blood. It was 
speculated that the effects of adenosine on central hyperexcitability persist longer than 
the direct action of adenosine on the receptors.4OO 
Shock 
A COlrtnlon feature of shock is an inadequate circulation with diminished perfusion of 
tissues, resulting in hypoxia and injury to various tissues. The rescuscitation period 
after shock is also associated with development of tissue injury and loss of organ 
function,46 
Several ill vivo animal studies show that following hemorrhagic shock, infusion of 
ATP-MgCh has a positive effect on the surviva1,65,66,68,79,145,195,196,310,473 Various 
studies indicate that ATP and adenosine have protective effects on tissue injury 
following reperfusion after a preceding period of ischemia, ATP-MgCh improves rat 
. kidney,70,315 rat liver,67,70 dog heart,231,283 rabbit lung209 and rat gut function398 after 
a period of ischemia, The use of intramuscular ATP-MgCh is also protective in rats 
with burns,473 
In patients with acute renal failure or multiple organ failure, beneficial effects of 
ATP-MgCh were observed in a single study. Thirty-two patients were randomly 
divided into two groups. One received intravenous ATP-MgCh (40-50 flM/kg) and the 
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other served as a control. The survival rate was 100% in the ATP group and 73.3% in 
the control group. 197 
Control of blood pressure 
ATP and adenosine have been used to cause hypotension during anesthesia and surgery 
in patients. Already in 1951, Davies et a1. 106 showed in patients that an intravenous or 
intra-arterial injection of 40 mg ATP induced a moderate fall in blood pressure without 
change ill heart rate. Controlled hypotension may be employed to reduce intraoperative 
haemorrhage. The hemodynamic effects of ATP and adenosine have been investigated 
in over 150 patients undergoing oral,163 orthopedic,86 abdominal aortic aneu-
rysm,319.321 cerebral aneurysm235,318.320,402 and unspecified surgery. 162. 164 
Intravenous ATP or adenosine infusion (50 to 350 fIg/kg. min) induced significant 
reductions in blood pressure (20 to 43 %) with a major decrease in systemic vascular 
resistance (36 to 67%) and increase in cardiac output (14 to 42%), and only a small 
increase· in heart rate (3 to 16%). The hemodynamic parameters returned to tl\eir 
baseline values immediately after stopping the infusion.162.164 Tachyphylaxis and re-
bound-hypertension were not observed.87,t62,164,318-320.402 In contrast, Segerdahl et 
a1.379,383 showed no change in blood pressure during treatment with 80 fig/kg. min 
adenosine in patients with abdominal, breast and shoulder surgery. The reason for this 
discrepancy is not clear. 
ATP and adenosine (150 to 300 flg/kg.min intravenously) have been used 
successfully during surgery for pheochromocytoma to reduce systelnic blood 
pressure. 14,i4,181 ATP has been used to antagonize the vasoconstrictive activities of 
noradrenaline (norepinephrine) and/or' sympatlletic nerve stirnulation. 14 Low-dose 
adenosine hlfusion (30 to 50 fig/kg. min) in patients undergoing bypass surgery evoked 
coronary vasodilatation with only mirlor effects on the systemic circulation, and, 
tllerefore, may possibly be useful in the prevention of early occlusion of coronary 
artery bypass grafis.430 
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2.3.2 CARDIOLOGY 
Pulmonary hypertension 
Pulmonary hypertension can be a serious problem after thoracic surgery in patients witil 
chronic obstructive pulmonary disease (COPD), and in children with congenital heart 
defects. Vasodilators have often heen unsllccessful, because they act simultaneously on 
pulmonary and systemic vessels with predominant systemic effects.362 However, low-
dose intravenous ATP or adenosine has been shown to exert predominant pulmonary 
vasodilating effects. 165, 168 
llnewborn lamb models, intravenous administration of ATP was effective against 
pulmonary hypertension.146.230.325 Several studies showed a predominant decrease in 
pulmonary arterial pressure during intravenous infusion of about 100 J.lg/kg.min ATP, 
while systemic arterial pressure and vascular resistance decreased at higher 
levels. 146.168.213,326 
Studies in healthy individuals,352.436 patients with COPD,166-t68 and children with 
pulmonary hypertension,53 showed significant decreases in mean pulmonalY arterial 
pressure and puhnonary vascular resistance during intravenous ATP infusion (to 100 
Ilg/k~.min), without a change in mean systemic arterial pressure and systemic vascular 
resistance. In seven children with pulmonary hypertension after surgical repair of 
congenital heart defects, ATP induced a decrease in pulmonary arterial pressure; three 
children showed complete disappearance of pulmonary hypertensive crises. 53 The 
children did not have rebound pulmonary hypertension,53 although in some studies 
rebound pulmonary hypertension was observed after discontinuation of ATP. 167,213 
Recently, the effectiveness of intravenous ATP treatment against puhnonary 
hypertension has also been shown in 20 patients with septal defects during cardiac 
surgery. 171 
Fullerton et a!. 165 reported two patients with acute life-tllleatening pulmonary 
vasoconstriction after tllorax surgery. In both, when standard treatment had failed, 
adenosine (25 to 50 Ilg/kg.min intravenously) achieved lowering of pulIllonary arterial 
pressure WitllOut lowering of systemic arterial pressure. 
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Supraventricular tachycardias 
The anti-arrythmic effects of purines have been known for decades. In 1929, Drury and 
Szent-Gyorgil29 described the effect of adenosine on myocardial conduction. The use of 
intravenous adenosine to terminate supraventricular arrhythmias was first described in 
1933 by Jezer et al.2IO In 1955, Soml0403 reported the first successful clinical trial with 
ATP in paroxysmal tachycardias. 
There has been renewed interest in potential cardiac applications of ATP and 
adenosine in recent years. Several studies have demonstrated efficacy of intravenous 
ATP and adenosine in paroxysmal supraventricular tachycardias (PSVT) in both 
children and adults. In a double-blind study in 39 patients during 68 episodes of 
supraventricular taChycardias, there was no difference in the clinical efficacy of ATP 
and adenosine341 The actions of ATP may be primarily mediated by its breakdown 
product, adenosine 83,401 In newborn children, intravenous ATp113,176 and adenosine 
administration80.328 successfully stopped supraventricular tachycardias. In patients with 
adult PSVT, bolus injections of 5 to 20 mg ATP or 6 to 12 mg adenosine induced 
normalization of heart rate in over 90% of them. 25, 122,358.387,410,446,475 
Most autllOrs described no difference in efficacy between adenosine and tlle stand-
ard therapy for PSVT, verapamil,49.t22,140,172,272 whereas some authors showed a 
significantly greater overall efficacy of adenosine than of verapamil: 89 versus 61 %387 
or 100 versus 80% .25 Moreover, adenosine elicited a much more rapid antiarrhytlmuc 
response than verapamil. Adenosine terminated tachycardia within only 30 
seconds,50,80,140,297,328,387 whereas in two studies in which verapamil was given, it 
took 142387 and 248 seconds,140 respectively, to terntinate tachycardia. Thus, the 
efficacy of adenosine would appear to be at least equivalent to verapanuI, with a 
considerably more rapid onset of action. 
Adenosine has also been used as a diagnostic tool of wide QRS complex 
tachycardias where the mechanism was uncertain. Wide complex ventricular 
tachycardia is often misdiagnosed as wide cdmplex supraventricular tachycardia with 
abberancy. Use of verapamil in these misdiagnosed patients can result in severe 
hypotension and cardiac arrest 342,390 Because of its specific action on 
atrioventricular nodal conduction, adenosine can help to differentiate between 
supraventricular taChycardia with aberrant conduction and ventricular tachycardia. In 
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facilitating this diagnosis, a positive response to adenosine had a sensitivity of 90% 
and a specificity of 94 %, based on electrophysiological studies.180.342,390 
Pharmacological stress test 
Assessment of myocardial ischemia and coronary artery disease is used in the 
evaluation of risk before major surgery, and to select patients for coronary 
angiography, percutaneous transluminal coronary angioplasty or coronary bypass graft 
surgery after acute myocardial infarction, in addition to assessment of atypical chest 
pain. Because many patients are unable to perform an adequate exercise stress test, 
noninvasive methods to evaluate coronary arteIY disease have been developed,136 For 
several years, thallium-201 or technetium-99m sestamibi myocardial perfusion imaging 
by single photon emission computed tomography (SPECT) has been used. Because 
maximal dilatation is needed to produce optimal SPECT images, these imaging 
techniques are often performed during Infusion of a vasodilator. 
Several studies clearly demonstrate the potential diagnostic use of the vasodilators 
ATP and adenosine for detection of coronary artery disease, using coronaIY 
angiography as gold standard. The pharmacological stress test of A TP or adenosine (to 
a maximum of 140 fIg/kg. min intravenously for 6 min) in combination with thallium-
201 scintigraphy has an overall sensitivity of 83 to 88% and a specificity of 78 to 
100%.95,139,445 Technetium 99m-sestalnibi SPECT with adenosine had a sensitivity of 
91 to 95% and a specificity of70 to 75% in detecting coronary artery disease. 10,450 
Echocardiography in conjunction with adenosine-induced coronary vasodilatation 
also produced accurate resuIts with a sensitivity of 75 to 81 % and a specificity of 86 to 
100% .125,438 The sensitivity and specifIcity values of the adenosine stress tests are ap-
proximately similar to those currently obtained during exercise stress tests.274,450 
2.3.3 PuLMONOLOGY 
Cystic fibrosis 
CF is an autosomal recessive disease characterized by an excessive production of 
airway secretions, resulting in bronchial obstruction and recurrent episodes of respira-
tory tract infections. Electrolyte transport across the airway epithelia is abnormal: 
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excessive sodium absorption and defective regulation of the apical membrane chloride 
channel result in decreased water secretion and in increased reabsorption of periciliary 
fluid caused by decreased mucociliary transport. Furthermore, chloride secretion 
through the CFTR-chloride channel is absent.42,338 
Because therapeutic agents are not available to improve chloride secretion in 
airways of CF patients, nucleotides have been tested. In normal as well in CF airway 
epithelia, ATP induced chloride secretion.81.279.412 ATP and also uridine 5'-
triphosphate (UTP) evoked stimulation of ciliary beat frequency237,338 and mucus 
secretion by goblet cells. 107,221,251.287 ATP and UTP also induced net water secretion 
across excised airway tissues.29.211 It is possible that tile endogenous triphosphate 
nucleotides may serve as coordinating factors of the airway clearance system.313 
Knowles et a1.226,227 studied the effects of inhaled aerosolized ATP and UTP in 
nine healthy individuals and 12 CF patients. These authors showed an ATP- and UTP-
induced chloride secretion, with a maximal effective concentration at 100 JIM. The 
efficacy of both ATP and UTP was greater in CF patients than in healthy 
individuals.227 Extracellular UTP may be a potentially better agonist than ATP, because 
the nucleoside breakdown product of ATP, adenosine, is a bronchoconstrictor of human 
airways.lOO.313 In a study in 14 CF patients, the administration of an UTP/amiloride 
combination was also demonstrated to improve mucociliary clearance from the 
peripheral airways of CF lungs to near normal basal rates. 3D The sodium channel bloc-
ker amiloride, has been shown to effectively inhibit sodium absorption by respiratory 
epithelium.42.225 These data support the concept for the use of UTP in combination 
with amiloride as a therapy to improve clearance of secretions from the bronchi of 
patients with CF. 
2.3.4 ONCOLOGY 
Cancer cachexia 
Cancer cachexia is a syndrome of progressive weight loss associated with depletion of 
liver and skeletal muscle energy stores. 374 This depletion is caused by elevated 
lipolysis,128.391 protein breakdown,266,306 and gluconeogenesis. 103.267.389 Dietary76,317 
and enteral supplements76 fail to reverse the cachexia. In liver tissuelOl ,374.434 and in 
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skeletal muscle374 of tumor bearing rats, significantly lower A TP levels have been 
demonstrated, and this is associated with an increased gluconeogenesis.434 
Administration of ATP and adenosine to a suspension of isolated hepatocytes 
inhibited gluconeogenesis from lactate and pyruvate, but not from glycerol or fructose. 
III vivo, daily intraperitoneal injections of 25 mM ATP, AMP or adenosine for 10 
consecutive days into mice bearing colon nmlOfs, induced a significant inhibition of 
host weight_loss.347,348 Tllis inhibition was associated with expansion of hepatic ATP 
pools.348 Rapaport et al. 345 suggested ATP may inhibit Cori cycle activity (I.e., tile 
gluconeogenesis from lactate followed by reconversion of glucose to lactate in 
peripheral tissues), which is a potential means of inhibiting weight loss. 
In the United States, a phase 1111 trial was recently carried out in stage IIlB/IV non-
small-cell lung cancer patients (n=8), After treatment with two to three intravenous 
ATP courses of 96 hours at 4-week intervals, stabilization of body weight was 
observed. 188 In a subsequent open-ended phase II trial (n= 15), an average weight gain 
of 1.3 kg was demonstrated after four ATP courses 286 Despite the small sample sizes, 
these data suggest that ATP may have modulating effects on weight loss in cancer 
patients. 
Inhibition of tumor growth 
Extracellular ATP can modulate the growth of neoplastic cells ill vitro. Below 100 
f.M,l,343,461 from 100 to 500 f.M,I35,299,405,443 from 500 to 1000 fjM,405,476 and 
above 1000 f.M, 189,190,476 extracellular ATP exerted cytostatic and cytotoxic effects on 
many transformed cell lines. In general, these effects appear to be greater than the 
effects on nontransformed mother cells. 
hI animal cell lines, ATP inhibited the gtowth of transformed fibroblasts,28,224,461 
leukemia cells, 63,189,190 mastocyloma cells, 143 lymphoma celis, 117 thymocytes,476 
melanoma celis,299 and ureter carcinoma celis.357 In human cell lines, ATP inhibited 
Ihe growth of pancreatic carcinoma celis, colon adenocarcinoma celis,343,344 melanoma 
celis,224,343 androgen-independent prostate carcinoma celis,135 breast cancer 
celis,3,343,405,443 myeloid and monocytic leukenlia celis,36 and multidrug resistant 
colon carcinoma celis,92 Similar exposure of nontransformed cell lines to ATP 
produced relatively less inhibition of cellular growth compared with transformed celis, 
or no inhibition at all. 189,190,224,299,343 
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Hatta et a!. 190 revealed the possibility of ex vivo purging of leukemia cells by ATP 
in autologous bone marrow transplantation. Mice injected with an untreated mixture of 
normal marrow cells and Ll210 leukemia cells (10:1) died of leukemia within 18 days. 
In contrast, 85 % of the recipients given A TP-treated mixture cells survived for more 
than 70 days. 
In mice with CT26 colon tumors, daily intraperitoneal bolus injections of ATP (25 
to 50 mM) significantly inhibited tumor growth. 344,345,347,348 ATP-induced growth 
inhibition was also demonstrated in rats with ureter carcinomas,356 mice with lymp-
homas 301 fibrosarcomas 161 Ehrlich ascites tumors 239,327 and breast tumors3 Further-, , , 
more, intraperitoneal ATP administration resulted in' a significantly prolonged survival 
of these animals, 134,239,309 
Recently, in an open-labeled phase II study, IS untreated patients with advanced 
non-small-cell lung cancer (stage lIIB/IV) received one to four intravenous ATP 
courses (50 to 65 fIg/kg. min for 96 hours), adntinistered at 4-week intervals. No 
complete or partial tumor responses to ATP were reported, although stable disease was 
found in about two-thirds of the patients during the courses of treatment 286 No further 
studies on ATP as a single anticancer agent in humans are available. 
Chemotherapy 
In cancer cell lines, ATP may enhance the efficacy of several chemotherapeutic agents. 
Addition of 200 to 500 flM ATP to doxorubicin in cultures of human ovarian carci-
noma cells doubled the cell mortality, when compared with doxorubicin alone. Thirty to 
50% more doxorubicin accumulated in the cancer cells when given together with ATP, 
whereas in healthy human fibroblasts practically no effect of ATP on doxorubicin 
uptake was observed 281 Furthermore, in transformed Chinese hamster ovary cells 
(CHO-KI), the presence of 100 to 500 flM ATP and vinblastine or vincristine induced 
passive permeability of deoxy[3H)glucose, while the drugs alone did not induce this 
change.222 In mouse melanoma cell lines (clone-M3), 500 flg/kg.min ATP 
administration markedly increased the passive permeability for chemotherapeutic agents 
such as fluorouracil, doxorubicin, mitomicin and nimustine. The cytotoxic effects of 
these chemotherapeutic agents were additively potentiated by treatment with ATP. Vin-
cristine combined with ATP showed even a synergistic cytotoxic effect; the effective 
concentration of vincristine was lowered 10- to 50-fold by ATP-treatment299 
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RecentIy, a tendency of potentiating effects of cytostatic agents was also observed 
in one study in vivo after administration of adenosine. In mice inoculated with B-16 
melanoma cells, adenosine (5 mM) was injected five days before administration of 
cyclophosphamide (50 mg/kg). This combined treatment reduced the number of 
melanoma foci by 60%, while the chemotherapy alone only reduced them by 45 %. 
Moreover, a protective effect of adenosine against chemotIlerapy-induced decrease of 
leucocyte counts was seen in tIlis studyl48 The use of ATP in combination WitIl otIler 
agents for patients has been proposed, but no studies have been published. 
In the treatment of acute myeloid leukemia, a combination of interferon-y and ATP 
might provide a potential chemotherapeutic regimen. In bone marrow blast cells 
obtained from patients with acute myeloid leukemia, a dose-dependent lysis of 
malignant cells by ATPwas demonstrated.36 Furthermore, it was suggested that ATP 
might provide substantial benefit for chemotherapeutic treatment of brain tumors. In 
patients with malignant glioma selective enhancement of intra tumoral blood flow after 
intercarotid administration of 0.5 to 1.3 fIg/kg. min ATP was reported. It was 
hypothesized that in tIlis way, greater amounts of cytostatic drugs might be transported 
into the brain tumor, witllOut hanning healthy brain tissue. 16 
Radiotherapy 
Radiation causes DNA-bond breakage and rearrangement. Because of radiation 
damage, tissue levels of the lytic enzyme acid phosphatase and the neurotransntission 
enzyme cholinesterase are increased. In contrast, the activities of the glycolytic key 
enzymes hexokinase and lactate dehydrogenase are drastically decreased.422 Stress such 
as by radiation in a living organism, may cause an increased demand for energy and 
glucose to repair damaged tissues.419 
It has been suggested that extracellular ATP may provide energy for cellular repair 
processes. 420 Several studies have shown protection of ATP against damage caused by 
irradiation. Administration of ATP decreased the activities of acid phosphatase421 and 
cholinesterase,423 and augmented tIle activities of hexokinase and lactate dehydro-
genase.421 Moreover, it has been demonstrated that exogenous ATP may stinmlate 
glycogenolysis59 and glucose production in perfused liver of non-irradiated rats.244 
In various animals, including mice and monkeys, the protecting effects of ATP 
against radiation damage enhanced survival rates from 5 to 50%,304 4 to 40%,427 40 to 
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85%,422 and from 26 to 86%.421 In addition, Senagore et al. 386 demonstrated that 
intravenous ATP-MgCh infusion (60 flM/kg) in pigs offered significant cytoprotection 
from pelvic radiotherapy. ATP infusion lead to diminished colorectal seromuscular 
ischaemia, decreased skin and subcutaneous tissue injury, and significantly decreased 
perianastomotic inflanmlatory reaction.386 
Furthermore, when radiation was given in combination with ATP, the frequency of 
formation of aberrant mitoses in epithelial cells of the mouse cornea was lower than 
when no ATP was given.448 Moreover, this combination reduced the tumor growth rate 
of transplanted fibrosarcomas in mice161 and led to significant regression of Ehrlich 
ascites tumors in mice. 134 
2.4 ADVERSE EFFECTS 
In general, ATP and adenosine, when given as either continuous intravenous infusion 
or by intravenous bolus administration, induce similar adverse effects. Adverse effects 
of ATP and adenosine include general discomfort,140 breathing deeper of more 
frequently,33,106,122,212,334,456 headache,90,122,445 flushing, chest pressure or chest 
pain, and nausea. I22,127,334,341,342,387,417,445,446 Sinus bradycardial22,342 and atrial 
fibrillation26,41Q have been observed in patients receiving a bolus of adenosine. The 
respiratory stimulation started before chest discomfort and showed characteristics of 
adenosine receptor mediated responses,212 The chemoreceptors of the carotic artery 
wall are described as the most likely site of these responses.33,457 Studies to 
characterize chest pain demonstrated that higher concentrations of adenosine increased 
the intensity of the pain.417 The chest pain provoked by adenosine is angina-like, but 
electrocardiogram signs of myocardial ischemia are absent. The algogenic effect of 
adenosine is related to activation of peripheral nociceptive afferents.96,236,414-416,418 In 
angina pectoris, adenosine may he involved as an early messenger hetween myocardial 
ischemia and pain.416 Methylxanthines reduce this pain significantly,96,416,417 while 
dipyridamole just increases the intensity of pain.416,417 
The adverse effects with bolus administration of ATP and adenosine are generally 
mild and transient because of the short plasma half-life (0,6 to 1.5 sec).294 Frequent 
dosage titration is possible because of the rapid adenosine clearance in plasma, 136 
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Clinical studies with continuous incremental adenosine infusion, used for the provo-
cation of pain and for the diagnosis of myocardial ischemia, revealed that an adenosine 
infusion above approximately 75 ~,glkg.min is associated with angina-like pain symp-
toms.96,236,308.409 During intravenous ATP infusion in a phase I study in patients with 
advanced cancer, Haskell et al. 188 observed a cardiopulmonary reaction, typically 
characterized as a combination of a feeling of chest tightness without frank pain, and a 
sensation of ' needing to take a deep breath'. No significant hematological toxicity was 
noted. The most appropriate dose of ATP in patients with advanced cancer was 50 
~,glkg.min. Adverse effects during intravenous infusion resolved within seconds after 
discontinuing the A TP infusion. 
As reviewed by Faulds et aI., t36 rapid bolus administration of intravenous 
adenosine induced transient hemodynamic effects, which were usually mild at doses 
at which ATP induced electrophysiological activity. Intravenous adenosine infusion 
usually induced a small but significant increase in heart rate, small variations in 
systolic blood pressure, and a small but significant decrease in diastolic blood 
pressure and mean arterial pressure in conscious patients and volunteers. 
2.5 CONCLUSION 
ATP, adenosine and UTP have been shown to have a wide variety of beneficial effects 
in various clinical situations. The effects are probably mediated by PI and P2 receptors. 
A TP, adenosine and UTP have been found to have potential in the management of 
pain, cancer and some cardiovascular and pulmonary diseases. Much work still needs 
to be done to define the full range of indication for their compounds, their interactions 
with other dmgs, and ideal dosage schemes. P I and P2 receptors are also potential 
targets for novel agonists and antagonists. 
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ABSTRACT 
Background: Extracellular adenosine 5'-triphosphate (ATP) is involved in the 
regulation of a variety of biological processes, including neurotransmission, muscle 
contraction, and liver glucose metabolism, via purinergic receptors. In 
nonrandomized studies involving patients with different tumor types including non-
small-cell lung cancer (NSCLC), ATP infusion appeared to inhibit loss of weight and 
deterioration of quality of life (QOL) and performance status. We conducted a 
randomized clinical trial to evaluate the effects of ATP in patients with advanced 
NSCLC (stage IIIB or IV). 
Methods: Fifty-eight patients were randomly assigned to receive either 10 
intravenous 30-hour ATP infusions, with the infusions given at 2- to 4-week 
intervals, or no ATP. Outcome parameters were assessed every 4 weeks until 28 
weeks. Between-group differences were tested for statistical significance by use of 
repeated-measures analysis, and reported P values are two-sided. 
Results: Twenty-eight patients were allocated to receive ATP treatment and 30 
received no ATP. Mean weight changes per 4-week period were -1.0 kg (95 % 
confidence interval [CI] = -1.5 to -0.5) in the control group and 0.2 kg (95% CI = 
-0.2 to +0.6) in the ATP group (P=0.002). Serum albumin concentration declined 
by -1.2 gil (95 % CI = -2.0 to -0.4) per 4 weeks in the control group but remained 
stable (0.0 gil; 95% CI = -0.3 to +0.3) in the ATP group (P=0.006). Elbow flexor 
muscle strength declined by -5.5 % (95 % CI = -9.6 % to -1.4 %) per 4 weeks in the 
control group but remained stable (0.0%; 95% CI = -1.4% to +1.4%) in the ATP 
group (P=O.OI). A sintilar pattern was observed in knee extensor muscles (P=0.02). 
The effects of ATP on body weight, muscle strength, and albumin concentration were 
especially marked in cachectic patients (P=0.0002, P=O.OOOI, P=O.OOOI, 
respectively, for ATP versus no ATP). QOL score changes per 4-week period in the 
ATP group showed overall less deterioration than in the control group-physical 
scores (-0.2% versus -2.4 %; P=0.0002); functional scores (+0.4 % versus -5.5 %; 
P=0.02), psychological scores (-0.7% versus -2.4%; P=O.ll); overall QOL score 
(+0.1 % versus -3.5%; P=O.OOOI). 
Conclusions: This randomized trial demonstrates that ATP has beneficial effects on 
weight, muscle strength, and QOL in patients with advanced NSCLC. 
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INTRODUCTION 
Cachexia contributes significantly to the high morbidity and mortality in patients with 
advanced non-small-cell lung cancer (NSCLC).116,440 Maintenance of weight and of 
quality of life (QOL) is therefore an important issue in the palliative treatment of 
patients with advanced NSCLC. Dietary counseling76.317 and the use of enteral sup-
plements 76 have failed to reverse weight loss. Drugs, including corticosteroids, 56 
cyproheptadine,215 hydrazine sulfate,259 pentoxifylline,174 and anabolic steroids,15 
were also shown to be ineffective. Prostagens reduced weight loss or increased 
weight, mainly as fat gain.261 ,395 Although QOL was not influenced by prostagens in 
all studies,IOS,395,426 in some studies it was also improved.27,54 
Adenosine 5' -triphosphate (ATP) is a naturally occurring nucleotide that plays a 
central role as an energy source in every cell of the human body. In addition, 
extracellular ATP is involved in the regulation of a variety of biological processes, 
including neurotransmission, muscle contraction, and liver glucose metabolism, by 
stimulation of purinergic receptors. 130 Intravenous ATP may offer a novel palliative 
approach in the treatment of NSCLC. ATP given by daily intraperitoneal injection for 
10 days to mice with colon tumors significantly inhibited weight loss.348 Recently, in 
the United States, a small open phase II trial in 15 patients with NSCLC (stage IIlB 
or IV)IS7 demonstrated maintenance of weight, QOL, and performance status after 
treatment with two to four intravenous infusions of ATP (50-65 fIg/kg. min) for 96 
hours given at 4-week intervals. These results supported earlier findings from a phase 
I study in 14 cancer patients. 1S8 On the basis of these promising preliminary reports, 
we conducted a randomized clinical trial to evaluate the effect of ATP infusion on 
body weight, muscle strength, and QOL in patients with advanced NSCLC (stage IIlB 
or IV). 
PATIENTS AND METHODS 
Patient eligibility, randomization, and study design 
From January 1996 through November 1998, 58 patients were entered in the study. 
Eligible subjects were patients with histologically or cytologically proven NSCLC of 
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stage IIIB or IV,295 and a Karnofsky index of 60% or higher.216 Exclusion criteria 
were as follows: eligibility for curative treatment, liver failure, renal failure (defined 
as patients needing limitation of fluid intake), respiratory failure (dermed as 0, 
dependence), heart failure, angina pectoris, cognitive dysfunction, or psychiatric 
illness. The study was approved by the Medical Ethical Committee of the Erasmus 
University Medical Center Rotterdam. Written informed consent was obtained from 
all patients prior to the study. 
A randomization list was prepared by the Medical Oncology Trial Office of the 
Erasmus University Medical Center Rotterdam with the use of block randomization in 
permutation blocks of four. After baseline measurements, patients were stratified 
according to tumor stage (lIIB versus IV), previous treatment (chemotherapy versus 
no chemotherapy), and performance status (Karnofsky index >70% versus <;70%); 
they were then randomly assigned to receive either supportive care and ATP (ATP 
group) or supportive care alone (control group). Supportive care, provided by the 
patients' attending physicians, included analgesics, antibiotics, anticough medication, 
antiemetics, bisphosphonates, corticosteroids, and palliative radiotherapy for local 
control of the primary tumor or metastases. 
Patients in the ATP-treatment arm were admitted to the Clinical Research Unit of 
the Erasmus University Medical Center Rotterdam to receive a maximum of 10 ATP 
courses. To keep hospitalization at a minimum for ethical reasons, we chose not to 
use the schedule used by Haskell et al. t87,188 with ATP infusions for 96 hours once 
every 4 weeks; instead, we gave 30 hours infusions at shorter time intervals, i.e., the 
Hrst seven ATP courses at 2-week intervals, followed by three ATP courses at 4-
week intervals. ATP infusions (6.lmg in I ml 0.9% NaCI) were started beginning at 
a dose of 20 fIg/kg. min, and were increased by increments of 10 fIg/kg. min every 30 
minutes until a maximum dose of 75 llg/kg.min was reached or until the maximally 
tolerated dose, if this was lower, had been reached. Thereafter, ATP was infused at a 
continuous rate. If any side effects occurred, the dose was reduced to the last lower 
dose or further reduced until side effects disappeared. Follow-up was continued until 
28 weeks, i.e., 4 weeks after the last ATP course that was given at 24 weeks. 
Patients in the control arm were followed up at the outpatient department of the 
Erasmus University Medical Center Rotterdam for 28 weeks. In both groups, 
anthropometry, blood serum albumin levels, muscle strength, and QOL were assessed 
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before treatment randomization and after randomization at 4-, 8-, 12-, 16-, 20-, 24-
and 28-week periods. 
Anthropometry and muscle strength 
Body height was determined to the nearest centimeter. Body weight was measured 
with an electronic scale (Seca Ltd, Birmingham, UK) to the nearest 0.1 kg. 
Strengths of two muscle groups (Le., elbow flexor muscles and knee extensor 
muscles) were assessed by use of a hand-held Microfet2R dynamometer (Biometrics 
Europe, Amersfoort, The Netherlands). This teclmique has been validated in several 
patient groups, mostly in those patients who were limited in muscle strength.41 ,234 
The patient while sitting exerted a maximal force with the 90' flexed right elbow, 
while the examiner pushed with the dynamometer against the patient's thumb pad 
until the muscle strength was overcome (break test). Similarly, the patient exerted a 
maximal force with the 90' flexed right knee, while the examiner pushed with the 
dynamometer against the patient's ankle until the muscle strength was overcome. The 
strength of both muscle groups was measured three times at an interval of 
approximately 10 seconds. Muscle strength was expressed in Newtonmeter (Nm) 
units and was calculated by dividing the measured mean strength (dynamometer 
reading) by the distance from dynamometer position point to the humeral epicondylus 
medialis (elbow) and the femural epicondylus medialis (knee). The same observer 
(H.I. Agteresch) carried out all measurements. 
Quality of life (QOL) 
QOL was assessed with the use of The Rotterdam Symptom Checklist (RSCL), a 39-
item self-report questionnaire. I1O The reliability and validity of the RSCL in cancer 
patients have been confirmed in both cross-sectional199 and longitudinaI109,349 studies 
in patients with a wide range of cancers, This questionnaire, which assesses symptoms 
during the preceding week, was filled out by the patients. The RSCL measures scores 
on four domains: 1) a physical score (23 items), 2) a psychological score (seven items), 
3) a functional score (eight items), and 4) an overall score (one item). Each item is 
rated on a 4-point scale. Results per item were transformed into standardized scores, 
ranging from 0 to 100 with the use of the following formula: 100 - [100 * (item scale 
score - minimum item score) I (maximum score - minimum score)]. A lower score 
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represents a greater level of distress. 1 10 
Statistical analysis 
Differences over time between body weight, serum albumin levels, muscle strength, 
and QOL scores in the two groups were analyzed according to the "intention·to-treat" 
principle by repeated-measures analysis of covariance with the use of the linear 
regression model. To account for the within-patient correlation in the measurements 
of the dependent variable and, simultaneously, for possible non-normality of the 
dependent variable, the Generalized Estimating Equations121 approach was followed. 
These analyses were performed with the SAS procedure Proc Mixed (version 6.12-
Windows; SAS Inc., Cary, NC, USA), with the use of the independence working 
correlation structure. Independent variables in the model were the treatment indicator 
variable, baseline measurement, measurement time, and interaction between time and 
treatment. This model assumes a linear relation between measurement and time in 
both treatment groups, which was checked by adding quadratic time terms. Statistical 
significance of the treatment effect was assessed by testing the null-hypothesis that the 
coefficients of the treatment indicator and its interaction with time are simultaneously 
equal to zero. Survival was compared between groups by means of the log-rank test 
with the use of SPSS (version 6.1.3-Windows; SPSS Inc., Chicago, USA). Two-
sided P-values less than 0.05 were considered statistically significant. 
RESULTS 
Data 011 patients 
Twenty-eight patients were allocated to ATP treatment, and 30 were assigned to no 
ATP. The trial design is sununarized in Figure 3.1.1. Age, stage, performance 
status, previous treatment, and outcome parameters were similar at baseline between 
the ATP and control arms. Assessable patients in the ATP group weighed more and 
had lost more weight than patients in the control group. In both groups, the majority 
were male (Table 3.1.1). However, when the statistical analyses for all outcome 
parameters were adjusted for age, sex, body weight, weight loss, and histologic type, 
this did not alter the results in both groups. 
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Figure 3.1.1. Flow diagram for the randomized trial.of adenosine 5'~triphosphate (ATP) in the 
treatment of advanced non-small-cell lung cancer. Body weight was not assessable because of 
hospitalization of one patient in the ATP group and two patients in the control group; muscle 
strength was not assessable because of hospitalization of two patients in the ATP group and 
three patients in the control grouP. and two additional patients in the control group were not 
assessable because of a technical defect in the dynamometer before treatment randomization. 
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Table 3.1.1. Baseline patient characteristics of the randomly assigned and assessable patients 
in the adenosine 5'-triphosphate (ATP) trial 
ATp· 
Randomly assigned Assessablet 
(n - 28) (n - 26)' 
Sex 
male 20 (71%) 19 (73%) 
female 8 (29%) 7 (27%) 
Age (y) 64 ± 13 64 ± 13 
Tumor histology 
adenocarcinoma 11 (39%) 11 (42%) 
squamous cell carcinoma 10 (36%) 10 (38%) 
undifferentiated large~ceU carcinoma 4 (14%) 4 (15%) 
unspecified 3(11%) 1 (4%) 
Chemotherapy as pretreatment 
yes 12 (43%) 11 (42%) 
no 16 (57%) 15 (58%) 
Slage§ 
1118 13 (46%) 11 (42%) 
IV 15 (54%) 15(58%) 
Karnofsky score (%) 
.:S 70 12 (43%) 11 (42%) 
> 70 16 (57%) 15 (58%) 
Prior weight loss (kg)1l 5.8 ± 6.5 6.2 ± 6.8 
Prior weight loss {%t 6.7± 7.1 7.1 ± 7.3 
Weight (kg) 75.0 ± 16.4 75.1 ± 17.1 
Body mass index (kg/m2 ) 25.3± 5.5 25.5. 5.9 
Albumin (g/l) 40.7± 4.5 40.6 ± 4.6 
Elbow flexor strength (Nm) 533.110 541.114 
Knee extensor strength (Nm) 828.177 839 ± 151 
Physical QOL score1r 78.5 ± 13.7. 77.9. 13.9 
Psychologic QOL score'il 69.0 ± 23.0 68.8.23.8 
Functional QOL score'il 80.1.19.4 79.9. 19.6 
Overall QOL score'il 62.3 + 21.5 60.7.24.5 
* Scores were expressed as mean ± standard deviation or number (%) 
t At least one follow-up analysis was performed 
Control' 
Randomly assigned Assessablet 
(n = 30) (n = 27)' 
18 (60%) 16 (59%) 
12 (40%) 11 (41%) 
61 ± 10 62 ± 11 
6(20%) 6(22%) 
11(37%) 10 (37%) 
9 (30%) 7 (26%) 
4 (13%) 4 (15%) 
14 (47%) 13 (48%) 
16 (53%) 14 (52%) 
14 (47%) 13 (48%) 
16 (53%) 14 (52%) 
14 (47%) 13 (48%) 
16 (53%) 14 (52%) 
4.9 ± 6.7 4.1 ±6.8 
6.8 ± 9.7 5.6 ± 9.6 
68.2 ± 12.3 69.2.12.1 
23.8.4.0 24.3.4.0 
40.0.4.5 40.5.4.2 
512.116 527± 121 
797.219 838 ± 207 
77.2 ± 12.2 78.1 ± 12.3 
70.3' 20.2 71.4 ± 19.5 
77.7± 21.6 79.3.22.2 
57.2.18.4 59.3'18.1 
t Characteristics for weight and muscle strength, n = 25 and 24, respectively, in the ATP group, and n = 
25 and 22, respectively, in the control group 
§ See reference 295 
II Weighlloss in relation to weight before illness 
~ Quality of life (QOL) scores ranging from 0 to 100; a lower score represents a greater degree of symptoms 
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Twenty-eight patients in the ATP group received a total of 176 ATP courses. 
Eleven patients received one to three ATP courses, five received four to six courses, 
and 12 received seven to 10 courses. Fifty-two infusions of ATP were given as low-
dose infusions of 25-40 ~tg/kg.min, 47 as middle-dose infusions of 45-60 ~tg/kg.min, 
and 77 as high-dose infusions of 65-75 ~tg/kg.min. Sixty-seven percent of the ATP 
courses were without side effects (36% and 73% of first and subsequent courses, 
respectively). Side effects were monitored according to Common Toxicity Criteria 
(National Cancer Institute) graded on a 4-points scale according to seriousness. 
During ATP infusions, the most frequently reported side effects (expressed as'percent 
of total number of infusions [n = 176] resulting in the side effects) were of type I 
(chest discomfort, 15%; urge to take a deep breath, 10%; flushing, 5%; nausea. 5%; 
Iightheadedness, 3%; headache, 2%; sweating, 2%; mood alteration-anxiety, 2%; 
and palpitations, I %). Few side effects were of type 2 (injection side reaction, 3%), 
and none were of type 3. Although mild, one side effect was of type 4 (dyspnea, 
3%). In patients with chest discomfort during ATP infusion, electrocardiography 
(ECG) was performed. In no case were ECG changes suggestive of myocardial 
ischemia detected. The side effects always resolved within minutes of lowering the 
ATP dose. 
Body weight 
In control patients, the mean weight loss over the 28-week study period (expressed as 
change per 4 weeks) was -1.0 kg (95% CI = -1.5 to -0.5) per 4 weeks, whereas 
ATP-treated patients experienced no weight loss (0.2 kg; 95% CI = -0.2 to +0.6; P 
for between-group difference = 0.002; Figure 3.1.2, A). For further analysis, the 
participants were stratified according to the presence of cachexia prior to the study 
(~5% versus < 5% weight loss in relation to weight before the illness; 16 patients in 
the ATP group and 13 patients in the control group versus 9 patients in the ATP 
group and 12 patients in the control group). In cachectic patients, progressive weight 
loss of -1.6 kg (95% CI = -2.1 to -I.l) per 4 weeks was observed in the control 
group, while no additional weight loss occurred in the ATP group (+0.3 kg; 95% CI 
= -0.5 to +1.1; P for between-group difference = 0.0002). In non-cachectic 
patients statistical significance between the study groups was not reached (P=0.22). 
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Figure 3.1.2. Changes in A) body weight and B) elbow flexor (top) and knee extensor 
(bottom) muscle strength. Graphs represent mean values, and bars represent 95% confidence 
intervals. Two-sided P-values for differences between patients in the adenosine S'-triphosphate 
(ATP) group and patients in the control group were determined with the use of repeated-
measures analysis. 
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Serum albumin levels 
SelUm albumin concentration (gil) declined by -1.2 (95% CI ~ -2.0 to -0.4) per 4 weeks 
in the control group, whereas no change was detected in the ATP group (0.0 gil; 95% 
CI ~ -0.3 to +0.3; P for between-group difference ~ 0.006; Figure 3.1.3). The effect of 
A TP on albumin was highly significant in patients who were already cachectic at the 
beginning of tile study (~0.0001) but not in non-cachectic patients (~0.37). 
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Figure 3.1.3. Changes in serum albumin concentration (mean ± 95% confidence interval). Two-
sided P-values for difference between patients in the adenosine 5'-triphosphate (ATP) group and 
patients in the control group were determined with the use of repeated-measures analysis. 
Muscle strength 
The strength of elbow flexor muscles declined by -5.5% (95% CI = -9.6% to -1.4%) 
per 4 weeks in the control group, whereas values remained stable in the ATP group 
(0.0%; 95% CI = -1.4% to + 1.4%; P for between-group difference = 0.01; Figure 
3.1.2, n, top). A similar pattern was observed for knee extensor muscles. Muscle 
strength in control patients decreased by -4.5% (95% CI = -9.7% to -0.7%) per 4 
weeks. whereas muscle strength in ATP-treated patients showed no significant change 
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witlltime (+1.4%; 95% CI = -0.2% to +3.1%; P=0.02; Figure 3.1.2, B, bottom). 
The effect of ATP on the strength of elbow flexor and knee extensor muscles was 
highly significant in patients who were already cachectic at the begimling of the study 
(both P=O.OOOI) but not in noncachectic patients (P=0.38 and P=0.44, respectively). 
Quality of life 
During follow-up, patients in the control group showed an impairment in their 
physical score of -2.4% (95% CI = -4.1 % to -0.6%) per 4 weeks, whereas patients 
in the ATP group showed no change (-0.2%; 95% CI = -1.1% to +0.7%; P for 
between-group difference = 0.0002, Figure 3.1.4, A). The functional score 
deteriorated by -5.5% (95% CI = -9.6% to -1.4%) per 4 weeks in patients in the 
control group, whereas patients in the ATP group showed no significant change 
(+0.4%; 95% CI = -1.8% to +2.6%; P=0.02, Figure 3.1.4, B). The 
psychological score deteriorated by -2.4% (95% CI = -5.9% to + 1.1 %) per 4 
weeks in patients in the control group but showed no significant change in the ATP 
group (-0.7%; 95% CI = -2.0% to +0.6%; P=O.ll). With regard to the overall 
score of QOL, patients in the control group showed a deterioration in QOL by -3.5% 
(95% CI = -6.5% to -0.5%) per 4 weeks, whereas patients in the ATP group 
showed no change (+0.1%; 95% CI = -1.8% to +2.0%; P=O.OOOI, Figure 3.1.4, 
C). The positive effects of ATP on QOL were similar in both cachectic and 
noncachectic patients. 
Comparison of single items contributing to significant differences in physical 
scores between the two groups showed beneficial effects of A TP on tiredness 
(P=O.OOOI), lack of energy (P=O.OOI), appetite (P=0.0004), shortness of breath 
(P=O.OOI), sore muscles (P=0.0007), shivering (P=0.006), constipation 
(P=0.003), and difficulties in concentrating (P=0.0005). Items contributing to the 
significant difference in functional deterioration between the ATP and the control 
groups included self-care (P=0.009), doing light housework (P=0.031), doing heavy 
housework (P=0.002), climbing stairs (P=0.016), and walking outdoors (P=O.Oll). 
Of the items contributing to the psychological scores, only the score for irritability 
(P=0.047) was significantly different between the two groups. 
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Figure 3.1.4. Changes in The Rotterdam Symptom Checklist quality of life (QOL) scores 
(mean ± 95 % confidence interval). A) Physical score, B) functional score, and C) overall 
score. Two-sided P-values for difference between patients in the adenosine 5'-triphosphate 
(ATP) group and patients in the control group were determined with the use of repeated-
measures analysis. 
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Concomitant supportive treatment 
During the 28-week follow-up period, none of the patients underwent surgery, One 
patient in the control group was treated with chemotherapy, which consisted of five 
courses of a combination of cisplatin and etoposide given at 3-week intervals, 
followed by radiotherapy involving all lesions, Palliative radiotherapy was given to 
seven patients in the control group and to six patients in the ATP group, Thirteen 
patients in the control group and nine patients in the ATP group used corticosteroids 
to treat symptoms of brain edema (four patients in the ATP group and one patient in 
the control group), dyspnea (four patients in the ATP group and 12 patients in the 
control group), and nausea (one patient in the ATP group and no patients in the 
control group), 
Survival 
Twenty-eight weeks after randomization, the median survival time was 5.6 months 
(95% Cl = l.l - lO,lmonths) for patients in the ATP group and 4,7 months (95% 
CI = 2,5 - 6,8 months) for patients in the control group (P for between-group 
difference = 0,51), 
DISCUSSION 
Traditional outcome variables in clinical oncology have been survival and tumor 
response, Although evaluation of functional status, the QOL, and the body weight of 
cancer patients is increasingly perceived as a major aspect of cancer treatment,292.349 
the number of studies investigating these parameters remains limited, 
The aim of our study was to investigate the effect of ATP on body weight and QOL 
in patients with advanced-stage NSCLC as well as its effect on arm and leg muscle 
strength as functional and patient-relevant parameters. Since tlle trial was performed in 
patients with advanced lung cancer, hand-held dynamometry was chosen because this 
technique is noninvasive, Clearly, the ideal method for assessing treatment effects 
regarding QOL would have been a double-blind, placebo-controlled study, However, 
blinding was not feasible because of the complexity of ATP administration. Some side 
effects are relatively specific to ATP so that both patients and investigators would have 
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easily recognized that ATP was being given. In addition, there were ethical reasons for 
not giving 10 placebo infusions to patients with advanced lung cancer with a short life 
expectation (three to six months). Despite these limitations, the remarkable consistent 
positive effects of ATP on QOL and on objective parameters, such as body weight and 
serum albumin levels, seem to underline the validity of our results. 
During treatment and follow-up, a significant difference in mean weight loss was 
observed between patients in the ATP group and those in the control group. Patients in 
the control group lost approximately I kg per 4 weeks or 6.5 kg over a 6-month period, 
whereas patients in the ATP group had an average stable weight during the 6-month 
period. In cancer patients, loss of body weight is mainly due to loss of fat and of 
skeletal muscle mass. 194 In our study, control patients lost approximately one third of 
their muscle strength in both arms and legs over a 6-month period, whereas ATP-
treated patients lost no muscle strength. The significant difference between patients in 
the ATP group and tllOse in the control group in concentration of the nutritional 
parameter albumin provides a biochemical confirmation of the beneficial effects of ATP 
on the nutritional and functional status of patients with advanced lung cancer. It is 
noteworthy that the effect of ATP on weight loss, muscle strength, and semm albumin 
concentration was especially marked in patients who were already cachectic at the start 
of the study, whereas no statistical significance was reached in noncachectic patients. 
Furthermore, a statistically significant difference in overall scores on the QOL 
instrument evolved between patients in the ATP group and those in the control group. 
In the control group, the deterioration expected in patients with progressive cancer 
was seen, whereas this deterioration was not observed in the ATP group. The QOL 
of the patients in the control group deteriorated significantly both at the physical (2 % 
per 4 weeks) and functional (5% per 4 weeks) levels, whereas these domains 
remained practically unchanged in patients in the ATP group. The physical and 
functional scores were significantly different between patients in the ATP group and 
those in the control group, whereas the psychological scores were not different. 
Furthermore, patients in the ATP group showed a significantly better general activity 
level, including doing housework, climbing stairs, and walking outdoors, which 
supports the validity of the beneficial effects of ATP on muscle strength. Items 
contributing to the better physical scores in patients in the ATP group included lung 
cancer-related (e.g. shortness of breath) as well as general symptoms. It is 
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noteworthy that the items include two of the most common cancer-related symptoms: 
tiredness and lack of energy, II Scores for chest pain and coughing did not 
significantly differ between the two groups (P=O,05 and P=O,21, respectively), 
In both groups of patients, palliative radiotherapy treatment was given to 
approximately the same number of patients, whereas more patients in the control 
group than in the ATP group used corticosteroids, None of the patients used 
corticosteroids as appetite-stimulating dl1lgs or other appetite stimulators, such as 
cyproheptadine and megestrol acetate, One ATP-treated patient used marihuana tea 
for nausea; however, in a recent placebo-controlled study in patients with acquired 
innnunodeficiency disease syndrome,20 no significant effect of dronabinol (the active 
ingredient of marihuana) 011 body weight was shown, This finding indicates that 
differences between the patients in the ATP group and those in the control group 
were not due to confounding effects of concomitant supportive treatment. 
ATP was administered as a constant intravenous infusion without side effects in the 
majority of courses; if side effects occurred, they disappeared rapidly when the infusion 
rate was lowered, The reported side effects were mostly of type I and sometimes of 
type 2, Although during the courses some patients showed dyspnea (type 4), this side 
effect was mild in nature, Since, in addition, no side effects were observed between the 
ATP infusions, ATP treatment appears to be a nontoxic therapy in patients WiOl 
advanced lung cancer. 
The mechanisms contributing to the effects of ATP on body weight, muscle 
strength and QOL are not well understood, It is unlikely that the beneficial effects of 
ATP on body weight and QOL would be caused sinlply by appetite-stimulating 
effects, since appetite stimulators, such as cyproheptadine215 and corticosteroids336 
did not influence the body weight of cancer patients, Rather, our results would 
suggest that A TP may also influence specific metabolic pathways, In addition to the 
well-established role of ATP in cellular metabolism, extracellular ATP appears to be 
involved in the regulation of a variety of biological processes, including 
neurotransmission, muscle contraction, cardiac function, vasodilatation, and liver 
glycogen metabolism130 ATP can be released from the cytoplasm of several cell 
types and interacts with purinergic PI and, particularly, P2 receptors on the surface 
of niany cells,130 Significantly lower ATP levels have been found in liver and in 
skeletal muscle of tumor-bearing rats,374 Rapaport and Fontaine348 showed that 
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intraperitoneal ATP administration doubled hepatic ATP pools and inhibited weight loss 
in tumor-bearing mice. These authors suggested that ATP may inhibit Cori cycle 
activity (i.e., conversion of glucose to lactate in peripheral tissues followed by 
gluconeogenesis from lactate followed in the liver). Studies in isolated hepatocytes 
showed that extracellular ATP induced Ca2+ mobilization and influx by stimulation of 
surface P2 receptors311 that are involved in the control of gluconeogenesis 13 and 
glycogenolysis.218 Furthermore, since albumin levels are affected by both nutrition 
and acute-phase response, it is possible that the stabilization of serum albumin levels 
by ATP may be caused by inhibition of the acute-phase response. In animals, ATP 
has been shown to decrease the production of the proinflallIlnatory cytokines 
interleukin I and interleukin 6453 This observation is noteworthy, since increased 
serum levels of these interleukinesl9.291 have been found in patients with advanced 
cancer and were suggested to play a prominent role in progressive weight loss in 
cancer316 In addition to the effects described above, ATP may have other benefits in 
oncology. Preclinical studies showed that ATP administration may potentiate the 
antitumor effects of cytostatics281 and radiotherapy,134 and may also have protective 
effects against radiation tissue damage. 386 
In conclusion, our results demonstrate that A TP infusion has marked beneficial 
effects on the QOL of patients with advanced NSCLC. In patients who are losing 
weight, ATP prevents further weight loss and maintains muscle strength of both the 
upper and the lower extremities. ATP can be administered as a constant intravenous 
infusion without side effects in the majority of courses; if side effects occur, they are 
mild and transient. In contrast to earlier pharmacological attempts to reverse cancer 
cachexia, it appears that ATP might. be the first agent with beneficial effects on 
skeletal muscles of cachectic cancer patients. We conclude that ATP has potential in 
the palliative management of lung cancer. Further clinical trials using an appropriate 
placebo control are warranted. 
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ABSTRACT 
Purpose: Adenosine 5' -triphosphate (ATP) has been demonstrated to inhibit loss of 
body weight and quality of life in non-small-cell lung cancer (NSCLC)7 In a 
randomized clinical trial we aimed to investigate the effects of A TP infusion on body 
composition, energy intake and energy expenditure of NSCLC patients. 
Patients and methods: Patients with NSCLC, stage IlIB or IV were randomized to 
receive either 10 intravenous 30-hour ATP infusions every 2 to 4 weeks, or no ATP. 
Fat mass (FM), fat-free mass (FFM), and arm muscle area were assessed at 4-week 
intervals during 28 weeks. Food intake, body cell mass (BCM) and resting energy 
expenditure (REE) were assessed before randomization, and at 8 and 16 weeks. 
Between-group differences were tested for statistical significance by repeated-
measures analysis. 
Results: I;'ifty-eight patients were randomized (28 ATP, 30 control). No change in body 
composition over the 28-week follow-up period was found in the ATP group, whereas 
the control group lost -0.6 kg (95% confidence interval [CI]= -0.9 to -0.3) of FM 
(between-group difference: P=0.004), -0.5 kg (95% CI = -0.85 to -0.1) of FFM 
(P=O.OZ), -1.8% (95% CI = -4.0% to +0.4%) of arm muscle area (P=0.02), and 
-0.6% (95% CI = -1.0% to -0.2%) ofBCM / kg body weight per 4 weeks (P=0.054). 
Appetite, as assessed by a validated questjomlaire, decreased significantly in the control 
group, but remained stable in the ATP group (P=0.0004). Expressed as change per 4 
weeks, contnil patients showed a significant decrease in energy intake of -568 KJ/day 
(95% CI = -793 to -343), whereas ATP patients demonstrated a non-significant 
increase of 110 KJ/day (95% CI = -106 to +326; between-group difference: 
P=O.OOOI). No significant differences in REE between the ATP and control group 
were observed. 
Conclusion: The inhibition of weight loss by ATP infusions in patients with advanced 
NSCLC is due to counteracting the loss of both metabolically active (skeletal muscle 
and BCM as parts of FFM) and inactive (PM) tissues. These effects are partly 
ascribed to maintenance of energy intake. 
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INTRODUCTION 
Cancer-associated cachexia is a syndrome of progressive weight loss associated with 
extensive wasting of energy stores of fat~ skeletal muscle and liver tissues;374 and 
with elevated lipolysis, 128,391 protein breakdown,266,306 and gluconeo-
genesis. 103,267,389 Cachexia in cancer patients is associated with increased morbidity 
and mortality 94,116,204,407,440 In clinical practice, dietary counseling,76,317 use of 
enteral supplements,76 and phannacological approaches56,75,174,215,259 have failed to 
reverse cancer-associated cachexia. Treatment with progestagens resulted in 
attenuation of weight loss or in weight gain, but this was attributed mainly to gain of 
fat mass.396 
In uncontrolled phase I and II studies in patients with non-small-cell lung cancer 
(NSCLC), adenosine 5'-triphosphate (ATP) was shown to inllibit weight loss.187,188 
We have recently confirmed these effects in a randomized clinical trial in patients 
with advanced NSCLC, ATP infusions induced maintenance of not only body weight, 
but also muscle strength, quality of life, and serum albumin levels over a 6-month 
period. 7 In the present paper, effects of ATP on body composition, energy intake, 
and energy expenditure in the same patients are reported. 
PATIENTS AND METHODS 
Patients 
Patients with histologically or cytologically proven NSCLC, stage IIIB or IV without 
curative options,295 and a Karnofsky index of 60% or higher216 were eligible for the 
study. Patients with cognitive dysfunction or liver, renal, respiratory, or heart failure, 
and patients undergoing surgery, concurrent chemotherapy, or radiotherapy involving 
all lesions were excluded. The study was approved by the Medical Ethical Committee 
of the Erasmus University Medical Center Rotterdam. Written informed consent was 
obtained from all patients prior to the study. 
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Treatment allocation 
Randomization was performed by the Medical Oncology Trial Office of the Erasmus 
University Medical Center Rotterdam, using block randomization in permutation 
blocks of four. Following baseline measurements patients were stratified for tumor 
stage (IIIB versus IV), prior treatment (chemotherapy versus no chemotherapy), and 
performance status (Karnofsky index >70% versus :;70%), and were then randomly 
assigned to receive either supportive care and ATP (ATP group), or supportive care 
alone (control group). 
Treatment schedule 
Patients in the ATP-treatment arm received a maximum of 10 A TP courses of 30 
hours each: i.e., seven courses at 2-week intervals, followed by three ATP courses at 
4-week intervals. ATP infusions (6.1 mg ATP-Na"3H,O in I ml 0.9% NaCl) were 
started at a dose of 20 ~lg/kg.min and increased by steps of 10 ~lg/kg.min every 30 
minutes until a maximum dose of 75 ~lg/kg.min, or the maximally tolerated dose, had 
been reached. Thereafter, ATP was infused at a continuous rate. If any side effects 
occurred, the dose was reduced to the last given dose or further until side effects 
disappeared. Follow-up was continued until 28 weeks, i.e. four weeks after 
termination of the last ATP course which was given at 24 weeks. Patients in the 
control arm were followed up in the outpatient department at 4-week intervals until 
28 weeks after randomization. Because of possible confounding effects on metabolism 
and appetite,258,435 patients who started corticosteroid treatment during the study 
were excluded from evaluation of appetite, food intake, body cell mass and energy 
expenditure from the time point of starting the medication. Since at 28 weeks, 28 out 
of 30 control patients had died, were hospitalized, or used corticosteroids, statistical 
analysis for body cell mass, food intake and energy expenditure was only performed 
before randomization and after randomization at 8- and 16-week periods. 
Anthropometry 
Body height was determined to the nearest centimeter. Body weight was measured 
with an electronic scale (Seca Ltd, Birmingham, UK) to the nearest 0.1 kg. 
Skinfold thicknesses were measured in triplicate to the nearest 0.2 mm with a 
HoltainR skinfold caliper (CMS weighing equipment LTD, London, UK), and the 
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median used for further calculations. Total body fat mass (FM) was estimated from 
the sum of median skinfold thicknesses at four sites (triceps, biceps, subscapula, and 
supra-iliac) using the age- and gender-specific tables from Durnin and Womersley l32 
Fat-free mass (FFM) was calculated by subtracting FM from body weight. 
Mid-upper arm circumference of the left arm was measured with a flexible 
measuring tape. Arm muscle area was derived using the equation: (arm 
circumference - 7{ x triceps skinfold)'! 47{.182 
Throughout the study anthropometric measurements were performed by one 
trained observer (H.]. Agteresch). 
Deuterium oxide and bromide dilution 
After an overnight fast of approximately 12 hours, patients received a oral dose of 15 
or 20 grams deuterium-labeled water (99.9%; Isotec inc., Miamisburg, USA) at 
about 9.30 hours a.m. Following D,O administration, patients had to abstain from 
eating and drinking until blood sampling completed. Venous blood samples were 
drawn into heparin tubes from the forearm at baseline and after 21;\, 3, and 3 1;\ 
hours. Blood samples were immediately placed on ice and then centrifuged for 10 
min 1300 x g at 4' C. Deuterium oxide in plasma was measured by infrared 
spectrophotometry (Miran IFF, Foxboro, South Norwalk, USA). Total body water 
(TBW) volume was calculated by dividing D,O dose by D,O concentration in plasma. 
FFM was calculated using a constant water percentage of 73.322 FM was calculated 
by subtracting FFM from total body weight. 
Extracellular water (ECW) was estimated by bromide dilution. Following Ule same 
protocol as to the deuterium oxide dilution method, patients drank a known dose of 
sodium bromide solved in water. Bromide concentration in plasma ultra filtrate was 
determined with high-performance liquid chromatography according to the anion-
exchange chromatographic method.288 
Body cell mass (BCM) was defmed as (TBW - ECW) ! 0.73, which is the same as 
intracellular water! 0.73. 392 
Energy intake 
Before randomization, all participants kept a 7-day food record. Three-day food 
records were repeated at 8 and 16 weeks. Intake of energy, protein, fat and 
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carbohydrate was calculated using the software program Komeet (version 2.0, VBS 
Nutrition Software, Amhem, The Netherlands). 
Appetite was evaluated as a part of the Rotterdam Symptom Checklist (RSCL), a 
39-item validated self-report quality of life questionnaire. 1 to The item 'lack of 
appetite' was rated on a 4-point scale (not at all=4, a little=3, quite a bit=2, very 
much = 1). The RSCL, which assesses symptoms over the preceding week, was filled 
out by the patients before randomization, and at 4-week intervals until 28 weeks. 
Resting enel'gy expenditul'e 
Before randomization and at 8 and 16 weeks, resting energy expenditure (REE) was 
assessed by indirect calorimetry using a ventilated hood system (DeltatracThI MBM-l00, 
Datex Instmmentarium Corp, Helsinki, Finland). After an overnight fast and a resting 
period of approximately half an hour, CO, production and 0, consumption were 
measured during a period of 30 minutes between 9 and 11 a.m. lying down at complete 
rest. REE was calculated by using the abbreviated Weir fOl'lnula. 459 Measured REE 
was compared to predicted REE using the Harris-Benedict equations186 which are age-, 
height-, weight-, and gender-specific. The equipment was calibrated at the start of each 
experiment. 
Statistical analysis 
The differences over time between FM, FFM, ann muscle area, BCM, appetite, 
energy intake, and energy expenditure in the two groups were analyzed by repeated-
measures analysis of covariance using the linear regression model. To account for the 
within-patient correlation in the measurements of the dependent variable, and 
simultaneously for possible non-normality of the dependent variable, the Generalized 
Estimating Equations121 approach was followed. These analyses were performed with 
the SAS procedure Proc Mixed (version 6.12-Windows; SAS Inc., Cary, NC, USA), 
using the independence working correlation structure. Independent variables in the 
model were the treatment indicator variable, baseline measurement, measurement 
time and interaction between time and treatment. This model assumes a linear relation 
between measurement and time in both treatment groups, which was checked by 
adding quadratic time terms. Statistical significance of the treatment effect was 
assessed by testing the null hypothesis that the coefficients of the treatment indicator 
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and its interaction with lime are simultaneously equal to zero. Two sided P-values 
below a .05 were considered statistically significant. 
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Figure 3.2.1. Flow diagram. * Body cell mass was not assessable because of a technical reason 
(1 control) or burden (7 control); Resting energy expenditure was not assessable because of 
technical reason (2 ATP, 1 control) or burden (7 control). 
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RESULTS 
Patient characteristics and treatment 
Fifty-eight patients were randomized to the ATP (n=28) or control group (n=30). 
The trial profile is summarized in Figure 3.2.1. General baseline characteristics 
including age, stage, performance status, and prior treatment were similar in the ATP 
and control group, both for randomized and assessable patients. In both groups the 
majority were male (ATP 71 %, control 60%). Baseline anthropometric parameters of 
assessable patients are listed in Table 3.2.1. Compared to control patients, assessable 
patients in the ATP group weighed more, but had a higher degree of weight loss at 
time of randomization. 
Table 3.2.1. Baseline anthropometric parameters of assessable patients 
ATP Control 
Prior weight loss (%)* 7.1 ± 7.3 
Weight (kg) 75.2 ± 17.0 
Body mass index (kg/m') 25.5 ± 5.9 
Fat mass (%) 28.0 ± 7.0 
Fat-free mass (%) 72.0 ± 6.7 
Arm muscle area (cm2) 70.4 ± 25.7 
Body cell mass (kg/kg body weight)' 0.37 ± 0.03 
'Lack of appetite' score* 3.2 ± 0.8 
At least one follow-up analysis perfonned (25 A TP t 25 control) 
Scores expressed as mean ± standard deviation 
* Weight loss relative to pre-illness weight 
t Characteristics for 17 ATP patients and 10 control patients 
5.6 ± 9.6 
69.2 ± 12.1 
24.3 ± 4.0 
29.3 ± 8.4 
70.7 ± 8.4 
64.0 ± 15.7 
0.37 ± 0.04 
3.4 ± 0.9 
t Four-point scale for presence of 'lack of appetite': 4) oot at all, 3) a little, 2) quite a bit, 1) very much 
Twenty-eight patients in the ATP group received a total of 176 ATP courses. 
Eleven patients received one to three ATP courses, five received four to six courses, 
and 12 received seven to 10 courses. Fifty-two infusions of ATP were given as low-
dose infusions of 25-40 fIg/kg. min, 47 as middle-dose infusions of 45-60 fIg/kg. min, 
and 77 as high-dose infusions of 65-75 flg/kg.min. As previously reported,7 67% of 
ATP courses were without side effects (36 % and 73 % of first and subsequent 
courses, respectively). Side effects occurring in the remaining courses were mainly 
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cardiopulmonary reactions such as chest discomfort which were mild and transient, 
resolving within minutes after lowering the ATP dose. 
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Figure 3.2.2. Changes in A) fat mass (FM), and B) fat-free mass (FFM). Graphs represent 
mean values, and bars represent standard error of the mean (SEM). P~values shown are 
differences between patients in the adenosine 5'·triphosphate (ATP).group and patients in the 
control group as determined by repeated~measures analysis. 
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Body composition 
As previously reported,7 weight loss over the 28-week study period, expressed as 
change per 4 weeks, was -1.0 kg (95% CI = -1.5 to -0.5) in control patients 
(P=O.OOOI), whereas in ATP treated patients no weight loss (0.2 kg; 95% CI = -0.2 
to +0.6; between-group difference: P=0.002) was observed. Changes in PM and 
PPM for both study groups during the 28-week follow-up period are plotted in 
Figure 3.2.2. In the control group a significant loss of -0.6 kg (95% CI -0.9 to -0.3) 
PM per 4 weeks was observed (P=0.0002) which was not seen in the ATP group 
(+0.1 kg; 95% CI = -0.3 to +0.5; between-group difference: P=0.004). PPM of 
patients in the control group remained relatively stable for the first 16 weeks, but 
then showed a marked drop; during the overall 28-week study period PPM decreased 
by -0.5 kg (95% CI = -0.9 to -0.1) per 4 weeks (P=0.03), whereas no significant 
change was observed in ATP-treated patients (+0.1 kg; 95% CI = 0.0 to 0.2; 
between-group difference: P=0.02). 
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Figure 3.2.3. Changes in arm muscle area expressed as percentage of baseline values. Graphs 
represent mean values, and bars represent SEM. Two-sided P-values for differences between 
patients in the adenosine 5'-triphosphate (ATP) group and patients in the control group were 
determined by repeated-measures analysis. 
Mid-upper arm muscle area (Figure 3.2.3) showed a non-significant decline of -1.8% 
(95% CI = -4.0% to + 0.4%) per 4 weeks in the control group, but a significant 
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increase of 1.1 % in the ATP group (95% CI = +0.3% to 1.9%; P=0.02; between-
group difference: P=0.02). 
Changes of BCM per kg body weight for a subgroup of control patients and A TP-
treated patients at 8- and 16-week periods are plotted in Figure 3.2.4. As described in 
the legend of Figure 3.2.1. in eight control patients BCM was not assessable because of 
burden (n=7) and a teelmical reason (n= I). The control group showed a significant 
decline in BCM of -0.6% (95% CI = -1.0% to -0.2%) of body weight per 4 weeks 
(P=0.OO04). whereas the ATP group showed no change (-0.1 %; 95% CI = -0.5 to 
+0.3; between-group difference: P=0.054). 
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Figure 3.2.4. Changes in body cell mass (BCM) per kg body weight (BW). Graphs represent 
mean values, and bars represent SEM. Two-sided P-values for differences between patients in the 
adenosine 5'-triphosphate (ATP) group and patients in the control group were determined by 
repeated-measures analysis. 
Energy intake 
Intake of energy and selected nutrients is summarized in Table 3.2.2. Expressed as 
change per 4 weeks, the control group showed a highly significant decrease in energy 
intake of -568 kJ/day (95% CI = -793 to -343; P=O.OOOI), whereas the ATP group 
showed a non-significant increase of 110 kJ/day (95% CI = -106 to +326; P=0.32). 
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The difference in change of energy intake between the two groups was significant 
(P=O.OOOI). This difference between the ATP and control groups was the result of 
significant differences in changes of both protein (P=O.005), carbohydrate 
(P=O.OOO2), and rat intake (P=O.OO2), without changes in the proportions of these 
nutrients. 
Table 3.2.2. Energy intake and energy expenditure at 0, 8, and 16 weeks 
ATP Control ATP vs C 
0 8 16 0 8 16 P-value* 
n = 17 n = 16 n = 15 n = 17 n = 18 n=6 
Energy intake (MJ/d) 7.2. 2.2 7.9 ± 2.0 7.9. 2.2 7.6. 1.8 7.0'1.8 5.2. 2.1 0.0001 
Protein intake (g/d) 62.22 67.23 72 ± 22 72 ± 14 70.21 45.20 0.005 
Protein intake (%) 15.18 15.20 16.18 17 ± 14 18.21 16.17 NS 
Carbohydrate Intake (g/d) 208' 73 232.74 213.72 220' 57 199.54 147.46 0.0002 
Carbohydrate intake (%) 52. 61 52.66 48.58 52.58 51.53 51.39 NS 
Fat Intake (g/d) 63± 22 73.23 74 ± 26 70' 17 63.18 48 ± 26 0.002 
Fat intake (%) 33.39 35 ± 43 36.28 35 ± 15 34.37 35.46 NS 
REE (MJ/d)' 6.4 • 0.9 6.3.0.5 6.4.1.1 6.3' 0.6 6.4.0.6 7.0.0.8 NS 
Values expressed as mean ± standard deviation 
* Based on repeated-measures analysis 
t Resting energy expenditure 
At baseline, appetite reported by the patients as part of a validated questionnaire 
was similar in the two groups. During the 28-week study period, reported appetite 
deteriorated in the control group, whereas the ATP group showed no change (Figure 
3.2.5; between-group difference P=O.0004). 
Energy expenditure 
Comparison of total resting energy expenditure (REE) as measured by indirect 
calorimetry revealed no significant differences between patients in the ATP and the 
control group at 8 and 16 weeks (P=O.33; Table 3.2.2). There was also no difference 
between the two groups when REE was expressed per kg body weight, per kg FFM, 
per kg BCM, or as a percentage of the Harris Benedict value. 
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Figure 3.2.5. Changes in the 4-point scaled item 'appetite', as part of the quality of life 
Rotterdam Symptom Checklist. A lower value shown in this figure implies Jess appetite. Graphs 
represent mean values, and bars represent SEM. Two-sided P-values for differences between 
patients in the adenosine 5'-triphosphate (ATP) group and patients in the control group were 
determined by repeated-measures analysis. 
DISCUSSION 
Weight loss is a frequent phenomenon in cancer patients and particularly in patients 
with lung cancer. t16 The ainl of the present randomized clinical trial was to investigate 
the effects of A TP on body composition, energy intake, and energy expenditure in 
patients with NSCLC (stage IlIB or IV). 
Weight loss is tlle result of an imbalance between energy intake and energy 
expenditure. Fredrix et al. 156 found an elevated REE (> 115% of the predicted Harris 
Benedict value) in two-thirds of newly detected patients witll primary lung cancer. 
Since the elevation was more pronounced in weight-losing patients, these authors 
suggested that hypermetabolism might contribute to weight loss. However, results of 
the present study indicate that the inhibitory effects of ATP on weight loss were not 
caused by a reduction in REE by ATP. 
We found that the progressive weight loss in the control group was due to loss in 
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FM and, to a lesser degree, FFM. These results confirm the fmdings of Heymsfield et 
al. 194 who demonstrated that weight loss in cancer patients is primarily caused by loss 
of FM and muscle mass, whereas total FFM appears to decrease to a smaller extent 
because of maintenance of visceral organ mass and tumor growth. 194 We found that 
ATP significantly inhibited the loss in upper arm muscle area, as an indication of 
muscle mass. 262 This fmding is consistent with our recent observation that control 
patients lost approximately one-third of strength in both elbow flexor and knee extensor 
muscles over the 28-week study period, whereas muscle strength of ATP-treated 
patients remained stable.7 
A key component of weight loss in cancer cachexia is the loss of BCM which is the 
vital compartment containing the oxygen-exchanging, potassium rich, and metabolically 
active tissue.293 Simons et al 397 demonstrated a correlation between BCM and 
Karnofsky performance status in weight-losing lung cancer patients, and between 
decreased BCM and increased systemic inflammatory state. It is noteworthy that ATP 
treatment appears to counteract BCM wasting in advanced lung cancer patients. 
The beneficial effects of ATP not only on FM but also on muscle and BCM as 
parts of the FFM are noteworthy in view of the lack of positive results from other 
randomized clinical studies using pharmacological approaches to treat cachectic cancer 
patients. Corticosteroids56.lt4,336 and the anti-seritonergic drug cyproheptadine215 
induced an increase in appetite, however without positive effects on body weight. The 
phosphoenolpyrnvate-carboxykinase inhibitor hydrazine sulfate had no effect on either 
appetite or body weight. 259 Anabolic steroids also failed to influence weight in NSCLC 
patients75 Administration of medroxyprogesterone acetate or megestrol acetate induced 
an increase in appetite,55.137 attenuation of weight loss,137 and weight gain.396 
However, as assessed by dual-energy X-ray absorptiometry261 and deuterium oxide 
dilution,396 this was attributed to gain in FM, and not in FFM. 
The mechanisms underlying the positive effects of ATP on nutritional status are not 
clear. The scores on the item 'lack of appetite' which was part of the quality of life 
questionnaire revealed a significant difference in appetite appearing over time between 
the ATP and control group. This subjective finding was confirmed by food records kept 
by the patients which showed a significant decline in energy intake in the control group 
but not in the ATP group. This would suggest that ATP may have appetite-regulatory 
effects contributing to increased food intake. However, approximate calculations of 
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differences between the ATP and control group Witll regard to energy intake (",10.000 
kJ over 4 weeks) and energy expenditure from both fat and fat-free body mass wasting 
(",22.000 kJ over 4 weeks) indicate that differences in food intake cannot entirely 
account for the observed differences in body composition between the two groups. 
Moreover, the appetite stimulator megestrol acetate was shown only to increase FM but 
not FFM.396 lt is therefore unlikely that the inhibitory effects of ATP on loss ofBCM 
and skeletal muscles would be solely caused by appetite stimulating effects of ATP. 
This would suggest that ATP may also influence specific metabolic patllways involved 
in weight loss. 
In experimental cancer models, depletion of ATP levels in liver101 ,374,434 and 
skeletal muscle374 were reported to be significantly reduced. Recently, reduced liver 
ATP levels were also demonstrated in advanced lung cancer patients,l04 particularly in 
weight-losing patients 246 Intraperitoneal ATP administration doubled hepatic ATP 
pools and inhibited weight loss in tumour-bearing mice348 It is noteworthy that ATP 
infusion leads to a significant rise in liver ATP pools also in weight-losing lung cancer 
patients.245 Rapaport et al,345 suggested that ATP may inhibit Cori cycle activity (Le., 
conversion of glucose to lactate in peripheral tissues followed by gluconeogenesis from 
lactate in the liver). Studies in isolated hepatocytes showed that extracellular ATP 
evoked Ca2+ -mobilization and influx by stimulation of surface purinergic P2 
receptors311 which are involved in the control of gluconeogenesis 13 and 
glycogenolysis. 218 It is speculated that these ATP-induced effects might attenuate 
energy-consuming catabolic processes like gluconeogenesis, which could contribute to 
maintenance of body fat and cell mass in cancer patients, 
In conclusion, our study demonstrates that inhibitory effects of ATP on weight 
loss are due to counteracting the loss of both metabolically active (skeletal muscle and 
BCM as parts of FFM) and inactive (FM) tissues in cachectic patients with advanced 
NSCLC, The beneficial effects of ATP on body composition are associated with 
maintenance of energy intake but not with reduced REE. Further studies are 
warranted to elucidate the mechanisms underlying the observed clinical effects of 
ATP in metabolically active tissues. 
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ABSTRACT 
Purpose: To evaluate the effect of adenosine 5'-triphosphate (ATP) on ttlmor response 
and overall survival in a randomized clinical trial in patients with non-small-cell lung 
cancer (NSCLC). 
Patients and methods: Fifty-eight NSCLC patients (stage IIlB or IV) were randOlniy 
assigned to receive either 10 intravenous 30-hour ATP infusions every two to four 
weeks over a 24-week period (n=28), or no ATP (control patients, n=30). 
Results: ATP was given for a median of 6.5 infusions. Forty-nine patients were 
evaluable for tumor response. None of the evaluable patients showed a complete or 
partial response. Median time to progression was 3.9 months (95% confidence 
interval [CI] = 2.3 to 5.5) in the ATP group compared to 3.0 months (95% CI = 2.4 
to 3.7) in the control group (P=0.71). Median survival was 5.6 months (95% CI = 
l.l to 10.1) for the ATP group, and 4.7 months (95% CI = 2.6 to 6.8) for the 
control group (P=0.68). ATP treatment was associated with a significant increase in 
survival in weight-losing patients with stage lIlB NSCLC: median survival was 9.3 
months (95% CI = 2.1 to 16.5) for ATP-treated patients versus 3.5 months (95% CI 
= 2.3 to 4.7) for control patients (between-group difference: P=0.02). 
Conclusion: ATP as a single therapy does not lead to tumor regression or increased 
survival in patients with advanced lung cancer but may prolong survival in weight-
losing patients with stage IIlB lung cancer. 
INTRODUCTION 
The prognosis of patients with locally advanced or metastatic non-small-cell lung 
cancer (NSCLC) remains poor because most tumors are refractory to chemotherapy. 
The high morbidity and poor overall survival is not only due to progressive tumor 
growth but is also aggravated by the high frequency of weight loss in this patient 
population. 116,440 Adenosine 5'-triphosphate (ATP) may offer a novel approach in 
the treatment of lung cancer patients. Administration of ATP has been shown to 
inhibit growth of various human tumor cell lines36,92,135,224,343,405 and of 
experimental tumor models ill vivo. 134 ,61,239,301,309,327,344,345,347,348 In addition, 
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intraperitoneal ATP administration inhibited weight loss and significantly prolonged 
survival in these ani111als. 134 ,239,309 In an uncontrolled phase II study, 15 untreated 
patients with advanced NSCLC (stage IIIB or IV) were treated with one to seven 
intravenous ATP courses (50-65 fIg/kg. min) for 96 hours, administered at 4-week 
intervals. Although no complete or partial tumor response was seen after the ATP 
courses, ten patients showed stable disease. In addition, mean body weight and quality 
of life were maintained at a stable level in the total group.IS7 Recently, in a 
randomized clinical trial,? we confirmed that ATP infusions contribute to 
maintenance of body weight, muscle strength, selUm albumin levels, and quality of 
life in patients with advanced NSCLC during a 6-month period. In the present paper 
we report on the effect of ATP on tumor growth and survival in the same group of 
patients. 
PATIENTS AND METHODS 
The study was approved by the Medical Ethical Connnittee of the Erasmus University 
Medical Center Rotterdam. Written informed consent was obtained from all patients 
prior to tlle study. 
Patient selection 
Patients were eligible if they had stage IlIB or IV, 295 histologically or cytologically 
proven NSCLC, and a Karnofsk-y index of 60% or higher. 216 Exclusion criteria were: 
eligibility for curative treatment; liver failure; renal failure defined as the need for 
limited fluid intake; respiratory failure defined as 0, dependence; heart failure; 
angina pectoris; cognitive dysfunction, and psychiatric illness. 
Randomization and h'eatment schedule 
A randomization list was prepared by the Medical Oncology Trial Office of the 
Erasmus University Medical Center Rotterdam using block randomization in 
permutation blocks of four. After baseline measurements, patients were stratified for 
tumor stage (IIlB versus IV), prior treatment (chemotherapy versus no chemotherapy) 
and performance status (Karnofsky score> 70% versus ,;70%); and then randomly 
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assigned to receive either supportive care and ATP (ATP group), or supportive care 
alone (control group). Supportive care, provided by the patients' attending physician, 
included analgesics, antibiotics, anticough medication, antiemetics, bisphosphonates, 
corticosteroids, and intercurrent palliative radiotherapy for local control of the 
primary tnmor or metastases. 
Patients in the ATP-treatment arm were admitted to the Clinical Research Unit of 
the Erasmus University Medical Center Rotterdam to receive a maximum of 10 ATP 
courses of 30 hours each: seven courses at 2-week intervals, followed by three ATP 
courses at 4-week intervals. ATP infusions (6.1 mg ATP-NadH,O in 1 mI 0.9% 
NaCl) were started beginning at a dose of 20 flg/kg.min and were increased by 
increments of 10 J.1g/kg.min every 30 minutes until a maximum dose of 75 
flg/kg.min, or the maximally tolerated dose if lower, had been reached. Thereafter, 
ATP was infused at a continuous rate. If any side effects occurred, the dose was 
reduced to the last given dose or further until side effects disappeared. 
In both ~tudy arms the minimum evaluation of tnmor response for all patients 
included history and physical examination, chest X-ray, and biochemistry. Patients 
were evaluated for response at 4-week intervals. 
TUlllor response 
Tumor response was evaluated by standard WHO criteria (WHO, 1979). Partial 
response required > 50% reduction of the product of the perpendicular diameters of 
all measurable lesions. Stable disease was defined as < 50% reduction and < 25 % 
increase in measurable or evaluable lesions, whereas progressive disease was defined 
as > 25 % increase in the size of tumor lesions or the appearance a new lesion. 
Statistics 
Differences in time to progression and survival between patients in the ATP group 
and patients in the control group were tested by means of the log-rank test. Survival 
curves were fitted according to Kaplan-Meier. Survival analysis was based on the 
entire stndy population according to the intention-to-treat prinCiple. Because of 
demonstrated inhibitory effects of ATP on weight loss,7 the effect of ATP on survival 
was also assessed separately in patients who were losing weight prior to the ATP. 
Cox proportional hazards model was used for survival analysis. Since ATP-treated 
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patients had higher baseline body weight (Tables 3.1.1 and 3.3.2), baseline body 
weight was included as a covariate in all survival analyses. Results were expressed as 
median months (95 % confidence interval [CIl). P-values below 0.05 were considered 
statistically significant. 
RESULTS 
Patients 
Fifty-eight patients (38 men and 20 women) entered in the trial from January 1996 
through November 1998. Twenty-eight patients were allocated to ATP treatment, and 
30 were assigned to no ATP treatment. General baseline characteristics including 
age, stage, performance status, and treatment before inclusion in this trial were 
similar in the ATP and control group. Patients in the ATP group weighed more than 
patients in the control group. Patient characteristics are shown in Table 3.3.1. Of the 
58 patients, nine were not evaluable for tumor response because of concomitant 
chemotherapy (one patient in the control group), radiotherapy (two patients in the 
control group), patient refusal (one patient in the control group), hospitalization 
elsewhere (one patient in the ATP group), and early death (two patients in the ATP 
group and two patients in the control group). 
Treatment 
Twenty-eight patients in the ATP group received a total of 176 ATP courses. ATP 
was given for a median of 6.5 (range 1-10) infusions. Eleven patients received one to 
three ATP courses, five received four to six courses, and 12 patients received seven 
to 10 courses. Fifty-two infusions of ATP were given as low-dose infusions of 25-40 
flg/kg.min, 47 as middle-dose infusions of 45-60 flg/kg.min, and 77 as high-dose 
infusions of 65-75 flg/kg.min. The reasons not completing all ATP cycles were death 
(n= 15), progressive disease (n=2), or patients refusal (n= 1). 
As previously reported,7 67% of ATP courses were without side effects (36% of 
the first and 73% of the subsequent courses). Side effects occurring in the remaining 
courses were mainly cardiopulmonary reactions such as chest discomfort and the urge 
to take a deep breath (both grade 1) which were transient, and resolved within 
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minutes after lowering the ATP infusion rate. These reactions were most common in 
patients with a history of cardiovascular dysfunction or chronic obstructive 
pulmonary disease. None of the patients developed hematological toxicity. Between 
the ATP courses, no side effects of the ATP treatment were reported. 
Table 3.3.1: Baseline patient characteristics of the 58 randomized patients 
AlP Control 
(n = 28) (n = 30) 
Gender 
male 20 (71%) 18 (60%) 
female 8(29%) 12 (40%) 
Age (y) 64 ± 13 61 ± 10 
Tumor histology 
adenocarcinoma 11 (39%) 6 (20%) 
squamous-cell carcinoma 10 (36%) 11(37%) 
undifferentiated large cell carcinoma 4 (14%) 9 (30%) 
unspecified 3 (11%) 4 (13%) 
Previous chemotherapy 
yes 12 (43%) 14 (47%) 
no 16 (57%) 16 (53%) 
Stage 
IIIB 13 (46%) 14 (47%) 
IV 15 (54%) 16 (53%) 
Karnofsky Index (I',) 
s70 12 (43%) 14 (47%) 
> 70 16 (57%) 16 (53%) 
Prior weight loss (kg)' 5.8 ± 6.5 4.9 ± 6.7 
Prior weight loss (%)* 6.7± 7.1 6.8 ± 9.7 
Weight (kg) 75.0 ± 16.4 68.2 ± 12.3 
Body mass index (k9/m2) 25.3 ± 5.5 23.8 ± 4.0 
Findings are expressed either as a percentage in brackets or as mean ± standard deviation. 
* Weight loss in relation to pre-illness weight. 
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Tumor response 
No complete or partial responses were observed. The median time to progression was 
3.9 months (95% CI = 2.3 - 5.5) in the ATP group (n=25) compared to 3.0 months 
(95% CI = 2.4 - 3.7) in the control group (n=24; between-group difference: 
P=0.71). 
Survival 
Kaplan Meier plots of survival in all patients given ATP versus no-ATP are shown in 
Figure 3.3.1. Because patients in the ATP group weighed more at randomization, the 
survival analysis was adjusted for baseline body weight. The median survival time 
from randomization was 5.6 months (95% CI = 1.1 to 10.1) for patients in the ATP 
group, and 4.7 months (95 % CI = 2.6 to 6.8) for patients in the control group. 
There was no statistically significant difference between the two groups (P=0.68). In 
the ATP group six patients (21 %) survived for more than one year, and in the control 
group five patients (17%). On the census date, four of 58 patients (two patients in the 
ATP group and two patients in the control group) were still alive. 
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Figure 3.3.1. Kaplan-Meier plot of overall survival of ATP-treated (n=28, solid line) and 
control (n=30, dotted line) patients with advanced non-small-cell lung cancer (stage IHB or 
IV). 
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In univariate analysis, weight loss was an unfavorable prognostic factor for 
survival (P=0.03). Subgroup analysis for weight-losing patients stage IJIB and stage 
IV separately (adjusting for age and body weight at randomization) demonstrated a 
significant survival benefit of ATP-treatment given to stage IJIB patients with <':5 % 
weight loss before randomization (Figure 3.3.2): median survival in ATP-treated 
patients (n=8) was 9.3 months (95% CI = 2.1 to 16.5) compared to 3.5 months 
(95% CI = 2.3 to 4.7) in control patients (n=8; between-group difference: P=0.02). 
Baseline characteristics of these patien", are shown in Table 3.3.2. No significant 
survival difference was seen in weight-losing patients with stage IV: ATP-treated 
patients (n=9) died after a median of3.1 months (95% CI = 2.6 to 3.6), and control 
patients (n= 10) after 2.3 months (95% CI = 0.0 to 6.8). 
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Figure 3.3.2. Kaplan-Meier survival plot for a subgroup of eight ATP-treated (solid line) and 
eight control (dotted line) patients with stage IlIB non-small-cell lung cancer and 5% weight 
loss at randomization. 
Treatment as cointervention 
Three months after randomization one patient in the control group (stage [JIB, no 
weight loss) was treated with combination chemotherapy, which consisted of five 
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courses of a combination of cisplatin and etoposide, given at 3-week intervals, 
followed by radiotherapy involving all lesions. One year after randomization one 
patient in the ATP group was enrolled in a phase I trial with six courses of PNU-
159548 <an alkylcycline). Palliative radiotherapy was administered to seven patients 
in the control group, and to six patients in the ATP group. 
Table 3.3.2. Baseline patient characteristics of stage lIIB patients with weight loss 
AlP Control 
(n = 8) (n = 8) 
Gender 
male 6 (75%) 5 (63%) 
female 2 (25%) 3 (37%) 
Age (y) 66 ± 14 59 ± 7 
Tumor histology 
adenocarcinoma 1 (13%) 0(0%) 
squamous-cell carcinoma 4 (50%) 5 (63%) 
undifferentiated large cell carcinoma 1 (13%) 2 (25%) 
unspecified 2(25%) 1 (12%) 
Previous chemotherapy 
yes 3 (37%) 3 (37%) 
no 5(63%) 5 (63%) 
Karnofsky Index (%) 
<70 4 (50%) 4 (50%) 
> 70 4 (50%) 4 (50%) 
Prior weight loss (kg)' 9.3 ± 5.2 9.8 ± 3.7 
Prior weight loss (%)* 10.4 ± 4.5 14.2 ± 7.0 
Weighl (kg) 78.4 ± 27.8 63.9 ± 16.2 
80dymass index (kglm2) 26.3 ± 9.0 22.4 ± 5.0 
Findings are expressed either as a percentage in brackets or as mean ± standard deviation. 
* Weight loss in relation to pre-illness weight. 
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DISCUSSION 
This is the first randomized clinical trial to examine the effects of intravenous ATP 
infusions on tumor growth and survival in patients with advanced NSCLC (stage IlIB 
or IV). In the present study, ATP did not contribute to objective tumor response. 
Furthermore, no effect of ATP treatment on overall survival of this patient group was 
demonstrated. Univariate analysis showed that patients with weight loss prior to 
randomization survived significantly shorter than patients without weight loss. This 
finding is consistent with earlier reports which show that weight loss is an 
unfavorable prognostic variable for survival. 116,407,440 We previously reported7 that 
ATP inhibited weight loss in these patients, while weight loss continued in patients 
not receiving ATP infusion. Our data suggest that in the subgroup of weight-losing 
patients with stage IIIB NSCLC, ATP treatment did have a survival benefit. This 
effect could not be attributed to differences in baseline characteristics since both 
treatment arms were well balanced, except for age and body weight for which the 
survival a(lalysis was adjusted. It is possible that the observed survival benefit in 
these patients with non-metastatic disease is related with the inhibition of weight loss 
by ATP. 
We conclude that despite its beneficial effect on weight loss and quality of life,7 
ATP as a single therapy did not affect tumor response or increase survival in patients 
suffering from advanced NSCLC, stage IlIB or IV. Nevertheless, despite the lack of 
a direct anti-tumor effect in these patients, treatment with ATP may be worth further 
study. Firstly, our data suggest that ATP infusions may prolong survival in weight-
losing stage IIIB lung cancer patients, possibly by reducing weight loss. Secondly, 
several animal model studies demoI\strated ATP-induced inhibition of tumor 
growth. 134,161,239,301,309,327,344,345,347,348 Thirdly, ATP has been reported to 
potentiate the cytotoxic effect of chemotherapeutic agents36,222,281 and 
radiotherapy,134,448 and could therefore be examined as an adjuvant to these therapies. 
We conclude that further phase III studies of ATP in non-metastatic cancer patients 
with weight loss are warranted. 
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ABSTRACT 
Intravenous adenosine has been shown to reduce pain in animals, healthy volunteers 
and several patient groups, but no data are available on the effects of adenosine in 
cancer pain. The present pilot study was aimed at exploring the potential value of 
intravenous adenosine infusion for relief of nociceptive pain in advanced cancer 
patients. Six cancer patients with no satisfactory pain relief from previous therapy 
were included. After two days of baseline, two four-hour infusions were administered 
on two successive days, with one day of follow-up. Pain scores were assessed by 
numerical rating scale. (NRS), verbal rating scale (VRS), and pain relief scale. Scores 
over time were tested by repeated-measures analysis SAS Proc Mixed. Pain scores 
for both NRS and VRS decreased significantly during adenosine treatment as 
compared to baseline (P=O.OOOl). The mean NRS (± SD) decreased from 5.5± 10 
at baseline to 3.2±1.8 during the first adenosine infusion, and 2.2±1.5 during the 
second infusion. The VRS decreased from 3.8±0.6 at baseline to 2.7±0.7 during the 
first infusion, and 2.2±0.9 during the second adenosine infusion. At follow-up, pain 
scores were still reduced, with values of 2.8±1.7 for NRS and 2.2±0.6 for VRS. 
Compared to baseline, three patients decreased > 2 points on the NRS (strong-
responder) during the two adenosine infusions, one patient > 1 point (weak-
responder), and one decreased < 1 point (non-responder). There was a significant 
correlation between NRS and pain relief score of r=-0.63 (P<O.OOI). The mean 
number of rescue doses was reduced by approXimately 50%, i.e., from 2.3 ±2.2 per 
day at baseline to 1.2± 1.2 per day at fallow-up (P=O.l1). The analgesic effects of 
adenosine suggested by this exploratOlY study warrant further study in patients with 
cancer pain. 
INTRODUCTION 
Pain is reported by over 70% in advanced cancer337 and can be a major cause of 
anxiety, depression, or anger. Pain is treated according to the analgesic ladder of the 
WHO. When these steps fail, more invasive methods are indicated. 
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During the last decade, it has been shown that adenosine may relieve pain in both 
animal models I75 ,240,371,372)85 and man. Randomized blinded studies show pain-relief 
effects of intravenous adenosine infusion in healthy volunteers (50 to 70 
~lg/kg.min),380.399 patients with neuropathic pain, hyperalgesia and allodynia (50 
~lg/kg.min),24,400 and in breast379 and gynecological surgery (80 ~lg/kg.min). 382 In one 
study, adenosine infusion contributed to reduction of perioperative isofluorane and 
opioids postoperatively.382 Combination of adenosine with mOlphine or ketamine may 
have an additive effect on pain reduction as shown in a double-blind, placebo-
controlled, cross-over study in healthy volunteers. 381 
Because no data are available on the effects of adenosine in can,cer, we conducted a 
pilot study aimed at exploring the potential value of intravenous adenosine infusion on 
nociceptive pain of advanced cancer. 
PATIENTS AND METHODS 
Patients with localized cancer pain due to radiologically documented tumor, a pain 
score of <:4, and requiring opioid therapy were eligible. Patients with failure of either 
liver (bilirubine > 40 ~unolll), kidneys (creatinine > 200 flmol/l), heart, or those 
undergoing chemotherapy or radiotherapy < 6 weeks before the study, were 
excluded. The study was approved by the Protocol Review Board and the Medical 
Ethical Connnittee of the Daniel den Hoed Cancer Center. Written informed consent 
was obtained from all patients prior to the study. 
Treatment schedule 
Patients were admitted to the Palliative Care Unit or the Outpatients Center of Daniel 
den Hoed Cancer Center to receive two intravenous adenosine infusions during four 
hours on two successive days. At approximately nine hours a.m., adenosine infusions 
(5 mg adenosine per ml NaCl 0.9%) were started at a rate of 20 flg/kg.min and 
increased by increments of 10 ~lg/kg.min every 15 minutes until a maxinlUm dose of 50 
~lg/kg.min, or the maximally tolerated dose if lower, had been reached. Thereafter, 
adenosine was infused at a continuous rate. If side effects occurred, the dose was 
reduced to the last given dose or lower until side effects disappeared. During the time 
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of the study, patients were not allowed to take coffee or tea with caffeine because of 
potential reversal of pain reduction by adenosine. 371 
Pain assessment 
Pain scores were recorded three times per day on two consecutive days at baseline, 
the two days of adenosine infusion, and the day of follow-up: i.e., in the morning, 
afternoon, and evening. In addition, patients scored the pain questionnaire every hour 
during the four hours of adenosine infusion. Pain intensity was assessed using a 
numerical rating scale ranging from 0 to 10 (NRS),324 a verbal rating scale (VRS) 
recorded as either no pain (1), slight (2), mild (3), considerable (4), severe (5), or 
excruciating (6), and a pain relief scale recorded as either complete (5), considerable 
(4), moderate (3), slight (2) or no pain relief (1) and pain worse (0).252,280,442 These 
scales were recorded in a pain diary. Patients were allowed to continue the use of 
opioids therapy either orally or intravenously. As rescue medication, patients took 10 
or 20 mg morphine sulphate orally, or received intravenous morphine doses. The 
numbers of rescue medications used were recorded by the patients in the diary, and 
verified in the patient's medication list which was kept at the ward. 
Side effects 
Side effects were monitored according to Common Toxicity Criteria version II 
(National Cancer Institute) scaled on a 4-point scale according to seriousness. In this 
system, dyspnea is graded as follows: 0, no change; 1, not defined; 2, dyspnea on 
significant exertion; 3, dyspnea at normal activity; 4, dyspnea at rest. In general, 
toxicity was graded as: 1, mild; 2, moderate; 3, severe; and 4, life-threatening. During 
adenosine infusions, electrocardiographics, heart rate, and blood pressure were 
monitored using a data-scope (Propaq, Protocol Systems Incorporated, Beaverton, US) 
Statistical analysis 
The mean scores of NRS and VRS were calculated for each patient. The baseline 
assessment was the mean score of the seven pain assessments before the first 
adenosine infusion. Treatment effects were calculated from the mean pain score 
during the first adenosine infusion (four scores), during the in-between infusion 
period (three scores), during the second adenosine infusion (four scores), after 
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discontinuation of the second adenosine infusion (two scores), and during one day of 
follow-up (three scores). The individual response rate was assessed by comparing 
pain scores during both adenosine infusions to the baseline scores. Patients were 
classified as non-responder (decreasing < I point on NRS), weak-responder 
(decreasing I point but <2 points on NRS), or strong-responder (decreasing 2 
points on NRS). Pain scores over time were tested by repeated-measures analysis 
using the SAS procedure Proc Mixed (SAS Inc., Cary, N.C. USA). This technique 
has been recommended to analyze all observations and time-varying covariates data 
simultaneously because of its relatively great power277 In order to compare 
repeatedly measured pain scores during and after adenosine treatment with their 
baseline scores, the independent variables in the model were the treatment indicator 
variable, baseline pain scores, measurement time, and interaction between time and 
treatment. In addition, the two-tailed Wilcoxon signed rank test was applied for 
comparing separate time periods with baseline values, using SPSS (SPSS Inc., 
Chieago, USA). The NRS and the pain relief scale were compared using the partial 
correlation coefficient, adjusting for patient. Results are expressed as means ± 
standard deviation (SD). P-values of less than 0.05 indicated significance. 
RESULTS 
Patient characteristics and treatment 
Six cancer patients (foUl' males, two females) with a mean age of 60±1O years and 
weight of 80± 16 kg participated in the study. All patients had previously been treated 
with non-steroidal anti-inflanmlatory drugs or morphine without satisfactory pain 
relief. Clinieal details of the remaining t1ve patients are shown in Table 3.4.1. 
Patient no.6 was not evaluable for pain assessment because he developed progressive 
malaise, headache, chest discomfort, and fever as a result of a radiologically 
confirmed pneumonia approximately one hour after starting adenosine infusion. The 
infusion was discontinued and treatment with intravenous amoxicilinlclavulan acid 
was started, and the patient recovered uneventfully. The five evaluable patients 
received infusion for four hours on two subsequent days with a mean dose of 33 ± 10 
fig/kg/min. Side effects reported during the total of 10 adenosine courses were 
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presented in Table 3.4.2. All side effects resolved within minutes after lowering the 
adenosine dose. Patient no.! did not report any side effects. Heart rate, systolic and 
diastolic blood pressures did not change during adenosine infusions. 
Table 3.4.1. Baseline patient characteristics 
Patient Age/sex Weight Type of 
cancer 
Localization 
of pain 
Pain treatment· 
(no) (kg) 
64m 
2 63 f 
3 61 f 
4 69m 
5 59m 
60 renal cell 
carcinoma 
lumbar 
75 non-Hodgkin lumbar 
lymphoma 
morphine iv 18 mgth 
naproxen 500 mg tid 
ms contln 60 mg bid 
103 breast lumbar/sacral diclophenac 100 mg bid 
73 
carcinoma 75fd 
chandra 
sarcoma 
sacral morphine sc 1mg/h 
87 aggressive subscapular nabumeton 500 mg lid 
fibromatosis phenlany[ patch 50 ~g/h 
amitriptylln 10 mg tid 
Morphine reset 
(mg) 
20 (iv) 
o 
o 
20 (orally) 
10 (orally) 
6 40m 69 adenoid 
carcinoma 
head phentanyl patch 75 ~lg/h 20 (orally) 
amilriplytin 10 mg tid 
Adenosine 
blg/kg,min) 
50 
25 
30 
35 
25 
o 
* Continuous pain treatment prior to and during adenosine infusion; f Rescues need throughout this study 
Pain relief 
Pain scores for the NRS showed a highly significant overall decrease during 
adenosine treatment compared to baseline (Figure 3.4.1; repeated-measures analysis: 
P=O.OOO!). The mean NRS (±SD) decreased from 5.5±10 at baseline to 3.2±1.8 
during the first adenosine infusion (Wilcoxon's signed rank test: P=O.OB), 3.4±2.2 
during the between-infusion period (p=O.OB), and 2.2± 1.5 during the second 
infusion (P=O.04). After discontinuation of tlie adenosine infusion on the second day, 
patients maintained significant pain reduction compared to baseline with a mean NRS 
of 2.8± 1.9 (P=O.04). On follow-up, the pain intensity was still reduced with a NRS 
of 2.B± 1.7 (P=O.04). A similar pattern was shown for the VRS which showed a 
significant reduction during adenosine treatment (repeated-measures analysis: 
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P=O.OOOI). The VRS decreased from 3.8±0.6 to 2.7±0.7 during the first adenosine 
infusion (P=0.08), to 2.8±0.9 between the two successive adenosine infusions 
(P=0.04), and to 2.2±0.9 during the second adenosine infusion (P=0.04). After 
discontinuation of adenosine infusion, the VRS pain score was still reduced at 
2.6± l.l (P=0.04), and 2.2±0.6 on the next day (P=0.07). 
Table 3.4.2. Side effects ascribed to adenosine during a total of 10 intravenous 
cycles (25-50 ~g/kg.min during 4 hours); eTe grading 
Grade: 0 2 3 4 
Chest discomfort 7 
Flushing 7 
Lightheadedness 9 
Headache 9 
Dyspnea 9 
Urge to take a deep breath 5 
3 
3 
o 
5 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
There was a significant correlation between the NRS and the pain relief scale of 
r=-0.63 (P< 0.001). As shown in Table 3.4.3, the mean number of rescue doses 
was reduced by approximately 50%, Le., from 2.3±2.2 per day at baseline to 
1.2±1.2 per day on follow-up (P=O.ll). On the NRS, patients no.2, 4, and 5 were 
strong-responders, patient no.3 was a weak-responder, and patient no.1 a non-
responder. 
Table 3.4.3. Number of morphine rescues needed per day 
oat Morphine rescues t P-valuet 
1 and 2 2.3 ± 2.2 
3 2.2 ± 2.0 0.28 
4 1.2±1.2 0.11 
5 1.2±1.2 0.11 
* Day I and 2 (baseline), day 3 and 4 (4-hour during adenosine infusions), 
and day 5 (follow-up) 
t Mean ± standard deviation 
: Compared to baseline (Wilcoxon signed-rank test) 
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Figure 3.4.1. Plot of mean (±SEM) pain intensity by numerical rating scale (NRS) on day 1-2 
(baseline, mean of seven scores), day 3 (during 4 hours of adenosine infusion, mean of four 
scores, respectively interval, mean of three scores), day 4 (during 4 hours of adenosine 
infusion, mean of four scores, respectively follow-up. mean of two scores), and day 5 (follo~v­
up, mean of three scores). Scores at days 3 to 5 compared to days 1-2 as tested by repeated-
measures analysis: P~O.OOOI. *) P< 0.05 (two-tailed Wilcoxon Signed Rank Test). 
DISCUSSION 
The aim of this pilot study was to explore potential pain reduction by intravenous 
adenosine infusion in advanced cancer. The rationale for using adenosine was based 
on studies reporting adenosine-induced pain relief in animals,175,371,372,385 healthy 
volunteers380,381 and patient groups.24.379,380,382,400 As far as we know, no clinical 
studies on intravenous adenosine in cancer have been performed to date, 
In the present study, five cancer patients suffering from nociceptive pain, without 
satisfactory pain relief from previous therapy received adenosine infusion for 4 hours 
on two subsequent days. Results based on the NRS, VRS, and pain relief scale showed 
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that adjuvant adenosine infusion reduced pain intensity substantially. Pain scores 
decreased by more then 50% on the second day of adenosine infusion compared to 
baseline. In spite of the short plasma half-life of adenosine (0.6 to 1.5 seconds after a 
bolus injection),294 pain scores were still reduced one day after adenosine 
administration, suggesting that adenosine may induce prolonged pain relief. This is in 
line with findings in animals240 and healthy humans.24 Adenosine infusion for 45 to 60 
minutes reduced evoked pain in six out of seven healthy subjects for periods varying 
from six hours to four days.24 
Adenosine was administered as a constant intravenous infusion without any severe 
side effects. If side effects occurred, they disappeared rapidly on lowering the inftlsion 
rate. The reported side effects were mostly of type 1. Although during one patient 
showed dyspnea (type 4), this was mild of cbaracter. 
Several mechanisms may explain the pain-reducing effects of adenosine. In the 
periphery, adenosine Al receptor activation induces suppression of pain. Adenosine 
Al receptors are present on the cell body of dorsal root ganglion cells270 and on the 
central tenpinals of primary afferent neurons,368 so tbat transport of these receptors 
to the peripheral aspect of this nerve is likely.370 Within the dorsal spinal cord, 
concentrated in the substantia gelatinosa,17.78.170 the antinociceptive effects are media-
ted through activation of both Al and A2 receptors.370-372 Possibly, central receptor 
stimulation by adenosine contributes to spinal hyperexcitabilitl40.4OO which may 
explain the prolonged duration of pain reduction. It is also conceivable that adenosine 
may counteract inflammatory processes contributing to cancer pain. Adenosine has 
been shown to inhibit neutrophil degranulation,43 neutrophil superoxide production,43 
anti-oxidant activation.273.340 adhesion of neutrophils.98 and expression of adhesion 
molecules.45 Adenosine has also beel) observed to inhibit the production of 
cytokines,44,45.453 eicosanoids.232 and complement.238 
In conclusion, this pilot study demonstrates a substantial reduction in pain scores 
during and after intravenous adenosine infusion in patients with cancer. If side effects 
occur. they are mild and transient, resolving within minutes of lowering the 
adenosine dose. Further study of analgesic effects of adenosine as a new modality in 
pain treatment seems warranted. 
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AnSTRACT 
Objective: To characterize the pharmacokinetics of adenosine 5'-triphosphate (ATP) 
in patients with lung cancer after intravenous administration of different ATP 
dosages. 
Methods: Twenty-seven patients received a total of 176 intravenous ATP courses of 
30 hours. Fifty-two courses were given as low-dose infusions of 25-40 flg/kg.min, 47 
as middle-dose infusions of 45-60 flg/kg.min, and 77 as high-dose infusions of 65-75 
fIg/kg. min ATP. Kinetic data of ATP concentrations in erythrocytes were available 
from 124 ATP courses. Results are expressed as means ± SEM. 
Results: Most ATP courses in cancer patients were without side effects (67%), and 
side effects occurring in the remaining courses were mild and transient, resolving 
within minutes after decreasing the infusion rate. Baseline ATP concentration in 
erythrocytes was 1554 ± 51 flM. ATP plateau levels at 24 hours were significantly 
increased by 53±3, 56±3, and 69±2% after low-dose, middle-dose and high-dose 
ATP infusions, respectively. At the same time, significant increases in plasma uric 
acid concentrations were observed: 0.06±0.01, O.li±O.OI, and 0.16±0.01 mM, 
respectively. The mean l'lz for disappearance of ATP from erythrocytes, measured in 
five patients, was 5.9±0.5 hours. 
Conclusions: During constant intravenous infusion of ATP in lung cancer patients, 
ATP is taken up by erythrocytes and reaches dose-dependent plateau levels 50 to 70% 
above basal concentrations at approximately 24 hours. 
INTRODUCTION 
Extracellular adenosine 5' -triphosphate (ATP) is involved in the regulation of a 
variety of biological processes including neurotransmissioll, muscle contraction, 
cardiac function, platelet function, vasodilatation, and liver glycogen metabolism. 
ATP can be released from the cytoplasm of several cell types and interacts with PI 
and particularly P2 receptors on the surface of many cells. These receptors playa 
fundamental role in cell physiology and are also a potential target in the treatment of 
various diseases, including paroxysmal supraventricular tachycardias,475 pulmonary 
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hypertension,168 shock,46 and pain syndromes.371 Furthermore, there is evidence that 
A TP administration may inhibit the growth of tumor cells and implanted tumors.3,345 
The range of physiological ATP concentration within mammalian cells is 1500 to 
4800 J.lM. ATP content in tissue cells is somewhat higher than in blood cells.432 In 
human erythrocytes ATP concentrations have been described to be between 1500 and 
1900 J.lM. 112,429,463 Much lower ATP concentrations have been reported for human 
plasma, in general a factor 1000 below erythrocyte ATP concentrations. 150.184 
When adenine nucleotides are administered intravenously, the nucleotides are taken 
up by erytllrocytes.431 Using suspensions of washed intact human erythrocytes and 
labeled purines, Parker et al.330 found that ATP was metabolized outside the cell via 
ADP and AMP to adenosine. Adenosine rapidly entered the erytllrocytes where it was 
incorporated into adenine nucleotides. At extracellular adenosine concentrations below 
3 ~IM, most intracellular adenosine was phosphorylated to adenine nucleotides, whereas 
at higher extracellular adenosine concentrations, adenosine was degraded to inosine and 
hypoxanthine within the erythrocytes. 375 
There is little information about pharmacokinetics of administered ATP in humans. 
In a phase I study, Haskell et al. 188 measured whole blood levels of ATP during 96 
hours of continuous intravenous ATP infusions in 14 patients with advanced cancer of 
different tumor types. Continuous ATP infusion of 50 ~Ig/kg.min induced a mean 63% 
increase in whole blood ATP levels in these patients after 24 hours. A higher dose of 
ATP infusion of 75 J.lg/kg.min gave only a marginally greater increase (67%). This 
study however did not provide information on the time interval until plateau values 
were reached. Furthermore, no study has attempted to detemtine washout parameters of 
ATP from blood cells. 
Recently, in a randomized clinical trial ill patients with advanced nOll-small-cell 
lung cancer, we demonstrated that ATP infusions contribute to maintenance of body 
weight, muscle strength, and quality of life in these patients. 7 The present 
pharmacokinetic study was aimed at investigating the ATP increase in erythrocytes 
during intravenous A TP infusion at different doses in patients participating in this 
trial. Furthermore, we wanted to determine the half-time (/'h) of disappearance of 
ATP from erythrocytes, which is needed to design an optimal dosing schedule. 
Finally, we attempted to measure changes in ATP concentrations in plasma during 
ATP infusion. 
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METHODS 
Patients 
The study protocol was approved by the Medical Ethics Committee of the Erasmus 
University Medical Center Rotterdam. Written informed consent was obtained from 
each individual prior to the study. In the A TP group were included 28 patients (20 
male and eight female) with locally advanced and metastatic non-small-cell lung 
cancer (stage lIIB or IV), of mean age 64 (range 30 to 85) years, and weight 75 
(range 54 to 133) kg. None had respiratory, cardiac, hepatic or renal failure. Baseline 
characteristics of the patients are listed in Table 4.1. 1. 
Design 
A maximal number of 10 A TP courses of 30 hours were given: the first seven 
courses at 2-week intervals, and thereafter three ATP courses at 4-week intervals. 
Eleven patients received one to three courses, five patients four to six, and II 
patients received seven to ten ATP courses. 
ATP treatments were started after an overnight fast of 10 to 12 hours, between 
9.00 and 11.00 hours. ATP was infused over 30 hours through a peripheral vein 
using an A Vl270ClR infusion pump. ATP infusions were started at 20 f'g/kg.min and 
increased by increments of 10 "g/kg.minevery 30 minutes until the maximum dose of 
75 J.lg/kg.min, or until the maximally tolerated dose (MTD) , if this was lower, had 
been reached. Thereafter, ATP was infused at a continuous rate. If any side effects 
occurred, the dose was reduced to the last given dose or further until side effects 
disappeared. Occurring side effects were registered systematically. 
Sampling 
Prior to ATP administration and at 4,7, 12,24,28 and 30 hours after starting ATP 
infusion, venous blood was sampled into EDT A tubes from the arm opposite to the 
arm in which ATP was infused. Half of the blood samples was iImnediately placed 
into separate cryo-tubes, and then frozen in liqUid nitrogen at -80 'C. The other half 
was immediately centrifuged for 10 min 1300 x g at 4 'C. Samples of plasma were 
also placed into separate cryo-tubes, and then frozen in liquid nitrogen at -80 'C. In 
order to obtain a more detailed estimate of time-concentration relationship and the 
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washout rate of ATP, in five patients blood samples were drawn at shorter time 
intervals during both the ATP course and the 12 hours after termination of the ATP 
infusion. Uric acid levels were measured at 0, 24, and 30 hours after starting ATP 
infusion. Information about the rate of renal uric acid clearance (CLR) was obtained 
from six patients who collected urine during 24 hours before treatment and during 30 
hours while ATP was being infused. 
Chemicals 
Adenosine 5'-triphosphate (ATP-NadH20) of >98% purity was obtained from 
Merck (Darmstadt, Germany) in 50 grams vials; 6.1 grams ATP were solved in 
I liter NaCI 0.9%, sterilized by ultrafiltration (0.2 ~M), and supplied in sterile glass 
bottles. As tested by the method using hexokinase and glucose-6-phosphate 
dehydrogenase,3! the obtained ATP solution was stable for at least 5 months at 
-20 "C, and >5 days at room temperature. Perchloric acid (71%) and other 
chemicals were also from Merck. 
Laboratory analyses 
Whole blood and plasma samples were deproteinized by addition of perchloric acid to 
obtain a final concentration of 4 % and centrifuged for 10 min 14000 x g at 4 'C. The 
supernatant was neutralized (pH 6-7) with 2 M K2COJ in 6 M KOH, and the sample 
was kept cold to precipitate the potassium perchloride. After storage at -20 'C the 
supernatant was taken for high-performance liquid chromatograph (HPLC) analysis of 
ATP. Analyses were performed on a Shandon Hypersil ODS (CI8) column ISO nnn 
x 4.6 nnn 3 U with a flow rate of 1.0 ml/min at room temperature, using a 0.1 M 
phosphate buffer (pH 6.0) as eluens. Identification and quantification of the samples 
was performed by comparing peak areas with appropriate standards. Peaks were 
detected by absorption at 254 nm and were identified by retention time. 377 Because 
A TP concentrations in erythrocytes have been reported to be a factor 1000 above 
plasma ATP concentrations, !50.t84 ATP concentration levels in the erythrocytes were 
calculated by dividing measured ATP concentrations in whole blood by individual 
hematocrit values. 
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Table 4.1.1. Baseline characteristics of the patients 
Patient Tumor Sex Age Weight Hematocrit Erythrocyte ATP Plasma uric acid 
(no) stage (mlf) (y) (kg) (III) ~M mM 
38 m 71 79.0 0.31 1261 0.27 
2 38 m 73 55.8 0.31 1535 0.27 
3 38 m 74 70.8 0.43 1698 0.29 
4 38 60 61.7 0.40 0.31 
5 38 m 76 89.6 0.48 1071 0.37 
6 38 m 48 79.7 0.39 1431 0.31 
7 38 m 41 87.9 0.32 1581 0.26 
8 38 m 46 80.2 0.34 1850 0.48 
9 38 m 85 53.9 0.40 1423 0.28 
10 38 m 71 71.0 0.44 1771 0.34 
11 38 m 54 74.5 0.45 1624 0.40 
12 38 65 133.2 0.38 0.36 
13 38 m 77 81.6 0.40 0.26 
14 4 62 68.2 0.38 1553 0.34 
15 4 m 69 70.8 0.39 1921 0.38 
16 4 m 30 71.6 0.32 1981 0.50 
17 4 m 82 75.4 0.40 1500 0.33 
18 4 m 73 60.2 0.37 1768 0.51 
19 4 71 74.7 0.41 1385 0.28 
20 4 m 77 66.6 0.33 1327 0.25 
21 4 52 65.0 0.42 1538 0.37 
22 4 57 57.5 0.31 2069 0.24 
23 4 m 66 68.4 0.36 1311 0.46 
24 4 53 69.0 0.31 1703 0.19 
25 4 m 68 114.0 0.47 1117 0.31 
26 4 m 68 65.5 0.41 1483 0.38 
27 4 62 68.8 0.29 1664 0.28 
28 4 m 67 73.3 0.34 1285 0.42 
-) not determined 
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Side effects 
Side effects were monitored according to Common Toxicity Criteria (National Cancer 
Institute) scaled on a 4-point scale according to seriousness. In this system, dyspnea 
is graded as follows: 0, no change; I, not defined; 2, dyspnea on significant exertion; 
3, dyspnea at normal activity; 4, dyspnea at rest. In general, toxicity was graded as: 
I, mild; 2, moderate; 3, severe; and 4, life-threatening. 
Pharmacokinetic analysis 
Results are expressed as means ± standard error of the mean (SEM). Results of 
independent groups were tested for significance by Student's I-test, and changes in 
time by Student's paired (-test. P-values of less than 0.05 indicated significance. The 
correlation between variables was analyzed using partial correlation coefficient 
controlling for patient. Half-time (tv,) of ATP disappearance from erythrocytes was 
calculated for each patient individually by fitting a mono-exponential curve to the 
washout data, using the software program MicroMath Scientist (Salt Lake City, Utah 
84121, USA). 
RESULTS 
Dosage and side effects 
Twenty-eight patients received a total of 176 ATP courses. Seventy-seven infusions 
were given as high-dose infusions of 65-75 pg/kg.minATP. Because of lower MTD, 
47 infusions were given as middle-dose infusions of 45-60 flg/kg.min ATP, and 52 as 
low-dose infusions of 25-40 fig/kg. min ATP. Side effects observed during the ATP 
infusions are reported in Table 4.1.2. The most frequent side effects were chest 
discomfort (15%) and an urge to take a deep breath (10%) which resolved within 
minutes after lowering the ATP dose. Electrocardiography (ECG) was performed in 
patients with chest pain/discomfort during ATP infusions. No ECG changes 
suggestive of myocardial ischemia were detected. The reactions were most common 
in patients with a history of cardiovascular dysfunction or chronic obstmctive 
pulmonary disease. Heart rate decreased from mean (± SEM) 88 ± I at baseline to 
85±1 beats/minute at 24 hours of ATP infusion (P<O.05). Systolic blood pressure 
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decreased from 129±2 to 127 ±2 (n.s.), and diastolic blood pressure from 75± 1 to 
n±1 IllIll Hg (P<O.005). 
Table 4.1.2. Side effects ascribed to ATP during a total of 176 intravenous ATP cycles (25-75 
).I.g/kg,min) in 28 patients; CTC~~rading. In some courses more then one side effect was observed 
0 2 3 4 
Palpitations 174 2 0 0 0 
Cardiac-ischemia 176 0 0 0 0 
Chest discomfort 150 25 0 0 
Sweating 171 5 0 0 0 
Flushing 168 8 0 0 0 
Injection side reaction 172 0 4 0 0 
Nausea 168 8 0 0 0 
Epistaxis 175 0 0 0 
Lightheadedness 170 6 0 0 0 
Mood alteration-anxiety 173 3 0 0 0 
Headache 171 5 0 0 0 
Dyspnea 171 0 0 0 5 
Take a deep breath 158 18 0 0 0 
Erythrocyte A TP levels before and dnring ATP administration 
Kinetic data of ATP concentrations in erythrocytes were available from 124 courses 
in 23 patients. In erythrocytes, the baseline ATP concentration prior to the first ATP 
course was 1554±51 J.lM. Mean baseline ATP concentrations prior to subsequent 
ATP courses did not show any significant differences from the initial baseline ATP 
concentrations (data not shown). 
We compared the increase in ATP concentrations in erythrocytes during low, 
middle, and high-dose ATP infusion, respectively. At all time points the mean ATP 
values were significantly higher compared to the baseline concentration of ATP 
(P<O.OOI). 
As seen in Fignre 4.1.1, plateau levels of ATP were reached at approximately 24 
hours. In a subgroup of patients in whom blood was sampled at 2-hour intervals, a 
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similar kinetic profile of blood ATP concentrations was observed. Compared to 
baseline levels, low-dose ATP infusions induced a 53±3% increase in erythrocyte 
ATP concentrations (P<O.OOI), and middle-dose ATP infusions a 56±3% increase 
(P<O.OOI), whereas high-dose ATP infusions evoked an increase of 69±2% 
(P<O.OOI). The rise in erythrocyte ATP concentrations after high-dose ATP infusion 
was significantly larger compared to middle-dose (P<0.05) and low-dose (P<O.OI) 
ATP infusions at all times points from 12 to 30 hours. In contrast, erythrocyte ATP 
concentrations during middle-dose ATP infusions did not differ significantly from 
those during low-dose ATP infusions. Nevertheless, a moderate overall dose-level 
relationship was observed at 24 and 30 hours (r=0.56 and r=0.49, respectively, 
P<0.005). 
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Figure 4.1.1. Erythrocyte ATP concentrations before and during intravenous ATP 
administration. Values are expressed as a percentage of baseline at ATP dose 25-40 ).lg/kg.min 
(0, n=35); 45-60 ~tg/kg.min (e, n=23); and 65-75 ~g/kg.min (0, n= 66). Differences as 
compared to middle dose: *) P<0.05, **) P<O.Ol. Data are presented as mean values ± 
SEM. 
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A TP concentrations in erythrocytes from one patient who received 10 successive 
ATP courses of 75 flg/kg,min are plotted in Figure 4.1.2, The standard deviation 
between erythrocyte ATP levels during tile different courses varied from 5 to 9%. 
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Figure 4.1.2. Erythrocyte ATP concentrations in one patient during 10 subsequent ATP 
courses of 75 ~lg/kg.min given as 2~ to 4-week intervals (see methods). Data are presented as 
mean values ± SD. 
Uric acid concentrations in plasma 
Plasma levels of uric acid as a breakdown product of ATP showed a dose-dependent 
increase after 24 and 30 hours of ATP infusions (Figure 4.1.3), Plasma uric acid 
concentrations increased by 0,06±0,01 mM after 24 hours during lOW-dose ATP 
infusion (P<O,OOI), by 0,11±0,01 mM with middle-dose infusion (P<O,OOI), and 
by 0.16±0.01 mM with high-dose ATP infusion (P<O.OOl). At all doses of ATP 
administration mean uric acid concentrations at 30 hours were almost identical to 
those at 24 hours. A significant ATP dose - lU'ic acid level relationship was observed 
both at 24 and 30 hours (r=0.76 and 1'=0.81, respectively, P<O.OOl). There was a 
poor relationship between ATP levels in erythrocytes and uric acid levels in plasma, 
with correlation coefficients 0[0.31 at t=24 hours (P=0.07), and 0.21 at t=30 hours 
(P=0.08), respectively. 
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Figure 4.1.3. Plasma udc acid concentrations (ruM) at baseline (white bars), 24 hours (hatched 
bars) and 30 hours (black bars) with ATP doses of 25-40 flg/kg.min, n=35; 45-60 flg/kg.min, 
n=27; and 65-75 ~,g/kg.min, n=43. Significantly different from baseline: *) P<O.OOI. Data 
are presented as mean values ± SEM. 
DisappeaI"ance of ATP f"om erythrocytes 
Information concerning the rate of disappearance of ATP from erythrocytes after 
termination of the ATP infusion was obtained in five patients. Figure 4.1.4 shows 
that the rates of ATP disappearance in 'these patients were approximately similar 
regardless of ATP infusion doses. ATP concentrations during washout followed a 
mono-exponential pattern, with a I'h of 5.9±O.5 hours. 
ATP concentrations in plasma 
In plasma no increases in ATP concentration were shown during ATP infusions. In 
several patients the data obtained before and during ATP infusions were highly 
scattered (range 0.5 to 8.5 ;IM). 
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Figure 4.1.4. Erythrocyte ATP concentrations in five patients during washout following 
intravenous ATP administration. Values are expressed as differences (~) from baseline values. 
Solid symbols: after low-dose ATP infusion. Open symbols: after high-dose ATP infusion. 
Dr~CUSSION 
The aim of the study was to investigate pharmacokinetics of ATP in erythrocytes in 
patients with lung cancer following intravenous ATP administration, In a subgroup of 
patients the disappearance of ATP from erythrocytes in vivo was measured, 
The mean baseline concentration of ATP in erythrocytes was 1554±51 flM, and 
comparable baseline ATP concentrations were observed prior to the subsequent ATP 
courses, Mean ATP concentrations in lung cancer patients in this study are in 
agreement with values reported by Stocchi et a1. 408 for 10 normal adult controls 
(1501 ±25 flM), but not with their finding of lower erythrocyte ATP concentrations 
in 10 patients with gastrointestinal adenocarcinoma (1099±41 fIM), We checked 
ATP values of erythrocytes in normal healthy subjects (11=9), and observed mean 
values of 1400±60 flM, Thus Stocchi's finding of lower erythrocyte ATP in patients 
with gastrointestinal adenocarcinoma do not seem to apply to patients with bronchus 
carcinoma. 
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A cascade of ectonucleotidases on the surface of endothelial cells is thought to be 
responsible for the hydrolysis of ATP. t78,333,363,365 It has been suggested that the 
ectonucleotidases may regulate plasma nucleotide levels83 and thus have a protective 
function by keeping extracellular ATP and adenosine levels within physiogical 
limits.431 Three types of ectonucleotidases have been described: ecto-ATPases, ecto-
ADPases and ecto-5'-nucleotidases 431 In blood, these enzymes have also been 
detected on erythrocytes,431 leukocytes,83 B-Iymphocytes,18 and both helper and 
cytotoxic T-lymphocytes. 143 In the extracellular space ATP is subject to breakdown 
by ecto-enzymes and xanthine oxidase to form uric acid which is excreted in urine. In 
the present study, continuous ATP infusions induced significant and dose-dependent 
increases in erythrocyte A TP concentrations with plateau levels between 24 and 30 
hours. This is in line with the findings of Haskell et al. 188 who infused ATP for 96 
hours and observed no further rise of ATP in erythrocytes after 24 hours of ATP 
infusion. Uric acid plasma concentrations at 24 and 30 hours were increased when 
compared with initial uric acid plasma concentrations. 
Low-dose ATP infusions (25-40 fIg/kg. min) induced a significant increase in 
erythrocyte ATP concentrations parallel with increasing plasma uric acid 
concentrations. At middle-dose ATP infusions (45-60 flg/kg.min) no further rise in 
erythrocyte ATP concentrations was measured, whereas the degradation of ATP 'was 
further increased as demonstrated by a further rise in uric acid concentrations. High-
dose ATP infusions (65-75 [lg/kg.min) induced not only an even larger increase in 
uric acid levels, but also showed an additional increase in erythrocyte ATP levels as 
compared to low and middle-dose ATP infusion. In order to exclude the possibility of 
ATP-induced inllibition of the CLR of plasma uric acid, we measured the rate of uric 
acid clearance in six patients who collected urine before and during A TP infusion. 
None of these patients who were treated with either low, middle, or high-dose ATP 
infusions, showed any change in uric acid CLR (P=0.91; paired I-test). 
A strong dose-level relationship was observed between ATP dose and uric acid 
concentrations in plasma. In the phase I study by Haskell et al.,188 ATP-infused 
subjects received allopurinol as a standard therapy because the first two subjects 
treated with ATP developed asymptomatic hyperuricemia and uricosuria. In the 
present long-term intervention study, we chose not to give allopurinol since the risks 
of asymptomatic hyperuricaemia are known to be small, and because allopurinol 
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treatment may itself induce side effects such as renal insufficiency, gastric irritation, 
diarrhea, skin rash, and occasionally vasculitis. 183,206 
We found a mono-exponential rate of ATP disappearance from erythrocytes with 
a fill of approximately 6 hours. This is in line with the finding of Rapaport et aJ. 345 
that after uptake of ATP by erythrocytes the subsequent release of ATP into plasma is 
relatively slow. In animal studies, ATP in plasma is rapidly broken down. In these 
studies ATP was administered as a bolus, so that erythrocyte ATP levels would 
increase only slightly. In rabbits, 40 seconds after an intravenous bolus injection of 
ATP only I % of ATP was detected in whole blood.388 Similarly, a bolus of ATP was 
found to be almost completely cleared during a single passage through either perfused 
dog lung35 or perfused guinea pig heart. 323 In a perfused rat lung, Ryan et aJ. 363 
showed a fIll of labeled ATP of less than 3 seconds. 
The few reports on physiological ATP concentrations in human plasma give mean 
values ranging from 0.02 JIM 151 to 10.9 JIM. 185 Determination of ATP in plasma is 
technically difficult as the concentration in plasma is three orders of magnitude lower 
than within. the cells. It is obvious that even limited hemolysis could cause 
considerable elevation of plasma adenine nucleotides184 since as little as 0.1 % 
hemolysis during sampling would double the ATP concentration in plasma. 184 In 
addition, EDTA can induce selective nucleotide release from cells. 83 Other factors 
influencing plasma ATP measurements may be released from platelets,364 thrombus 
formation,289 partial arterial occlusion, and exercise. 151 Furthermore,' the time 
between venous blood sampling and centrifuging may have a marked influence on 
plasma A TP concentrations. It is therefore not surprising that we obtained scattered 
data when attempting to measure ATP in plasma prior to and during ATP infusions. 
In conclusion, our study in cancer patients shows that during continuous ATP 
infusions in a dose range of 25-75 JIg/kg. min, ATP is taken up by the erythrocytes 
and reaches dose-dependent plateau levels within erythrocytes which are 1.5 to 1.7 
fold higher than baseline values at approximately 24 hours. After discontinuation of 
the ATP infusion, ttl, of ATP disappearance from erythrocytes was approximately 6 
hours. ATP infusions can be administered without side effects in the majority of 
courses, and when side effects occur they are mild and transient. Further study of 
ATP pharmacokinetics is warranted in order to optimize the ATP dosage scheme for 
further clinical trials in cancer and other diseases. It would be useful to perform a 
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study with infusions of 25 or 75 ~lg/kg.min ATP, respectively, in order to show 
whether there are differences in clinical results between low and high dose ATP. 
Courses should have a minimal duration of 24 hours to reach a plateau ATP level in 
erythrocytes. Patients suffering from cardiopulmonary disease may receive low dose 
ATP infusion in order to avoid side effects. In view of the observation that 
hyperuricaemia is only transient and asymptomatic, it seems umlecessary to give 
allopurinol in parallel to ATP infusions. 
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ABSTRACT 
Decreased liver adenosine 5'-triphosphate (ATP) levels and phosphorylation status 
have recently been observed in lung cancer patients with weight loss. The aim of the 
present study was to investigate whether ATP infusion restores liver energy status in 
advanced lung cancer patients using "p magnetic resonance spectroscopy (MRS). 
Nine patients with advanced non-small-cell lung cancer were studied one week before 
(baseline) and at 22 to 24 hours of continuous ATP infusion (37 to 75 ~lglkg.min). 
After an overnight fast, localized hepatic "p MR spectra (repetition time 15 sec) were 
obtained and analyzed for ATP and PI content. Ten healthy subjects (without ATP 
infusion) were studied as a control. 
Liver ATP levels in lung cancer patients increased from S.S±O.7% (of total MR-
detectable phosphate; mean ± SEM) at baseline to 12.2±O.9% during ATP infusion 
(P<O.05). These levels were similar to those in healthy subjects (11.9±O.9%). In 
patients with" 5% weight loss, the increase in ATP levels was most prominent (from 
7.9±O.7 to 12.S±1.0%, P<O.OI). 
In conclusion, ATP infusion restores hepatic energy levels in patients with advanced 
lung cancer, especially in weight-losing patients. These changes could have beneficial 
effects on the nutritional status of weight-losing lung cancer patients. 
INTRODUCTION 
Weight loss is a common phenomenon in lung cancer patients and contributes 
significantly to the high morbidity and mortality in this disease. 116,407 Alterations in 
intermediary host metabolism have been frequently described, including elevated 
protein turnover,191,265 glucose production228,425 and Cori cycle activity. 198 In an ill 
vitro study, gluconeogenesis in isolated hepatocytes from sarcoma-bearing rats was 
increased during incubation with lactate as compared to hepatocytes from healthy 
rats,434 This increased gluconeogenesis resulted in a 42% decrease in adenosine 5'-
triphosphate (ATP) levels, whereas in healthy rats no change in A TP was 
observed.434 This suggests that elevated rates of gluconeogenesis in the cancer-
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bearing host may put an increased demand on the energy stores and may contribute to 
weight loss. 
Alterations in hepatic energy status have been well documented in animal models 
of various tumors. Decreased liver phosphorylation status, as observed by increased 
PdATP ratios, was detected in rats bearing prostate tumors 102 01' sarcomas12,5t,374 
and was correlated with increasing tumor burden. 374 It is noteworthy that these 
alterations in liver energy status were already detected before the development of 
weight loss, t69 Decreased liver ATP levels as detected by 31p magnetic resonance 
spectroscopy (MRS) were reported in patients with various tumor types. 104 Recently, 
we reported decreased hepatic ATP and phosphorylation status in weight-losing lung 
cancer patients, when compared with weight-stable patients and healthy controls,247 
In mice bearing colon tumors daily intraperitoneal ATP injections increased total 
liver and erythrocyte ATP pools,348 These increases were associated with a 
significant inhibition of host weight loss348 The present study was aimed at 
investigating whetller continuous ATP infusion increases hepatic A TP levels and 
phosphorylation status in advanced lung cancer patients. 
SUBJECTS AND METHODS 
Subjects 
The study was approved by the Medical Ethical Connnittee of the Erasmus University 
Medical Center Rotterdam, All patients signed informed consent. Eligible for the 
study were patients with histological 01' cytologically proven non-small-cell lung 
cancer (NSCLC), stage IllB 01' IV (WHO grading system) without curative options, 
and Karnofsky index of 60% or more. Patients with cognitive dysfunction or liver, 
renal, respiratory, or heart failure, and patients undergoing surgery, concurrent 
chemotherapy, or radiotherapy involving all lesions were excluded. Ten healthy 
subjects (age range 37 to 69 years; body weight 76.4±3,6 kg (mean ± SEM» were 
included as a controL 
Study design 
In nine patients (seven males, two females) liver energy and phoshorylation status 
were studied using 31p MRS one week before (baseline) and during continuous ATP 
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infusion, i.e., 22 to 24 hours after starting ATP infusion. The patients received ATP 
infusion doses varying from 37 to 75 tlg/kg.min. Clinical characteristics of these 
patients are listed in Table 4.2.1. Healthy control subjects were only studied at 
baseline. ATP infusions (6.1 mg ATP-NadH,O per ml NaCI 0.9%) were given with 
an initial dose of 20 Ilg/kg.min and increased by increments of 10 Ilg/kg.min every 
30 min until a maximum dose of 75 Ilg/kg.min, or until the maximally tolerated dose 
had been reached. If any side effects occurred, the dose was reduced to the last given 
dose or further until side effects disappeared, usually within minutes after lowering 
the ATP dose. Thereafter, ATP was infused at a continuous rate. The most frequently 
occurring side effects were chest discomfort and the urge to take a deep breath. 
Table 4.2.1. Characteristic of non-small-cell lung cancer patients 
Patient Gender Age TUmor Weight Weight change* ATP dose 
(no) (mit) (y) stage (kg) (%) (jlg/kg.min) 
m 85 38 54.9 -10.2 75 
2 m 75 38 70.8 -1.7 67 
3 m 71 38 71.8 -4.2 75 
4 m 49 38 77.1 -1.0 75 
5 m 76 38 91.1 -11.7 42 
6 57 4 56.6 -22.5 40 
7 52 4 64.2 -9.0 75 
8 m 68 4 65.1 -0.3 37 
9 m 31 4 71.6 -20.4 67 
Mean±SEM 63 ± 6 69.2 ± 3.7 -9.0 ± 2.7 61 ± 6 
* Prior to MRS 
3lp MR spectroscopy of the liver 
Subjects were snldied after an overnight fast. MRS studies were performed with a 
whole-body MR system equipped with a Helicon magnet operating at 2 T (Vision 
Magnetom, Siemens AG, Erlangen, Germany). A 16 em diameter transmit/receive 
'H/31p surface coil was used for MRI localization, shimming and 3lp MR 
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spectroscopy. Elastic bands were used for positioning the coil lateral to the liver in 
the mid-axillary plane. Field homogeneity achieved in shimming resulted in water 
peak line widths which were usually less than 40 Hz (,,0.5 ppm). After obtaining an 
image of the region of interest, a one-dimensional chemical shift imaging (ID-CSI) 
sequence was applied on a transverse slice of 4 cm centered on the surface coil and 
the liver (lx4 phase-encoded matrix, field of view 40x40 cm'), yielding volumes of 
40x1Ox4 cm3394 Spectra were collected with a 640 msec Hanning-sinc shaped radio 
frequency pulse resulting in a flip angle of 135 0 in the center of the coil, where a 
methylene diphosphonate reference sample was positioned, and 60 0 (weighted 
average) in the liver volume. Spectra with repetition time of 15 sec (10 acquisitions) 
were obtained in each patient examination. Time domain data were Fourier 
transformed after Gaussian multiplication (center: ° msec, width 30 msec) and phase 
corrected. Quantification of spectral peak areas was performed using Numaris-3 
software package (Siemens AG, Erlangen, Germany) including polynomial baseline 
correction followed by frequency domain curve fitting. 393 Metabolite concentrations 
were calculated from peak areas and expressed relative to total MR-detectable 
phosphate as previously described104 ATP infusion did not change total liver 
phosphate levels (data not shown). 
Statistics 
Results are presented as means ± standard error of the mean (SEM). Changes of 
liver ATP concentrations and Pi IATP ratios during ATP infusion were tested for 
significance using Student's paired I-test. Between-group differences were compared 
using the Student's I-test for independent groups. Pearson's correlation coefficients 
were calculated to investigate possible relationships between parameters. P-values of 
< 0.05 indicated statistical significance. 
RESULTS AND DISCUSSION 
Baseline ATP levels in the liver of lung cancer patients were significantly lower than 
in healthy subjects (P<0.05, Table 4.2.2). When patients were stratified for 
presence of weight loss, it was shown that ATP levels in patients with ;,,5 % weight 
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loss were as much as 34% lower than in healthy subjects (P<O.05, Table 4.2.2). In 
contrast, ATP concentrations in patients with < 5 % weight loss were not significantly 
different from healthy controls. During ATP infusion, liver ATP levels in lung 
cancer patients increased by 48± 15% (P<O.05) reaching levels similar to those in 
healthy subjects (Table 4.2.2). In lung cancer patients with <: 5 % weight loss, ATP 
increased by 64±9% (P<O.OI). 
Table 4.2.2. Liver energy and phosphorylation status as observed by "P MRS in healthy 
subjects and advanced lung cancer patients before and during infusion of adenosine 
triphosphate (37 to 75 )lg/kg.min)' 
Healthy Lung cancer 
Total <5% weight loss ~5% weight loss 
(n = 10) (n = 9) (n = 4) (n = 5) 
ATP' 
Baseline 11.9 ± 0.9 8.8 ± 0.7' 10.3±1.3 7.9 ± 0.7' 
During ATP infusion 12.2 ± 0.9! 11.5±1.5 12.8 ± 1.0! 
P/ATP 
Baseline 0.73 ± 0.16 0.94 ± 0.15 0.77 ± 0.21 1.07 ± 0.21 
During ATP infusion 0.68 ± 0.11 0.68±0.11 0.68 ± 0.19 
iMean±SEM 
lExpressed as percentage of total MR-dclcclabJe phosphate 
Significance of difference from healthy subjects: *) P<O.05; significance of difference from baseline: 
t) P<0.05, t) P<O.Ol 
PJ ATP ratios during ATP infusion decreased to levels close to those in healthy 
subjects, although none of these changes were statistically significant. No significant 
correlations were observed between ATP dose and the change in liver ATP or 
phosphorylation status (r=0.08 and r=0.28, respectively). 
To our knowledge, no earlier studies have addressed the effect of ATP infusion 
on ATP concentrations in the liver of human subjects. In tumor bearing mice, single 
intraperitoneal injections of ATP increased total liver ATP pools from 3.2 to 8.3 
mM.348 Following this expansion of liver ATP pools, erythrocyte ATP levels 
increased from 0.6 to 2.4 mM 348 In patients in the present study we measured whole 
blood ATP concentrations of 0.71±0.02 mM at baseline. After 22 to 24 hours of 
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ATP infusion, blood ATP levels increased to plateau levels of 53±3 to 69±2% 
above baseline, depending on the ATP dose given. 
It could be argued that the observed increase in liver ATP levels in the present 
study might be caused by contamination of MR spectra by ATP in blood circulating 
in the liver voxel, due to elevated erythrocyte ATP concentrations andlor 
vasodilation. Although A TP concentrations in humans are three to four times higher 
in liver38,202 than in erythrocytes,112.429,463 and ATP infusions were reported to even 
further increase liver ATP levels in mice,348 no data are available on the contribution 
of ATP from blood to the 31p MR signal of liver ATP in humans ill vivo. Therefore, 
an estimation of ATP contamination from blood was made using in this study 
measured whole blood ATP concentrations of 0.7 mM, and assuming a liver ATP 
concentration of 2.5 mM,202 and a liver blood volume of 0.25 mIlg wet weight. 179 
Results showed a relative contribution of blood ATP to total liver ATP in the MRS 
liver voxel of ,,9%. During ATP infusion, whole blood ATP concentrations increased 
to 1.1 mM which would give a ?:5 % increase in total MRS-observed A TP 
concentrations in the liver voxe!. This is one order of magnitude less than the 50 to 
60% increase in liver ATP levels. 
Yet another effect of ATP is vasodilation6,359 mediated by purinergic receptors 
PI and P2 which are located on endothelial cells of blood vessel walls.39,217 
Vasodilation in the liver could affect the IIp MRS measurement by increasing blood 
volume within one liver voxe!. Indeed, increased liver ATP levels were observed by 
31p MRS in rat liver after dopamine administration, probably due to increased hepatic 
blood flow. 312 Based on reported maximal changes in hepatic blood volume in 
humans between _20%160 and +20%17 depending on the stimulus used, increased 
blood volume in the liver could account for an increase in liver ATP levels by 8%. 
Again, this is one order of magnitude 'short of the observed effect. If liver ATP 
values are corrected for the highest possible blood contribution from combined 
vasodilation and raised erythrocyte ATP levels (18 %), the increase in patients with 
5 % weight loss still remains highly significant (P<O.OI). We therefore conclude 
that the increase in total liver ATP as measured by 31p MRS during ATP infusion 
does reflect a significant rise in ATP levels in liver tissue and is not caused by altered 
ATP contamination from blood. 
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III conclusion, this study shows that intravenous ATP infusion is able to restore 
depleted liver ATP pools in patients with advanced lung cancer to levels similar to or 
above those in healthy subjects. This effect is most marked in weight-losing lung 
cancer patients. The increase in liver ATP pools could have beneficial effects on the 
nutritional status of weight-losing lung cancer patients. 
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ABSTRACT 
Cancer cachexia is associated with elevated lipolysis, proteolysis, and 
gluconeogenesis, Recently, adenosine 5' -triphosphate (ATP) infusion was found to 
significantly inhibit loss of body weight, fat mass and fat-free mass in advanced lung 
cancer patients, The present study was aimed at exploring the effects of ATP on 
whole body glucose turnover, alanine turnover, and gluconeogenesis from alanine. 
Twelve patients with advanced non-small-cell lung cancer (NSCLC) were studied one 
week before and at 22 to 24 hours of continuous A TP infusion, After an overnight 
fast, turnover rates of glucose and alanine, and gluconeogenesis from alanine were 
determined using primed-constant infusions of [6,6-'H'l-glucose and [3-13C]-alanine, 
Thirteen NSCLC patients and eleven healthy subjects were studied as control groups 
without ATP infusion, During high-dose ATP infusion (75 flg/kg,min), glucose 
turnover was 0,62±0,07 nllllOllkg.h compared to 0.44±O, 13 at baseline (P=0,04), 
For gluconeogenesis a similar but non-significant trend was observed (baseline, 
O,30±0,16; during ATP, 0.37±O.13 mmollkg,h (p=O,08), At lower ATP doses (37 
to 50 fIg/kg, min) these effects were not detected, The relative increase of glucose 
turnover during A TP infusion compared to baseline showed a significant correlation 
with the ATP dose (r=0.58, P=0,02), No change in alanine turnover was observed 
at any ATP dose, Results of this study indicate an increase in glucose turnover during 
high-dose ATP infusion compared to baseline, During high-dose ATP infusion 
glucose turnover is similar to that during low-dose ATP infusion and to control 
NSCLC patients, Between ATP infusions, glucose turnover in the high-dose ATP-
treated patients is significant lower than in the low-dose and control NSCLC patients 
(P=O,04 and P=0.03, respectively), and similar to that in healthy subjects, This 
would suggest that repeated high-dose ATP infusions may inhibit glucose turnover 
between infusion periods, 
INTRODUCTION 
Cachexia is a common phenomenon in lung cancer patients, and contributes 
significantly to morbidity and mortality,94.116.407 Cancer cachexia is associated with 
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metabolic alterations including elevated lipolysis, 128,391 protein breakdown,266,306,355 
and increased glucose turnover, 192 In patients with advanced cancer increased glucose 
production has been shown from lactate,389 glycerol,267 and alanine.248.455 
It has been argued that the liver plays an important role in the metabolic 
alterations contributing to the development of weight loss in cancer. 51 ,220 In 
liverlOl.374,434 and skeletal muscle374 of tumor bearing rats, significantly reduced 
adenosine 5'-triphosphate (ATP) levels have been demonstrated, which were associated 
with increased gluconeogenesis434 and increased gluconeogenic enzyme activity. 307 In 
mice bearing CT26 colon tumors, daily intraperitoneal injections of ATP, adenosine 5'-
monophosphate or adenosine for 10 consecutive days significantly inhibited host weight 
loss.348 This inhibition was associated WiOl increased hepatic ATP pools.347.348 
In a randomized clinical trial in patients with advanced non-small-cell lung cancer 
(NSCLC), we recently demonstrated beneficial effects of ATP infusions on body 
weight, muscle strength,7 skeletal muscle mass, and body cell mass. 4 The present 
pilot study was aimed at exploring effects of ATP infusion on whole-body glucose 
turnover, alanine turnover and gluconeogenesis from alanine. Based on the beneficial 
clinical outcomes we hypothesized that ATP would have an inhibitory effect on these 
processes. Alanine was selected as a gluconeogenic substrate because this amino acid 
is the key protein-derived precursor of glucose utilized by the liver,41l and one major 
component of muscle protein degradation. 
SUBJECTS AND METHODS 
Subjects and study design 
Patients with histOlogically or cytologically proven NSCLC (stage IllB or IV) without 
curative options, and a Karnofsk), index of 60% or more were eligible for the study. 
Patients with cognitive dysfunction or liver, renal, respiratory, or heart failure, and 
patients undergoing surgery, concurrent chemotherapy, or radiotherapy involving all 
lesions were excluded. The study was approved by the Medical Ethical Committee of 
the Erasmus University Medical Center Rotterdam. All participants signed informed 
consent. Eleven healthy subjects and 13 NSCLC cancer patients without ATP 
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infusion were included as control groups. The control NSCLC patients were matched 
for the ATP-infused NSCLC patients for age, sex, and weight loss. 
In the clinical trial, 28 patients were randomized to ATP treatment, to receive a 
maxhnum of 10 ATP courses of 30 hours each: seven courses at 2-week intervals, 
followed by three ATP courses at 4-week intervals. ATP infusions (6.1 mg ATP-
Na,·3H,O per ml 0.9% saline) were started with an initial dose of 20 ).lg/kg.min and 
were increased by increments of 10 fIg/kg. min every 30 minutes until a maxhnum 
dose of 75 fIg/kg. min, or until the maxhnally tolerated dose had been reached. If any 
side effects occurred, the dose was reduced to the last given dose or further until side 
effects disappeared, usually within minutes after lowering the ATP dose. Thereafter, 
ATP was infused at a continuous rate. The most frequently occurring side effects 
were chest discomfort and the. urge to take a deep breath. 5 
In 12 out of the 28 ATP-allocated patients, glucose turnover and gluconeogenesis 
from alanine were studied one week before (baseline) and during a ATP course (22 to 
24 hours after starting ATP infusion). Seven patients received low-dose infusions of 
37-50 fIg/kg. min ATP, and five high-dose infusions of 75 flg/kg.min ATP. 
The subjects were studied in the morning after an overnight fast. A cannula 
(0.8x25 nnn) was placed in the left cubital vein for the infusion of stable isotope 
tracers. In the contralateral cubital vein, an identical cannula was positioned for blood 
sampling. To study gluconeogenesis, a solution was prepared containing [6,6-'H,J-D-
glucose, 98 atom%, and [3-\3C]-L-alanine, 99 atom% (Mass Trace, Woburn, USA), 
in water and this was sterilised by autoclaving in glass vials. A priming dose of 0.03 
mmollkg [6,6-'H'J-D-glucose was administered followed by a continuous infusion of 
0.01 nnnol/kg.h [6,6-'H,J-D-glucose for 90 minutes. Simultaneously, a priming dose 
of 0.08 mmollkg [3-13C]-L-alanine was given followed by a continuous infusion of 
0.04 mmollkg.h [3-\3C]-L-alanine during 90 minutes. Both tracer solutions were 
infused using calibrated syringe pumps (PerfusorR fm, Braun, Germany). 
Venous blood samples were drawn immediately before the isotope infusions were 
started, and at 10 min intervals from 30 to 90 min, i.e., after steady state conditions 
during the tracer infusions had been achieved. 
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Analytical methods 
Blood samples were collected in tubes containing lithium heparin (Becton Dickinson 
Vacutainer", Meylan Cedex, France) and immediately stored on ice. After 
centrifugation (10 min., 1200 g, 4 'C), the plasma was collected and stored at -20 'C 
until analyzed. An aliquot of the infusate was analysed to document the actual 
concentrations of the tracers in each study. 
Blood glucose concentrations were determined enzymatically with a glucose-
oxidase / peroxidase assay system (Boehringer Mannheim, Mannheim, Germany). 
Plasma alanine was measured enzymatically as described by Williamson. 468 Isotopic 
enrichments were determined using the following procedures. Plasma was 
deproteinized by adding 0.3 M barium hydroxide (Sigma Diagnostics, St.Louis) and 
0.3 M zinc sulphate (Merck, Darmstadt, Germany). After centrifugation (8 
min,15000 g, 4 'C) the supernatant was applied to an ion exchange column (mixed 
bed: AGSOW-X8 and AGI-X8, 200-400 mesh, 0.2 g each; BioRad, California). 
Glucose and alanine were eluted from the column using water and 4 M anllllonium 
hydroxide (Merck, Darmstadt, Germany), respectively, and dried under nitrogen. 
A glucose derivative (aldonitril penta acetate) was prepared according to Varma 
et al.444 An alanine t-butyldimethylsilyl derivative was prepared as described by 
Chaves Das Neves et al. 72 
Isotopic enrichments were measured by injecting I fll samples with a split ratio of 
50: I on a fused silica capillary colunm of 25 m x 0.22 mm, coated with 0.11 flm 
HT5 (SGE, Victoria, Australia). The relative isotopic enriclllllents of deuterated 
glucose and carbon-13 alanine were determined using a Carlo Erba GC8000 gas 
chromatograph coupled to a Fisons MD800 mass spectrometer (GC-MS) (Intersience 
B.V., Breda, The Netherlands) in electron impact ionisation mode. In general, the 
variation coefficient in enriclllllent was 0.2 mole% for both [6,6-'H,]-glucose and [3-
"C]-alanine measurement, and no concentration effect was observed at this mole % 
enrichment level. Ions were selectively monitored at mass per unit charge (mlz) 187 
for natural glucose and 189 for the deuterated molecule. The isotopic enrichment of 
[3-"C]-alanine was determined at the IIIlz ratios 260 and 261 for carbon-12 and 
carbon-13 alanine, respectively.278 
Total enrichment of carbon-13 glucose was measured separately (aldonitril penta-
acetate derivation) using a gas chromatograph combustion isotope ratio mass 
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spectrometer (GC-IRMS) (Optima, Micromass UK, Middlewich, Cheshire, Great 
Britain). The ["C]-glucose enrichment in atom% excess (APE) was monitored after 
combustion to CO, at mass 44 for carbon-12 and 45 for carbon-13, respectively. 
Calculations 
Whole body rate of appearance (Ra) of glucose was calculated during steady state 
following a one-compartment model, using the equation: 
Ra = F x «lEi/lEe,,) -1), 
where F is the isotope infusion rate (mmol/kg.h), lEi the isotopic enrichment of the 
infusate (mole% excess), and IE", the isotopic enriclmlent of the extracellular fluid 
(mole% excess)47! The percentage glucose produced from alanine equals: 
IE "C-glucosepl~= I (IE "C-alaninepl~= x 0.33) 
The correction factor in formula (2) is applied in order to correct for the number of 
carbons in both glucose and alanine. Gluconeogenesis from alanine (mmollkg.h) was 
then obtained as: 
% glucose from alanine x Ra (['H,l-glucose) 
Finally, the percentage of alanine converted into glucose Was calculated by dividing 
the rate of gluconeogenesis from alanine by the rate of appearance of alanine 9 ! 
Statistical analysis 
Results are presented as means ± standard deviation (SD). Changes in turnover 
between baseline and ATP infusion were tested for significance by the two-tailed 
Wilcoxon's signed rank test. Results of independent groups were tested for 
significance by the Mann Whitney U test. Correlation between variables were 
calculated as Spearman's rank correlation coefficients. Results were considered 
statistically significant with a P-value <0.05. 
RESULTS 
Study population 
Characteristics of the study population are shown in Table 4.3.1. Twelve lung cancer 
patients (nine males, three females) with a mean (±SD) age of 64± 13 years and 
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weight of 72.7 ± 13.0 kg participated in the study. Mean weight loss was 7.1 ±9.0 %. 
Patients had received an average of 2.3 ±2.1 previous ATP courses. Furthermore, 11 
healthy subjects (three males, eight females; age 56± 12 years; body weight 
79.5±55.0 kg; no weight loss) and 13 NSCLC cancer patients (10 males, three 
females; age 64±14 years; body weight 67.8±13.1 kg; weight loss 6.3±9.9 kg) 
were included as control groups without ATP infusion. 
Table 4.3.1. Clinical details of non-small-cell lung cancer patients treated with ATP or not 
treated with ATP (controls) and healthy subjects (mean + standard deviation or number) 
Heallhysubjecls Cancer patients 
noATP noATP ATP 
Subject (no) 11 13 12 
Sex (m/I) 3/8 10/3 9/3 
Age (y) 56 ± 12 64 ± 14 64 ± 13 
Weight (kg) 79.5 ± 55.0 67.8 ± 13.1 72.7 ± 13.0 
Weight loss (%) O±O 6.3 ± 9.9 7.1 ± 9.0 
Previous ATP courses 2.3 ± 2.2 
ATP-dose (f.g/kg.min) 57 ± 16 
Glucose and alanine metabolism 
Baseline plasma glucose and alanine concentrations were 4.9±0.8 mM and 
0.36±0.02 mM, respectively, and did not change during ATP infusion. When data 
were analyzed for the ATP-treated patient group as a whole, turnover rates of glucose 
and alanine, and gluconeogenesis from alanine during ATP infusion did not differ 
significantly from baseline. However, as shown in Figure 4.3.1, stratification for 
ATP dose revealed clear differences according to ATP dose. In patients with low-
dose ATP infusion (37-50 ~tg/kg.min), no change was detected in glucose turnover 
(baseline, 0.58±0.1O mmollkg.h; during ATP infusion, 0.56±0.13 mmollkg.h) or 
gluconeogenesis from alanine (baseline, 0.34 ±0.17 mmol/kg.h; during ATP 
infusion, 0.35±0.24 mmollkg.h). In contrast, in patients with high-dose ATP 
infusion (75 ~tg/kg.min), glucose turnover was 0.44 ±0.13 nnnol/kg.h at baseline and 
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0.62±0.07 mmol/kg.h during ATP infusion (change: P=0.04). Gluconeogenesis 
from alanine amounted to 0.30±0.16 nunol/kg.h at baseline and to 0.37±0.13 
nnnollkg.h during ATP infusion (P=0.08). The change of glucose turnover from 
baseline was significantly correlated with the ATP-dose [r=0.58, P=0.02]. No such 
dose-effect relation was demonstrated for gluconeogenesis from alanine. 
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Figure 4.3.1. Whole body rate of turnover of glucose and gluconeogenesis from alanine before 
and during (22-24 hours) low-dose (37-50 ~tg/kg.min; 0; n=7) and high-dose (75 Mg/kg.min; 
.; n=5) ATP infusion. Turnover rates were assessed using primed-constant infusions of [6,6· 
'H2J-glucose and [3- JJC]-alanine. *) Significantly different from baseline (P<0.05). 
Mean glucose turnover rates in ATP-treated and control lung cancer patients, and 
healthy subjects are shown in Figure 4.3.2. Glucose turnover rates in lung cancer 
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patients during high-dose ATP infusion were similar to control (untreated) lung cancer 
patients, but significantly higher than in healthy control subjects (P=O.047). In 
contrast, baseline glucose turnover rates in high-dose ATP-treated patients were 
significantly lower when compared with both low-dose ATP and control cancer patients 
(P=O.04 and P=O.03, respectively), but were at a level similar to or even lower than 
in healthy sUbjects. 
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Figure 4.3.2. Whole body rate of glucose turnover in 1l healthy subjects (white bar), 13 
control non-small-cell lung cancer (NSCLC) patients (black bar), seven low-dose ATP (37-50 
~g/kg.min) treated NSCLC patients (hatched bars), and five high-dose ATP (75 ~g/kg.min) 
treated NSCLC patients (cross hatched bars). Turnover rates were assessed using primed-
constant infusions of [6,6-2HlJ-glucose. Bars and error bars represent means ± SEM. Bars 
with the same superscript letter are significantly different (P<O.05). 
DISCUSSION 
The aim of the present pilot study was to explore effects of intravenous ATP infusion 
On whole-body glucose turnover, alanine turnover, and gluconeogenesis from alanine, 
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as possible pathways contributing to the reported beneficial effects of A TP on body 
weight and body composition in advanced lung cancer patients. The effect of ATP on 
gluconeogenesis from the amino acid alanine was studied because ATP was shown to 
inhibit loss of skeletal muscle mass4 and muscle strength.7 Turnover measurements 
were performed at 22 to 24 hours after starting ATP infusion, i.e., after ATP had 
reached plateau levels in erythrocytesS All but one patients were studied during one 
of the subsequent ATP infusions. 
During high-dose ATP infusion (75 flg/kg.min), whole-body glucose turnover 
increased by approximately 50%, whereas no change whatsoever was shown at low-
dose ATP infusion (37-50 flg/kg.min). The ATP-induced increase of gluconeogenesis 
from alanine explained only part of the increase in total hepatic glucose production. 
This would suggest that A TP may also stimulate gluconeogenesis from other substrates 
and glycogenolysis. III vitro studies show that ATP administration stinmlates 
gluconeogenesis from lactate,133,366 pyruvate,62,366 and glutamine, 133,229,366,406 
Studies in isolated hepatocytes64,97,219 and perfused rat live,s9,244 showed that ATP 
also stimulates glycogenolysis by activating glycogen phosphorylase. It is conceivable 
that high-dose ATP infusion evoked innnediate stimulation of glycogenolysis in our 
patients since turnover measurements were performed after an overnight fast of 10 to 
12 hours. Glycogen stores in healthy subjects were reported to be depleted only after 36 
hours of fasting;305 no data on glycogen stores in cancer patients are available. 
The mechanisms responsible for increased glucose turnover and gluconeogenesis 
during 24 hours of high-dose ATP infusion remain to be elucidated. Mechanisms 
might include receptor-stimulating and catecholamine hormone-stimulating effects of 
ATP. Studies in isolated hepatocytes showed that extracellular ATP induced 
phosphatidylinositol hydrolysis, intracellular Ca2+ -mobilization, and extracellular 
Ca2+ -influx by stimulation of surface purinergic P2 receptors64,311 which are 
involved in the control of gluconeogenesis 13 and glycogenolysis. 218 Furthermore, 
ATP was shown to act as a cotransmitter of the catecholamine noradrenaline in the 
nervous system, and was suggested to modulate the release of other neurotransmit-
ters. l77 Noradrenaline is an activator of gluconeogenesis lO5,366 and 
glycogenolysis. 105 
However, the above reasoning would only apply to the immediate effects of A TP 
infusion within NSCLC subjects. Notably, baseline glucose turnover rates in the present 
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study were significantly lower in patients who had previously received high-dose ATP 
infusions when compared to patients who had received low-dose ATP or no ATP at all 
(controls). Since patients in the high-dose group had already undergone an average of 
two ATP courses before the present turnover measurements, our data would suggest 
that Ille previous ATP infusions had induced a reduction in whole body glucose 
turnover on a longer term, which would be consistent with the observed inhibition of 
weight loss in our long-term clinical trial in NSCLC patients. TIns hypothesis is 
supported by the observation that baseline glucose turnover rates in patients who had 
already received one or more high-dose ATP infusions were similar to or even lower 
than in control subjects. 
In contrast, baseline gluconeogenesis from almtine did not differ significantly 
between low- and high-dose ATP groups. This would be consistent with the flllding in 
several experimental ill vivo studies that the ATP degradation product adenosine 
inhibited gluconeogenesis from lactate,241,242,264 pyruvate242,264 and glutamine,242,264 
but not from alanine 24 I, 242 Inthe present human study, direct effects of ATP on 
glucose turnover and gluconeogenesis cannot be separated from potential effects of 
adenosine, 
In conclusion, the present study suggests that, despite a temporary dose-
dependent increase in whole-body glucose turnover during high-dose ATP infusion in 
advanced lung cancer patients, ATP seems to inhibit glucose turnover in the long run, 
This hypothesis is supported by the observation of reduced baseline glucose turnover 
rates, to levels similar to turnover in healthy subjects, in patients who had previously 
received an average of two courses of high-dose ATP. Larger studies are indicated to 
confirm and elaborate these differential direct and long-term effects of ATP infusions 
on gluconeogenesis in NSCLC patients. 
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ABSTRACT 
Background: Preliminary clinical data suggest that adenosine 5' -triphosphate (ATP) 
may inhibit lung tumor growth. Because studies to ATP on lung cancer cells are 
lacking, the aim of the present study was to explore effects of extracellular ATP on 
the growth and morphology of human lung tumor cells. 
Methods: Five human lung tumor cell lines derived from tumors with different 
cellular characteristics i.e., a small cell carcinoma (GLC4), a large cell carcinoma 
(H460) , a squamous cell carcinoma (H520), a mesothelioma (MER082), and a 
papillary adenocarcinoma (H441) were exposed to 0, 0.5, 1, 2, and 3 mM ATP. 
Total cell numbers and dead or damaged cells were measured on days 1, 2, and 3. 
Results: ATP induced a signit1cant, dose-dependent growth inhibition in GLC4, 
H460, H520, and MER082 cells. In contrast, H441 cells showed already maximal 
inhibition at 0.5 mM. Compa!ed to untreated control cell lines, a signit1cant growth 
inhibition (mean ± SEM) of 65±5% (GLC4), 59±5% (H460) , 45±5% (H520), 
38±2% (MER082), and 55±8% (H441) was shown after 3 days incubation with 3 
mM ATP. ATP also induced changes in morphology and attachment to the 
substratum. Although not demonstrated by the Trypan Blue exclusion test, on 
photographs it appears that ATP induces death of GLC4 and H460 cells at higher 
concentrations. 
Conclusions: In four out of t1ve explored lung tumor cell lines A TP induces a dose-
dependent growth inhibition. Lung adenocarcinoma cells show already maximal 
inhibition at the lowest tested ATP dose. There is a relationship between growth 
inhibition and morphology changes. 
INTRODUCTION 
Adenosine 5' -triphosphate (ATP) is a naturally occurring nucleotide which is present 
in every cell of the human body. In addition to its well-established intracellular 
energy-transferring role, ATP extracellularly is involved in biological processes 
including neurotransmission, muscle contraction, cardiac function, platelet function, 
vasodilatation, and liver glycogen metabolism. 57 The physiological concentration of 
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ATP in plasma is low, i.e., 0.02 to 10 jlM. 151 ,185 Extracellular ATP exerts its effects 
through cell surface P2 receptors, classified in G protein-coupled P2Y, and ionotropic 
P2X receptors. 155 
In vitro studies have shown that extracellular ATP can modulate the growth of 
neoplastic cells. In transformed cells, ATP induced mitogenesis at a concentration 
below 50 jlM,201,449 whereas higher ATP concentrations inhibited 
growd1.28,63, 135, 190,343,346,378,405,443 These effects were not observed in 
untransformed control cells. 189,190,224,299,343 In human lumor cell lines, ATP inhibited 
dIe growth of pancreatic adenocarcinoma cells,343 colon adenocarcinoma cells,343 mela-
noma cells,224,343 androgen-independent prostate carcinoma cells,135 breast cancer 
cells,3,405,443 myeloid and monocytic leukemia cells,l90 and multidrug resistant colon 
carcinoma cells.92 In rats and mice ATP was found to inhibit the growlh of Iymp-
homas,301 colon carcinomas,348 fibrosarcomas,161 Ehrlich ascites tumors,239 and 
breast tumors.3 
Recently, 15 palients with advanced non-small-cell lung cancer were treated with 
courses of intravenous ATP. Stable disease was found in 10 of these patients 
suggesting an inhibitory effect of ATP on tumor growth. 187 So far, studies on growth 
inhibitory effects of ATP on lung cancer cell lines are lacking, Therefore, the aim of 
this study was to investigate the effects of ATP on the growth and morphology of 
different human lung cancer cell lines. 
MATERIALS AND METHODS 
Chemicals 
Adenosine 5'-triphosphate (ATP-NadH20; MW~605) of >98% purity was 
obtained from Merck (Darmstadt, Germany). Two stock solutions of ATP were 
prepared to a final concentration of 10.5 mM (stock A) and 21 mM (stock B). ATP 
was dissolved in RPMI-I640 medium, adjusted to pH 7.4 with NaOH and stored at 
-20 'C until use. ATP stock solutions were sterilized by filtration through 0.2 flm 
syringe filters. High-performance liquid chromatograph (HPLC) testing showed that 
under these conditions ATP remained stable in time (data not shown). 
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Cell lines, media, and culture conditions 
Five cell lines were studied. Human papillary lung adenocarcinoma (H441), human 
large cell lung carcinoma (H460), and human squamous cell lung carcinoma (H520) 
cell lines were obtained from the American Type Culture Collection (Manassas, 
USA). Human small cell lung carcinoma (GLC4), and human mesothelioma cell lines 
(MER082) were kindly given by Dr. T. Boersma (Department of Oncology, Erasmus 
University Medical Center Rotterdam, The Netherlands), and Dr. M. Versnel 
(Department of Innnunology, Erasmus University Medical Center Rotterdam, The 
Netherlands), respectively. 
Cells were cultured on RPMI-1640 culture medium (BioWhittaker Europe, Vervier, 
Belgium) containing L-Glutamine (2 mM), supplemented with 2% NaHCOJ 
(BioWhittaker Europe), 100 units/ml penicillin (BioWhittaker Europe), 100 ~lg/ml 
streptomycin (BioWhittaker Europe), and supplemented with 10% heat inactivated 
fetal calf serum (GIBCO BRL, Life Technologies, Breda, The Netherlands). Cells 
were detached from their substratum by 0.5 g Trypsin / 0.2 g EDTA (GIBCO BRL, 
Life Teclmologies). 
The different cell lines were cultured in 75 cm' flasks (Costar, USA) on RPMI-1640 
culture medium at 37 'C in a 5% CO, humidified incubator. Heat-inactivated serum 
was prepared by heating FCS in a water bath at 60 'c for 30 min. The cells were 
routinely passaged at approximately 90% confluency with medium changes once per 
week. 
Experimental protocol 
On day -I of the experiment, the different cell lines were seeded in a number of 
4.75xlO' cells per well on 6-well culture plates (Costar, USA) and suspended in 5 ml 
RPMI-I640 medium per well. On day 0, cells were incubated in triplicate with ATP 
to final concentrations of 0, 0.5, 1,2, and 3 mM. On days 1,2, and 3, cell numbers 
and viability were determined. Cells were detached from their substrate by incubation 
with 1.2 ml Trypsin/EDTA per well for 10 min at 37 'C. The wells were rinsed once 
with I ml phosphate buffered saline (PBS). The solution (cells, Trypsin/EDTA and 
PBS) was centrifuged at 1000 RPM for 5 minutes at 22 'c and the supernatant was 
removed. Subsequently, the cells were resuspended in PBS and counted. 
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Determination of morphological changes due to A TP 
Cells were inoculated and incubated as described. Photographs were taken at 1, 2, 
and 3 days after incubation with ATP, using a Sony RBG CCD video camera 
attached to a Zeiss Axiovert 100 microscope and stored on a videotape by use of a 
Panasonic time-lapse video recorder. 
Cell growth determination 
Cell numbers and viability were determined by Trypan Blue dye exclusion, and each 
sample was scored in triplicate microscopically 
Statistical analysis 
Growth data are expressed as cell numbers per well, and as percentage growth 
inhibition compared to control cell cultures. Cell death or damage is expressed as 
percentage of the total cells counted. Each value is the mean of 27 measurements: i.e., 
all experiments were performed three times, every incubation was performed in 
triplicate, and cell numbers were determined in triplicate. Values are expressed as mean 
± SEM. Statistical significance of differences was appraised using Student's (-test. P-
values below 0.05 were considered statistically significant. 
RESULTS 
Growth inhibition 
Figure 4.4.1 A-E shows the growth curves of five human lung tumor cells exposed 
to ATP at concentrations of 0 (=control cell line), 0.5, 1,2, and 3 mM ATP for a 
period of 3 days. As shown in this figure and in Table 4.4.1, ATP induced a 
significant, dose-dependent growth jnhibition in GLC4, H460, H520, and MER082 
cells. Three days after exposure to ATP the growth inhibition of GLC4 cells was 
maximal at 3 mM ATP, less at 2 mM, minimal at 1 mM ATP, and absent at 0.5 mM 
ATP. At the same time point, the growth of H460, H520, and MER082 cells was 
maximally inhibited at 3 mM, less at 2 mM, and not at either 1 and 0.5 mM ATP. In 
contrast, H441 cells showed already maximal growth inhibition at 0.5 mM ATP, with 
no additional growth inhibition at ATP concentrations of 1, 2, and 3 mM. 
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Figure 4.4.1. Growth of A) small cell carcinoma (GLC4). B) large cell carcinoma (H460). C) 
squamous cell carcinoma (H520). D) mesothelioma (MER082). and E) papillary adenocarcinoma 
(H441) cell lines after administration of 0 (black square). 0.5 (open triangle), 1 (cross), 2 (open 
circle), and 3 (black diamont) ruM adenosine 5'-triphosphate (ATP). *) Significantly different 
growth inhibition compared to the control cell line (0 ruM ATP) at 3 days. 
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Table 4.4.1. Percentage growth inhibition of lung cancer cell after 3 days 
of exposure to different concentrations of adenosine 5'-triphosphate (ATP) 
as compared to control cell lines 
mMATP 
0.5 2 3 
GLC4 5±0 21 ± 1 * 45 ± 4' 65 ± 5* 
H460 O±O 7±0 36 ± 2' 59 ± 5' 
H520 23 ± 2 15 ± 1 38 ± 4' 45 ± 5' 
MER082 10 ± 1 16 ± 1 23 ± l' 38 ± 2' 
H441 51 ± 7' 49 ± 8- 53±?" 55 ± 8-
Values are mean of27 measurements, Results are expressed as mean ± Sm..-L 
*) indicates significant difference compared to control 
OmM ATP 
3mMATP 
2 
Days 
Growth inhibition 
3 
Figure 4.4.2. Growth and morfology changes of small cell lung carcinoma (GLC4) cells at 1, 
2, and 3 days after administration of 0 and 3 mM adenosine 5'-triphosphate (ATP). 
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Morphological changes 
Besides growth inhibitory effects, ATP had effect on the attachment of the lung tumor 
cells to the substratum and on their morphology. At higher ATP concentrations the 
cells became spheroidal, and detached from the substratum (Figure 4.4.2). As shown 
in Figure 4.4.3 higher concentrations of A TP induced more pronounced changes in 
morphology of GLC4, H460, H520, and MER082 cells than lower ATP 
concentrations. In contrast, H441 cells showed similar changes in morphology at both 
low and high ATP concentrations. Comparison of Table 4.4.1 and Figure 4.4.3 
shows a relationship between growth inhibition and changes in morphology of lung 
cancer cells. 
Table 4.4.2. Percentage dead or damaged cells on the total cell count of the 
different lung cancer cell lines 3 days after adenosine 5'-triphosphate (ATP) 
administration. 
mMATP 
0 0.5 2 3 
GLC4 11 ± 2 16 ± 2 13 ± 1 11 ± 2 9±1 
H460 16 ± 1 13 ± 1 15 ± 1 11 ± 1 14 ± 1 
H520 18 ± 1 13 ± 1 15 ± 2 18 ± 1 18 ± 3 
MER082 11± 1 9±1 9±1 13 ± 1 25 ± 3 
H441 20 ± 3 9±2 13 ± 2 12 ± 2 18 ± 3 
Values are mean of27 measurements. Results are expressed as mean ± SEM 
Cell death 
As tested by the Trypan Blue exclusion test, ATP at several concentrations did not have 
cytotoxic effects on the tested lung tumor cell lines (Table 4.4.2). In contrast, as seen 
in the photographs (Figure 4.4.2) ATP appears not only to exert cytostatic effects on 
lung tumor cell lines but also cytotoxic effects. Three days after 3 mM ATP 
administration, the number of the GLC4 cells decreased compared to days 1 and 2. 
This fmding was also observed in H460 cells (data not shown). 
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Figure 4.4.3. Effects of administered adenosine 5'~triphosphate (ATP) on the growth and the 
morphology of small cell carcinoma (GLC4), large cell carcinoma (H460), squamous cell 
carcinoma (H520), mesothelioma (MER082), and papillary adenocarcinoma (H441) cell lines 
at concentrations of 0, 1, and 3 mM at 72 hours incubation period. 
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DISCUSSION 
In the present study, we investigated the effects of extracellular ATP on the growth and 
morphology of, five human lung cancer cell lines, te" a small cell lung carcinoma 
(GLC4), a large cell lung carcinoma (H460), a squamous cell lung carcinoma (H520), a 
mesothelioma (MER082), and a papillary lung adenocarcinoma (H441), 
Incubation with 0,5 to 3 mM ATP resulted in a concentration-dependent growth 
inhibition of GLC4, H460, H520, and MER082 cell lines. In general, the most 
pronounced growth inhibitory effects (38 to 65% inhibition depending on cell type) 
were demonstrated at 3 mM ATP after an incubation time of 3 days. At this 
concentration GLC4 cells were most sensitive, whereas MER082 cells were least 
sensitive. It may be noted that small cell lung carcinomas (GLC4) also have a high 
sensitivity to chemotherapy,61 whereas mesotheliomas (MER082) are almost 
completely resistant to this type of treatment.47 In H441 cells, ATP induced 
significant growth inhibition at both high (3 mM) and low (0.5 mM) concentrations. 
It is intriguing that ATP also influenced the morphology of the lung cancer cells 
in a concentration-dependent maImer. Changes in morphology were related to the 
level of growth inhibition. Incubation with ATP induced changes in cell, shape, 
membrane movement, cell agglutination, and attachment of cells to the substrate. It 
has been reported that extracellular ATP influences the cytoskeleton. 222,476 Possibly, 
ATP induces changes in cytoskeletal structures which may contribute to increased 
permeability of transformed cells.476 In this connection it could be worthwhile to 
investigate effects of A TP on cell adhesion molecules including E-cadherin, integrins 
and vimentins, which may explain directly the spheroid nature of the cultured cells. It 
should be noted that loss of cell a((aclnnent by incubating the cells in 3 mM ATP 
during 3 days resulted not only in inhibition of growth, but also in cell death and cell 
loss as shown in Figure 4,4,2. The reason for not detecting A TP-induced cell death 
using the Trypan Blue test may be removal of dead cells which were detached from 
the substratum together with the supernatant. Possibly, as the photographs seem to 
suggest, there may have been more dead cells than were actually counted. 
Several mechanisms have been proposed to explain the ATP-induced growth 
inhibition and death of tumor cells. Firstly, exposure of human adenocarcinoma cells 
to extracellular ATP has been reported to cause intracellular accumulation of ATP and 
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arrest of tumor cells in the S-phase of cell replication, followed by cell death.343 A 
similar ATP-induced growth inhibition, due to prolonging of the S-phase, was found in 
human breast cancer cells 405 Secondly, ATP-induced tumor growth inhibition is 
associated with a decrease in glutathione (GSH) content of the tumor, but not of normal 
tissues. 134.239 Thirdly, in various transformed cells ATP adminislralion contributed to 
increased membrane permeability. 63.119.143.223,224.299.466,476 Increased cell 
permeability after exposure to extracellular ATP may be due to activation of P2X, 
receptors I54 ,413 which have been found on the cell surface of several tumor 
cells.52.214 Activation of the P2X, receptors causes opening of intrinsic ion channels 
which leads to massive efflux of K+, and influx of eaH and Na+, resulting in a 
decrease of the plasma membrane potentia1. 193,335 Activation of P2X, receptors 
furth~r results in formation of non-selective pores, which induces an increase in nonse-
lective membrane permeability for aqueous solutes Olat ordinarily do not cross the cell 
membrane.73.130.271 These effecls have been seen in many transformed 
cells28.63.135.343,346,405.443 but not in untransformed cells. 117.190,224,361.460 
Preclinical studies have shown that ATP administration not only induces growth 
inhibition of tumor cells, but also potentiates the cytotoxic effects of several 
chemotherapeutic agents222.281 and radiotherapy.134 It would be interesting 10 explore 
effects of combinations of chemotherapeutic agents and ATP on lung carcinoma cell 
lines. 
In summary, our results show that ATP induces a dose-dependent growth inhibition 
in four out of five lung cancer cell lines: GLC4, H460, H520 cells, and MER082 cells. 
Lung adenocarcinoma cells (H441) show already maximal (55%) inhibition at the 
lowest ATP dose tesled. There is a relationship between growth inhibilion and 
morphology. Although not demonstrated by the Trypan Blue exlusion test, the 
pholographs suggest that it seems Ihal ATP may induce cell death at higher 
concentrations. Experiments to explore underlying processes contributing to ATP-
induced cytostatic and cytotoxic effects, and morphology changes are warranted. Based 
on the marked growth inhibition of human lung adenocarcinoma cells by ATP at low 
dosage, further study with this tumor cell type would appear especially relevant. 
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ABSTRACT 
The accuracy of skinfold measurements to assess changes in fat and fat-free mass was 
estimated in 25 non-small-cell cancer patients (stage lIIB or IV), using the deuterium 
oxide dilution technique as a reference. Weight, skinfold thickness and total body 
water were measured at baseline and after 2 months. Fat mass (FM) and fat-free mass 
(FFM) were calculated from the sum of four skinfolds, and from the determination of 
total body water by deuterium oxide dilution. After 2 months, a mean weight loss 
(± SD) of 1.90±2.51 kg was observed (P<O.OOI). Body composition measurements 
by the two methods were highly correlated at t=O (for FM: 1'=0.84; for FFM: 
1'=0.92, both P<O.OOI) and t=2 months (1'=0.82 and 1'=0.93, respectively, 
P<O.OOI). Significant positive correlations between the two techniques were also 
found when assessing changes in FM (1'=0.63, P<O.OOI) and FFM (1'=0.55, 
P<O.OI) over a 2 months' period, with a mean overestimation of FM loss and 
underestimation of FFM loss of only 0.09±0.31 kg (mean ± SEM) by skinfold 
anthropometry. It is concluded that skinfold anthropometry is an useful and accurate 
technique for measuring changes in body composition in patient populations with 
advanced lung cancer, though not in individual patients. 
INTRODUCTION 
Patients with cancer cachexia suffer from extensive weight loss due to depletion of 
both adipose tissue and muscle mass. 194 Measurement of components of weight loss 
is important in order to assess the degree of depletion and to evaluate effects of 
nutritional and pharmacological interventions. A simple and non-invasive method to 
assess body composition is skinfold anthropometry. Although in several studies fat 
mass (FM) and fat-free mass (FFM) have been esthuated by skinfold anthropometry 
in cancer patients,8,1l5,194,373 there are only few longitudinal studies evaluating the 
validity of this simple technique in healthy subjects.208,439,464 
In the present study, we estimated the accuracy of skinfold anthropometry to 
assess changes in FM and FFM in lung cancer patients over a period of two months, 
using deuterium oxide dilution (D20) technique as a reference. 
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PATIENTS AND METHODS 
Patients 
Thirty-six patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) were 
included in the study. All patients had a Karnofslcy performance status score of 
;:>60%. The study was approved by the Medical Ethical Committee of the Erasmus 
University Medical Center Rotterdam. Written informed consent was obtained from 
all patients. 
The D,O dilution evaluation at 2 months could not be completed in 11 patients 
for reasons of physical deterioration or hospitalization (n=7), or because they found 
the return visit too burdensome (n=4). As a result, complete data for the present 
follow-up study were available from 25 patients (19 men, 6 women). Baseline 
characteristics of the patients participating in the present study are given in Table 
4.5.1. 
Anthrop,ometry (test method) 
At baseline and after 2 months, body weight and thickness of the skinfolds were 
measured. All measurements were performed as described by Durnin et al., 131 by the 
same observer (HJA). Adipose patients with skinfold ticknessess > 40 mm and pitting 
edema in the ankles or ascites were excluded for skinfold measurements. 
Body height was determined to the nearest cm with patients standing barefoot. 
Body weight was measured in the overnight-fasted state, with patients standing 
WitllOut shoes in light clothing, and read to the nearest 0.1 kg on a electronic scale 
(SECA Ltd, Birmingham, UK). 
Skinfold thicknesses were measured in triplicate to the nearest 0.2 mm using a 
HoltainR skinfold caliper (CMS weighing equipment LTD, London, UK). Total body 
fat mass (FM) was estimated from the sum of median skinfold thicknesses at four 
sites (triceps, biceps, subscapula, and supra iliac) using the age- and gender-specific 
tables from Durnin and Womersley.132 Fat-free mass (FFM) was calculated by 
subtracting FM from body weight. 
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Table 4.5.1. Baseline characteristics of patients 
n = 25" 
Sex (mil) 19/6 
Age (y) 64 ± 12 
Height (em) 173 ± 5 
Weight (kg) 70,0 ± 17,1 
Body mass index (kg/m') 23.4 ± 4,9 
Current weight (%)t 93,3 ± 6.2 
Total body water (I)' 35,5 ± 5,3 
Fat mass (kg)' 21.4±6,8 
Fat·lree mass (kg)' 48,6 ± 7,3 
* Scores expressed as mean ± standard deviation 
t As percentage of pre-illness weight 
t Assessed by deuterium oxide (D10) dilution 
Deuterium oxide dilution (reference method) 
range 
30 . 85 
160 . 185 
55,8 • 94,2 
17,0 • 30,8 
79,6·110.4 
26.2 • 44,5 
10,9·39,0 
35,9·61,0 
After an overnight fast of approximately 12 hours, patients received a oral dose of 15 
or 20 grams deuterium·labeled water (99.9%; Isotec inc, ,Miamisburg, USA) at about 
9,30 hours a,m, Following deuterium oxide (D20) administration, patients had to 
abstain from eating and drinking until blood sampling completed, Venous blood 
samples were drawn into heparin tubes from the forearm at baseline and after 21/2, 3, 
and 3'h hours, Blood samples were immediately placed on ice and then centrifuged 
for 10 min and 1300 x g at 4'C. Deuterium oxide in plasma was measured by 
infrared spectrophotometry (Miran IFF, Foxboro, South Norwalk, USA), Total body 
water (TBW) volume was calculated by dividing the D20 dose by D20 concentration 
in plasma,263,441 FFM was calculated using a constant water percentage of 73,322 
FM was calculated by subtracting FFM from total body weight. 
Statistical analysis 
Changes in time were tested for significance by Student's paired I-test. The test and 
reference methods were compared using Spearman's rank correlation coefficient and 
by graphic presentation according to BlaoP,and Altman in which the difference 
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between measurements with both methods is plotted against their average. 37 P-values 
of less than 0.05 indicated significance. 
RESULTS 
During the follow-up period of two months, the patients lost 1.90±2.51 kg of weight 
(mean ± SD; P<O.OOl). Mean loss of FM obtained by skinfold anthropometry was 
1.05±1.90 kg compared to 0.96±2.07 kg as assessed by deuterium oxide dilution. 
Mean loss of FFM as assessed by skinfold anthropometry was 0.85 ± 1.52 kg, and 
0.94 ± 1.60 kg by deuterium oxide dilution. Comparison of the two methods showed 
an overestimation of loss in FM, and an underestimation of loss in FFM, of mean 
0.09±0.31 kg (±SEM) when measured by skinfold anthropometry, relative to the 
deuterium dilution technique. 
Table 4.5.2. Measurement of fat mass (FM) and fat-free mass (FFM):correlation 
coefficients between deuterium oxide (D10) dilution and skinfold anthropometry 
Fat mass 
Fat-free mass 
*) P <0.01, t) P <0.001 
Baseline 
0.85' 
0.92' 
At 2 months Change 0·2 months 
0.63' 
0.55' 
Table 4.5.2 shows that body composition measurements as based on the two 
techniques were highly correlated both OIl t=O (for FM r=0.85; for FFM r=O.92, 
both P<O.OOI) and t=2 months (for FM: r=0.82; for FFM r=0.93, both 
P<O.OOl). Lower, but still highly significant positive correlations between the two 
techniques were observed for changes in FM (1'=0.63, P<O.OOI) and FFM (r=0.55, 
P<O.OI) over the 2 months' study period. 
As shown in Figure 4.5.1, the Bland & Altman analysis revealed a lower limit of 
agreement of -2.83 kg and an upper limit of 3.02 kg for individual estimations of 
changes in FM by the two techniques. The 95% limits of agreement of esthnation of 
changes in FFM were -3.02 and 2.83 kg. 
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Figure 4.5.1. Individual differences of changes in fat mass (PM) and fat-free mass (FFM) over 
a 2 months' period as calculated from skinfold anthropometry and deuterium oxide (DlO) 
dilution, plotted against the mean change measured by the two methods according to Bland & 
Altman. A) change of FM, B) change of FFM. The solid line represents the mean, the dotted 
lines represent upper and lower limits of agreement. 
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DISCUSSION 
For use in epidemiological field studies and clinical practice a method to measure 
body composition must be both simple and reliable. Skinfold anthropometry is such a 
rapid and simple-to-operate method. Previous studies have shown that skinfold 
anthropometry is significantly correlated with computerized tomography194 and 
underwater weighing. t32,205,243,256,447 Although skinfold anthropometry has been 
widely applied in clinical practice, information on the validity of this method for 
measuring changes of body composition over time is extremely scarce. In the present 
study, in NSCLC patients, the accuracy of skinfold anthropometry was compared 
with D,O dilution as the reference method. Although no 'gold standard', D,O dilution 
is conunonly used as a reference method to validate other teclmiques,285,339 
Measurement of total body water by deuterium oxide dilution has been reported as an 
accurate method to predict body composition,85,262,263,439 with a coefficient of 
variation of <2.5%263,44t However, this method of measuring body composition 
puts a considerable strain on patients with advanced disease, as demonstrated by the 
present study in which 11 out of 36 patients dropped out for the D,O dilution follow-
up measurement at two months. 
One reported disadvantage of skinfold anthropometry is that total body fat is 
assumed to have a constant proportion of subcutaneous fat which may lead to 
underestimation in elderly persons because of internal deposition of body fat 
reserves 384,462 In spite of this, our study demonstrates that FM and FFM values 
obtained by skinfold anthropometry were highly correlated with those as assessed by 
D,O dilution, both at baseline and at two months, During the 2 months' follow up 
period, patients lost approximately 2 kg of body weight. Over this period, mean loss 
in FM and FFM amounted to 1.0 and 0.9 kg, respectively, with only a small mean 
difference of 0.09 kg between skinfold anthropometry and D,O dilution. This equal 
loss of FM and FFM is in line with the findings of Heymsfield et aJ. 194 who 
demonstrated that weight loss in cancer patients is due to both loss of FM and muscle 
mass. 
We conclude that, although not in individuals, in patient populations with 
advanced cancer skinfold anthropometry is a useful and accurate technique for 
measuring changes in FM and FFM. 
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Chapter 5 
This thesis describes results of the first randomized clinical trial on the effects of 
adenosine 5'-triphosphate (ATP) treatment in cancer patients. Fifty-eight patients with 
locally advanced (stage IIIB) and metastatic (stage IV) non-smaIl-cell lung cancer 
were randomly assigned to receive either supportive care and 10 intravenous 3D-hours 
ATP infusions every 2 to 4 weeks, or supportive care alone. Outcome parameters 
were assessed at 4-week intervals, until 28 weeks after randomization. 
In this chapter, after a short description and interpretation of the clinical results 
in 5.1, the validity of this randomized clinical trial is discussed in 5.2. In 5.3, 
possible modes of action of ATP are briefly reviewed. Finally, the clinical 
implications of ATP infusions in oncology are discussed in 5.4. 
5.1 CLINICAL RESULTS 
Body weight 
During the half-year study period, a significant difference in mean weight loss 
emerged between the ATP and control group (Chapter 3.1). Patients in the control 
group lost mean 6.5 kg over 6 months, whereas patients in the ATP group had im 
average stable weight. The effect of ATP on weight loss was especially marked in 
patients who were already cachectic at the start of the study, whereas no statistical 
significance was reached in non-cachectic patients. 
Body composition 
Longitudinal studies evaluating the validity of the simple and non-invasive skinfold 
anthrometry for measuring changes in body composition in weight-losing patients are 
scarse. Using deuterium oxide dilution technique as a reference, we showed that 
skinfold anthropometry is useful for measuring changes in fat and fat-free mass in 
advanced lung cancer patients (Chapter 4.5). Using skinfold anthropometry we 
found that the progressive weight loss in the control group was comprised of a mean 
loss of approximately 5 kg fat mass and 2 kg fat-free mass over the half-year study 
period (Chapter 3.2). In contrast, in the ATP group no significant reduction in fat 
mass and fat-free mass was observed. Furthermore, anthropometric measurements 
showed that ATP significantly inhibited tpc loss in upper ann muscle area (Chapter 
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3.2), as an indication of muscle mass.262 The control group lost approxhuately 15% 
of muscle mass over 6 months, whereas the ATP group showed no change. Total and 
extracellular body water measurements suggest that ATP treatment counteracts body 
cell mass wasting in advanced lung cancer patients. This is an huportant finding since 
body cell mass is the vital compartment which contains the metabolically active cells. 
Whereas the control group demonstrated a significant decline in body cell mass, body 
cell mass in the ATP group remained stable over 4 months. In contrast with earlier 
pharmacological attempts to reverse cancer cachexia, ATP appears to be the first 
agent with beneficial effects on metabolically active tissue (skeletal muscles and body 
cell mass) in lung cancer patients. 
Body function & quality of life 
The loss of muscle tissue is thought to contribute to a number of symptoms which are 
part of the cancer cachexia syndrome, such as fatigue, weakness, compromised 
respiratory function, and gastrointestinal symptoms including nausea and 
constipation. 296 The described A TP-induced effects of counteracting loss of arm 
muscle mass and body cell mass (Chapter 3.2) may contribute to preventing these 
cachectic symptoms. Whereas elbow flexor muscle strength declined by 36% per 6 
months in the control group, no such decline was shown in the ATP group. A similar 
difference was observed in knee extensor muscles. Like the effect of ATP on body 
weight, the effect of ATP on muscle strength was especially marked in patients who 
were already cachectic at study onset, whereas the effect of ATP was not statistically 
significant in non-cachectic patients. 
Measures of several domains of quality of life, as assessed by the Rotterdam 
Symptom Checklist (Chapter 3.1) showed Significant differences between the ATP 
and control group. In the control group, the deterioration expected in patients with 
progressive cancer was seen, whereas this was not observed in the ATP group. Over 
6 months, the quality of life of control patients deteriorated significantly in the 
physical, functional, and overall domains. In contrast, practically no change in these 
quality of life domains was seen in the ATP group. The effect of ATP was 
statistically significant, except for the psychological domain where no significant 
difference was seen between the ATP and control groups. Items contributing to the 
better physical scores in the ATP group included lung cancer-related (shortness of 
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breath} as well as general symptoms (e.g. tiredness, lack of energy, lack of appetite, 
and constipation). It is noteworthy that these items include two of the most common 
cancer-related symptoms: tiredness and lack of energy. 11 The items contributing to 
the better functional scores in the ATP group include general activities including self-
care, doing housework, climbing stairs, and walking outdoors. 
Tumor response and sUl'vival 
In contrast to the marked beneficial effects on both quality of life as reported by the 
patients and objective outcome parameters such as body weight and body 
composition, we did not find obvious effects of ATP on tumor response and survival 
which are the traditional outcome variables in clinical oncology (Chapter 3.3). No 
significant effect of ATP treatment on overall survival was demonstrated. Median 
survival was 5.6 months for the ATP group, and 4.7 months for the control group. In 
weight-losing patients with stage IllB lung cancer, however, ATP treatment did 
contribute to a marked and statistically significant survival benefit (9.0 versus 3.4 
months). It is possible that the observed survival benefit in these patients with non-
metastatic disease is related with the inhibition of weight loss by ATP. 
Pain reduction 
Adenosine has been shown to reduce pain in healthy volunteers380.381 and patient 
groups.24.379.380.382,400 Because no data were available on the effects of adenosine in 
cancer a pilot study was performed in five advanced cancer patients with nociceptive 
pain (Chapter 3.4). During and after two 4-hour during intravenous adenosine 
infusions a substantial reduction in pain scores was seen. Further study of analgesic 
effects of adenosine as a new modality in cancer pain treatment seems warranted. 
S.2 VALIDITY OF THE STUDY 
Clearly, the ideal method for assessing the effect of treatment on quality of life would 
have been a double-blind, placebo-controlled study. However, blinding was not 
feasible because of the complexity of the A TP administration. Some side effects are 
relatively specific for ATP so that both patients and the investigator would have 
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easily recognized that ATP was being given. In addition, there were ethical reasons 
for not giving up to 10 placebo infusions to patients with advanced lung cancer with a 
short life expectation of between 3 to 6 months for the large majority of patients. 
Despite the fact that maximal supportive care was given in both groups, a 
potential placebo effect of A TP infusions on measurements of muscle strength and 
quality of life cannot completely be excluded. In addition, there was some imbalance 
in baseline characteristics such as body weight, age and histology which could have 
affected the comparison of A TP and control groups. 
Notwithstanding these limitations in our study design, several aspects seem to 
underline the validity of the results. Firstly, when we adjusted for possible confounders, 
in no case did this lead to significant alteration of the results. Secondly, there was a 
remarkable consistency of positive effects of ATP on quality of life measurements and 
objective parameters such as body weight and serum albumin levels (see 5.3). The same 
consistency was also found in self-reported appetite and objective food records, as well 
as between muscle strength and physical activities including housework, clinlbing stairs 
and walking outdoors, which contributed to the significant difference in functional score 
between ATP and control patients. Changes in individual scores of arm muscle strength 
and functional quality of life score over the 28-week study period showed a highly 
significant correlation of 1'=0.68 (P<O.OOOI). And thirdly, the psychological quality of 
life score did not differ significantly between the two groups, in contrast with physical 
and functional scores which did show significant positive effects of ATP. 
5.3 MODES OF ACTION 
Cellular uptake, ti'ansport, and receptor stimulation 
Our pharmacokinetic results show that during continuous intravenous ATP infusions in 
the dose range of25 to 75 flg/kg.min, ATP levels within erythrocytes increase to dose-
dependent plateau levels 1.5 to 1.7 fold above baseline values at approximately 24 
hours. After discontinuation of the ATP infusion, half-life of ATP disappearance from 
erythrocytes was approximately 6 hours (Chapter 4.1). This is in line with the 
suggestion that ATP from erythrocytes is slowly released into plasma.345 The clinical 
effects of ATP on nutritional status and quality of life described in 5.1 suggest a 
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prolonged duration of efficacy of ATP after stopping the infusion. Administered ATP 
may interact with specific purinergic receptors on the surface of many cells. These 
receptors play a fundamental role in cell physiology, and are divided in two major 
classes: PI and P2 receptors. In general, it is thought that the effects of adenosine are 
mediated through P1 receptors, whereas ATP binds to P2 receptors. P2 receptors are 
subclassified in G-protein-coupled receptors termed P2Y receptors, and intrinsic ion 
channels termed P2X receptors. 130 Stimulation of these purinergic receptors evokes 
diverse biological responses depending on the cell type. P2 receptors are expressed in 
many tissues including heart, brain, spleen, lung, liver, kidney, and skeletal 
muscles.428 
Appetite and energy intake 
Despite these proposed P 1 and P2 receptor-evoked effects, the precise mechanisms 
underlying the observed effects of A TP on quality of life and nutritional status remain 
to be elucidated. The scores on the item 'lack of appetite' as part of the Quality of 
Life questionnaire revealed a significant difference in appetite between the ATP and 
control group. This finding was consistent with food records kept by the patients 
which showed a significant decline in energy intake in the control group but not in the 
ATP group (Chapter 3.2). It is therefore possible that ATP has appetite-regulatory 
effects contributing to increased food intake, and further study of the underlying 
mechanisms of these effects seems warranted. 
However, model calculations of differences between energy intake and estimated 
energy needed for restoration of fat and fat-free mass suggest that differences in food 
intake cannot entirely account for the effects of ATP on weight and body composition 
between the two groups. Moreover, it is unlikely that the inhibitory effects of ATP on 
loss of body. cell mass and skeletal muscles would be sinlply caused by appetite 
stimulating effects since appetite stimulators like corticosteroids56 and 
cyproheptadine215 did not influence body weight, and megestrol acetate was shown 
only to increase fat mass 396 Our results therefore suggest that ATP may also 
influence specific metabolic pathways involved in weight loss. 
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Liver metabolism 
In experimental cancer models, ATP levels in liverl2, 101 ,374,434 and skeletalmuscle374 
have been reported to be significantly reduced. Recently, reduced liver ATP levels 
were also demonstrated in lung cancer patients, particularly weight-losing patients.249 It 
is interesting that, in the latter group only, ATP infusion was shown to lead to a 40% 
rise in liver ATP pools indicating restoration of depleted hepatic energy stores 
(Chapter 4.2). It could be hypothesized that the increase in hepatic ATP levels by ATP 
infusion restores tIle energy stores in the liver which were depleted by the elevated 
gluconeogenesis in weight-losing·lung cancer patients. However, this relation does not 
seem straightforward since changes in liver A TP content during ATP infusion were not 
correlated WiOl changes in glucose turnover or gluconeogenesis from alanine. Other 
mechanisms by which A TP infusion could stimulate glucose production by the liver 
may be through binding on purinergic P2 membrane receptors311 which are involved in 
the control of gluconeogenesis l3 and glycogenolysis,2lS or by acting as cotransmitter or 
noradrenaline in the nervous system thereby indirectly stinlUlating glucose production64 
ATP was also reported to inhibit binding of insulin to this receptor, which may 
stimulate glucose production as well.433 Although ATP infusion appears to stinllliate 
glucose produ1tion at short term (Chapter 4.3), to rates of glucose turnover similar to 
control lung cancer patients, our data (low glucose turnover between ATP infusions 
similar to that in healthy subjects) suggest that ATP infusion may in fact induce a 
reduction in glucose turnover at longer telm after the infusion has been stopped, which 
would be consistent with the observed attenuation of weight loss. 
Inflammatory response 
Biochemical support for the beneficial effects of ATP on nutritional and functional 
status of advanced lung cancer patients is given by the significant difference in serum 
albumin concentrations between the ATP and control group. It is noteworthy that the 
effect of ATP on serum albumin levels was especially marked in patients who were 
already cachectic at the start of the study, whereas no statistical significance was 
reached in non-cachectic patients (Chapter 3.1). Since albumin levels are affected by 
both nutritional status and acute phase response, the stabilization of serum albumin 
levels by ATP could in fact he caused by inllibition of the acute phase response. In 
animals ATP has been shown to downregulate the production of the proinflammatory 
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cytokines interleukin (IL)-I and IL-6, and tumor necrosis factor a (TNFa).453 This is 
noteworthy since increased serum levels of these cytokines,19,291 and also C-reactive 
protein (CRP) , 19 have been found in patients with advanced cancer, and were suggested 
to playa prominent role in progressive weight loss in cancer. 316 As seen in Figure 5.1, 
and tested by repeated-measures analysis, the control patients demonstrated a significant 
increase in CRPlevels of 12.1 mg/J (95% CI= 3.0 to 21.2) per 4 weeks (P=O.OI). 
The absence of this increase in the ATP group (0.3 mg/J per 4 weeks; 95% CI= -6.3 to 
+6.9; P=0.93) indicates that ATP may inhibit the inflammatory response in cancer 
patients (between-group difference: P=0.04). As serum levels of CRP, IL-6, and TNF 
receptors in cancer patients are positively correlated, 19 ATP infusion may contribute to 
downregulation of these proinflammatory cytokines. Furthermore, U\e degradation 
product of ATP, adenosine, is known to inhibit neutrophil degranulation,43 neutrophil 
superoxide production,43 activation of anti_oxidants,273,340 adhesion of neutrophils,98 
and expression of adhesion molecules,45 eicosanoids,232 and complement238 These 
effects suggest that A TP and/or adenosine inhibit inflanmlatory mechanisms in cancer 
patients which are related to the phenomenon cancer cachexia. 
75 
'B; 50 E-
n. 
n:: 
u 25 
.S 
(i) 
Ol 
c: 0 
'" .c: U 
-25 
0 
____ A TP -<r- Conlrol 
4 8 
Weeks 
12 
P=O.04 
16 
Figure 5.1. Changes in serum C-reactive protein (CRP) concentration (mean ± SEM). Two-
sided P-values for difference between patients in the adenosine 5'-triphosphate (ATP) group and 
patients in the control group were determined with the use of repeated-measures analysis. 
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Table 5.1. Effects of drugs on cancer-associated cacbexia as tested by randomized clinical trials 
Category Specific drug Reference n Dose Appetite CaUnt. Weight FM FFM Perf QoL Albumin Tumor Survival 
Progestagens MA 55 31 480 mgJd + + + + 0 0 
MA 137 150 240 mg/d 0 0 0 
MA 257 133 800 mg/d + + + 
MA 260 342 160-1200 mg/d + 0 0 
MA' 261 12 800 mg/d + + 0 
MA 360 243 800mg/d + 0 0 0 
MPA 395 206 500 rng bid + + 0 0 
MA 27 240 160-480 mg/d + 0 0 0 + 
MPA" 396 54 500 rng bid + + 0 
MA 108 33 320 mg/d + 0 0 0 
MA 437 150 160480 mg/d + + 0 0 
MA 54 53 160mgtid + 0 0 + 0 
MA 472 130 160 mgtid 0 0 0 
MA 426 67 1,600 mg/d + + 0 0 
MA 141 61 160 mg/d + + 0 0 
NSAIO Indomethacin 268 68 50 rng tid 0 0 + 0 0 
Prog.+ NSA1D MA + Ibuprofen 284 41 160+400 rng tid 0 + 0 0 + 0 
Corticosteroids Dexamethasone 290 116 0.75-1.5 rng qid + 0 0 0 
Methylprednisolone 56 40 32 mg/d 0 0 0 0 
Methylprednisolone 114 403 125 mg/d (iv) + + 0 
Methylprednisolone 336 173 125 mg/d (iv) + 0 + 0 
Prednisolone 469 41 Smgtid + 0 0 + 
Prednisolone 268 68 10 rng bid + + + 0 0 
Serotonin antagonist! Cyproheptadine 215 295 8 rng tid + 0 
inhibitor Melatonin 253 86 20 mg/d 0 + 
Inhibitor of Hydrazine sulfate 74 65 60 rng tid + 0 + 0 
gluconeogenesis Hydrazine-sulfate 259 243 60 mg qid 0 0 0 0 0 ~ Hydrazine sulfate 231a 291 60 mg tid 0 0 0 0 0 0 0 
Methylxanthine Pentoxifylline 174 70 400 mg tid 0 0 0 0 ~ 
derivate ~ 
Nucleotide ATP This thesis 58 25-75 mg/kg.mln (iv) + + + + + + + + 0 0 g 
-
0, 
V> *satellite study; MA = megestrol acetate: MPA = medroxyprogesterone acetate §' V> 
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5.4 CLINICAL IMPACT 
ATP - a new approach in oncology 
In Table 5.1, we have listed all known randomized clinical trials investigating the 
effects of dmgs in cachectic cancer patients. It should be noted that drugs which are 
used in routine clinical practice including progestagens (MegaceR) and corticosteroids 
(PrednisonR, DexamethasonR) influence only part of characteristics of cancer cachexia. 
In contrast, as shown in this table, ATP induces beneficial effects on a broad spectmm 
of cancer cachexia-related symptoms. Moreover, ATP would appear the first agent with 
demonstrated beneficial effects on skeletal muscle mass and strength of cachectic cancer 
patients. The ATP-induced counteracting of the loss of skeletal muscles may contribute 
to the maintenance of well-being and performance status in patients suffering from 
progressive lung cancer. 
ATP was administered without side effects in the majority of courses, and if side 
effects occurred, they disappeared rapidly on lowering the infusion rate. In the large 
majority of cases, reported side effects were of type 1 (=mild). As in addition no side 
effects wele observed between the ATP infusions, ATP treatment may be considered as 
an effective non-toxic palliative therapy in patients with advanced lung cancer. 
We conclude that the natural compound adenosine 5' -triphosphate (ATP) has 
potential in the palliative management of lung cancer. ATP may increase the comfort 
of terminally ill cancer patients. Further clinical trials using an appropriate placebo 
control are warranted. 
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SUMMARY 
Despite the continuing exploration of new cytotoxic drugs the prognosis of lung 
cancer is poor. The high morbidity and mortality in this disease are not only due to 
progressive tumor growth but also to the high frequency of cachexia. Cachexia is 
characterized by involuntary weight loss, fatigue, impaired physical performance 
and general malaise. 
This thesis presents the results of a randomized clinical trial of intravenous 
adenosine 5' -triphosphate (ATP) infusions on quality of life, body weight, muscle 
strength, nutritional status, tumor response, and survival in 58 advanced non-
small-cell lung cancer (NSCLC) patients (stage IIlB or IV). In addition, supportive 
studies in order to explore underlying mechanisms are described. 
In Chapter 1 an introduction is given about the development of ATP. Extracellular 
ATP has been known to exert its effects through P2 receptors on the surface of 
many cells. Preclinical studies showed that extracellular ATP induced growth 
inhibition of various human tumor cell lines. In animals ATP administration 
resulted in growth inhibition of implanted tumors, inhibition of weight loss, and 
prolonged survival. Previous uncontrolled phase I and II studies suggest that ATP 
modulate loss of weight, performance status and quality of life in lung cancer 
patients. 
Chapter 2 gives an overview of the potential and established clinical applications 
of ATP. It is suggested that intravenous administered ATP may be useful in, 
amongst others, the management of pain, cardiovascular and pulmonary diseases, 
and cancer. 
In Chapter 3 results of a randomized clinical trial on the effects of ATP in patients 
with NSCLC, stage IIlB or IV, and effects of adenosine in patients suffering from 
cancer pain are presented. 
Chapter 3.1 discusses the beneficial effects of ATP on quality of life, muscle 
strength, weight loss, and serum albumin concentration in the patients. The quality 
of life of control patients deteriorated significantly over a half year at both physical 
158 
SummolY 
(16%), functional (36%) and overall level (23%), whereas ATP-treated patients 
practically showed no change. No significant effect of ATP on psychological 
scores was seen. Arm muscle strength declined by 35 % per 6 months in the 
control group, but remained stable in the ATP group. A similar pattern was 
observed in leg muscles. Mean weight loss was 6.5 kg over 6 months in. the 
control group, and none in the ATP group. In the control group serum albumin 
level declined by approximately 6 gil (=15%) per half year, but remained stable in 
the ATP group. The effect ofATP on muscle strength, weight loss, and serum 
albumin levels was especially marked in patients who were already cachectic at the 
start of the study, whereas no statistical significance was reached in non-cachectic 
patients. 
In Chapter 3.2 it is shown that inhibitory effects of ATP on weight loss are 
due to counteracting loss of both metabolically inactive and active tissues. The 
control group lost fat mass, fat-free mass, muscle mass and body cell mass, 
whereas in the ATP group no change in these parameters was found. Food records 
as kept by the patients indicate that these inhibitory effects of ATP are partly, but 
not solely, dlle to maintenance of energy intake. 
In Chap\er 3.3, it is reported that ATP as a single therapy does not lead to 
tumor regression or increased survival in patients with advanced lung cancer. As 
shown by the median time to progression of 3.9 months in the ATP group, 
compared to 3.0 months in the control group, ATP does not inhibit tumor growth. 
In weight-losing stage IIIB lung cancer patients the anti-cachectic effects of ATP 
appear to lead to increased survival. 
In Chapter 3.4, a pilot study on the effect of intravenous adenosine infusions 
in five patients with cancer pain is presented. Results showed that during two 4-
hour infusions of adenosine, a degradation product of ATP, pain scores decreased 
substantially together with a trend for reduced need for rescue opioids. Significant 
pain reduction was still present at 24 hours after adenosine administration. 
In Chapter 4, four satellite studies on the underlying mechanisms and a validation 
study on skinfold anthropometry are reported. 
Chapter 4.1 discusses the pharmacokinetics of intravenous ATP in cancer 
patients. During continuous ATP infusions in the dose range of 25 to 75 
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fIg/kg. min, ATP was taken up by the erythrocytes and reached dose-dependent 
plateau levels 50 to 70% above basal concentrations at approximately 24 hours. 
After discontinuation of the ATP infusion, half-time of ATP disappearance from 
erythrocytes was approximatelY 6 hours. Constant intravenous infusion of ATP did 
not induce side effects in the majority of courses, and if side effects occur they 
were mild and disappeared rapidly when the dose was lowered. 
The study described in Chapter 4.2 was aimed at investigating whether ATP 
infusion restores liver ATP levels in advanced lung cancer patients. Patients with 
advanced NSCLC were studied one week before and at 22 to 24 hours of 
continuous ATP infusion. During ATP infusion 31p magnetic resonance 
spectroscopy-detected hepatic ATP levels in lung cancer patients increased to a 
level similar to that in healthy subjects. ATP levels tended to increase more in 
patients with ;,5% weight loss than in patients without weight loss. 
Chapter 4.3 describes the effects of intravenous ATP infusion on whole-body 
glucose turnover and gluconeogenesis from alanine in 12 patients with NSCLC, 
compared to 13 control NSCLC patients and 11 healthy subjects. Results of this 
study indicate a dose-dependent increase in glucose turnover. During high-dose 
ATP infusion (75 fIg/kg. min) glucose turnover was higher than at baseline, and 
was similar to that during low-dose ATP infusion (37-50 flg/kg.min) and to control 
NSCLC patients. However, between ATP infusions, glucose turnover in the high-
dose A TP-treated patients was significantly lower than in both lOW-dose and 
control NSCLC patients, and similar to that in healthy subjects. This would 
suggest that high-dose ATP infusion may inhibit glucose turnover in the long run. 
Chapter 4.4 shows that ATP induces growth inhibition in various lung cancer 
cell lines. This growth inhibition is dependent of the ATP dose (0.5 to 3 mM) in 
small cell lung carcinoma cells, large cell lung carcinoma cells, squamous cell lung 
carcinoma cells, and mesothelioma cells. Papillary lung adenocarcinoma cells 
show already maximal inhibition at the lowest ATP dose tested (0.5 mM). Growth 
inhibition is related to cell morphology. 
Chapter 4.5 describes the validity of skinfold measurements to assess changes 
in body composition in cancer patients, using the deuterium oxide dilution 
technique as a reference. In 25 patients with advanced lung cancer, positive corre-
lations between the two techniques were found when assessing changes in fat mass 
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and fat-free mass over a 2 months' period. Skinfold anthropometry gives with 0.1 
kg a marginal overestimation of fat mass loss and underestimation of fat-free mass 
loss. 
Finally, in Chapter 5, the role of ATP in patients with advanced NSCLC is 
discussed. For ethical reasons in the randomized trial presented above, no placebo-
treatment was given to these advanced cancer patients with a short life expectation 
between three and six months. Notwithstanding this limitation in the study design, 
the validity of the results is underlined by the consistency of findings regarding 
quality of life, food intake, muscle mass, muscle strength, and selUm albumin and 
C-reactive protein concentrations. 
We conclude that: 
1. In patients with non-small-cell lung cancer (stage IIIB or IV) ATP-treatment 
inhibits loss of: 
a. body weight; 
b. fat mass, fat-free mass, muscle mass, and body cell mass; 
c. muscle strength; 
d. quality of life. 
2. In patients with advanced lung cancer ATP-treatment does not influence: 
a. tumor response; 
b. survival. 
3. ATP inhibits growth of several human lung tumor cell lines. 
4. Adenosine infusion may lead to pain reduction in cancer patients. 
Effects above described may be caused by: 
1. Increase in intracellular ATP stores as shown for erythrocytes and the liver. 
2. Stimulation of appetite. 
3. Inhibition of inflaI1llnatory responses. 
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SAMENV ATTING 
De prognose van patienten met longkanker is nog steeds slecht te noemen, ondanks de 
voordurende ontwikkeling van nieuwe therapieen. De hoge ziekte- en sterftecijfers zijn 
niet aileen het gevolg van de snelle groei van de tumor, maar ook van de vaak bij deze 
aandoening bestaande cachexie. Het woord 'cachexie' is afkomstig van twee Griekse 
woorden: kakos (=slecht) en hexis (=conditie). Cachexie is een syndroom dat 
gekarakteriseerd wordt door gewichtsverlies, vermoeidheid, verminderde activiteit en 
algehele malaise. 
In dit prqefschrift worden de resultaten gepresenteerd van een gerandomiseerd (= loting 
bepaalt de groep) klinisch onderzoek naar het effect van intraveneuze (= in de bloedbaan 
toegediende) infusen met een natuurlijke stof, adenosine 5'-trifosfaat (ATP). Bij 58 
patienten met een niet-kleincellige vorm van longkanker, bij wie uitzaaiingen naar de 
lymfeklieren (stadium lIIB) of naar andere organen (stadium IV) waren aangetoond, is het 
effect van ATP onderzocht op de kwaliteit van leven, het gewicht, de spierkracht, de 
voedingstoestand, de tumorgroei en de overlevingsduur. Verder wordt een aantal studies 
beschreven wa,arin gepoogd wordt enkele van de onderliggende processen te ontrafelen. 
Hoofdslnk 1 bevat een korte inleiding tot dit proefschrift. ATP dat zich buiten de cel 
bevindt, bindt zich aan P2-receptoren die aanwezig zijn op de celmembraan van de cellen. 
Vervolgens wordt aan de binnenkant van deze cellen een signaal afgegeven, leidend tot 
een bij de celsoort passend effect. Laboratoriumstudies laten zien dat ATP groeiremming 
van diverse soorten tumorcellen bewerkstelligt. Bij dieren met een geiinplanteerde tumor 
en gewichtsverlies leidt ATP-toediening tot rennning van de tumorgroei en van verder 
gewichtsverlies, en tot een hogere overleving. Een tweetal ongecontroleerde studies bij 
patienten met longkanker doen vennoeden dat ATP invloed heeft op het gewicht, het 
welbevinden en de kwaliteit van leven. 
In hoofdstnk 2 wordt een literatuuroverzicht gegeven over de werkingsmechanismen en 
de toepassingsmogelijkheden van ATP. Beschreven wordt dat intravenens ATP bruikbaar 
is -of zou kunnen zijn- bij de bestrijding van pijn, hart- en vaatziekten, taai-slijmziekte, 
kanker en als combinatie-therapie met chemotherapie of bestraling. 
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In hoofds!nk 3 worden de resultaten van het gerandomiseerd klinisch onderzoek naar de 
effecten van ATP bij patienten met niet-kleincellige longkanker (stadium IIIB of IV) 
gepresenteerd. 
Hoords!uk 3.1 beschrijft het gUllStige effect van ATP op de kwaliteit van leven, de 
spierkracht, het gewichtsverlies en de concentratie van het eiwit albumine in het bloed. 
Metingen gedurende een half jaar tieten in de controlegroep een verslechtering zien van 
de kwaliteit van leven op een drietal gebieden: lichamelijk (16%), activiteit (36%) en 
algeheel (23%). Daarentegen toonden de met ATP behandelde patienten praktisch geen 
achtemitgang op bovengenoemde gebieden. De psychologische scores lieten geen verschil 
zien tussen de controle- en de ATP-groep. De armspierkracht verslechterde in 6 maanden 
met 35 % in de controlegroep, maar bleef stabiel in de ATP-groep. De beenspierkracht 
vet100nde eenzelfde patroon. De controlegroep verloor in een half jaar gemiddeld 6,5 kg 
gewicht, terwijl de ATP-groep geen gewicht verloor. Ook in het bloed was een verschil 
tussen beide groepen te meten. In 6 maanden daalde de concentratie van albumine bij de 
controlepatienten ongeveer 6 gram per liter (= 15%), maar bleef stabiel bij de met ATP 
behandelde patienten. 
Het effect van ATP op de spierkracht, het gewichtsverties en albumine-concentraties 
werd met name gezien bij patienten die aan het begin van het onderzoek reeds meer dan 
5 % gewichtsverlies hadden. Bij patienten die geen gewichtsverlies hadden werd dit effect 
van ATP niet aangetoond. Het effect van ATP op de kwaliteit van leven trad echter op bij 
aile patienten. 
In hoords!uk 3.2 wordt het gUllStige effect van ATP op gewichtsverlies verder 
uitgewerkt. Het blijk1 dat dit het gevolg is van het remmen van zowel afbraak van vet- als 
spierweefsel. De controlegroep verloor vetmassa, vetvrije massa, spiermassa en celmassa, 
terwijl dit in de ATP-groep niet werd aangetoond. Aan de hand van de door patienten 
bijgehouden voedingsboekjes werd de hoeveellteid genuttigde voeding berekend. Patienten 
in de controlegroep gingen steeds minder eten, terwijl patienten in de A TP-groep 
evenveel of zelfs meer aten. Dit doet vermoeden dat een deel van het gnnstige effect van 
ATP kan worden verklaard door stimulering van de eetIus!. 
In hoords!uk 3.3 wordt aangetoond dat toediening van ATP niet leidt tot verkleining 
van de tumor of tot eenlangere overleving van patienten met progressieve longkanker. Bij 
gewichtsverliezende patienten in een relatief vroeger stadium van uitgezaaide longkanker 
(stadium IIIB) lijken de anti-cachexie-effecten van ATP wei te leiden tot een verlengde 
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levensduur. 
In hoofdstuk 3.4 wordt het effect van adenosine -een afuraakproduct van ATP- bij 
vijf patienten met kankerpijn beschreven. Een adenosine-infuus van vier uur, gedurende 
twee opeenvolgende dagen, leidde tot verminderde pijnbeleving en tot venninderd gebruik 
van morfme. Vierentwintig uur na het laatste adenosine-infuus werd nog steeds minder 
pijn ervaren. Deze resultaten moeten met voorzichtigheid worden bekeken omdat in dit 
kleine deelonderzoek geen controlegroep was opgenomen. 
In hoofdstuk 4 wordt een viertal deelstudies naar de onderliggende mechanismen van de 
werking van ATP beschreven. Ook wordt de waarde van de huidplooi-meetmetllode 
aangetoond. 
In hoofdstuk 4.1 wordt de farmacokinetiek (=het gedrag van het lichaam op een 
medicijn) gepresenteerd van intraveneus toegediend ATP bij patienten met longkanker. 
ATP, gedoseerd in concentraties van 25 tot 75 fIg/kg per minuut, werd opgenomen door 
de rode bloedcellen. Na ongeveer 24 uur was de ATP-concentratie in de rode bloedcellen 
met 50 tot 70% toegenomen. Ongeveer 6 uur na het stoppen van het ATP-infuus bleek de 
helft van het ATP uit de rode bloedcellen te zijn verdwenen. 
De ATP-inftlsies leidden niet tot emstige bijwerkingen. Als bijwerklngen optraden 
waren deze mild van aard en verdwenen deze snel na het verlagen van de pompsnelheid. 
In het onderzoek beschreven in hoofdstuk 4.2 is nagegaan of een inftms met ATP het 
ATP-gehalte in de lever bij longkankerpatienten kan verbeteren. Dit werd onderzocht met 
behulp van een magnetische resonantie scan. Deze methode is gebaseerd op het meten van 
verschillen in magnetische eigenschappen tussen verschillende natuurlijke moleculen die 
een fosfor atoom bevatten. Negen patientenmet longkanker werden tweemaal onderzocht, 
en wei v66r en tijdens 22 tot 24 uur continu ATP-infuus. Het ATP-gehalte in de lever van 
longkankerpatienten nam toe van 9% van de totale hoeveelheid fosfor in de lever in de 
uitgangssituatie tot 12% tijdens het ATP-inftms. Deze laatste waarden waren gelijk aan 
die bij gezonde controlepersonen. Vermeldenswaard is dat het ATP-gehalte meer toenam 
bij patienten met gewichtsverlies dan bij patienten z6nder gewichtsverlies. 
Door glucose en alanine, een aminozuur afkomstig uit de afuraak van spierweefsel, in 
het bloed te 'merken' met deuterium (,H) en koolstof-13 ("C), kan de omzettingssnelheid 
van glucose en alanine gemeten worden. In hoofdstuk 4.3 wordt het effect van het ATP-
infuus op de glucose-omzettingssnelheid en op de glucoseproductie uit alanine 
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(=gluconeogenese) in twaalf patienten met niet-kleincellige longkanker beschreven. 
Dertien patienten met dezelfde ziekte en elf gezonde vrijwilligers dienden als controle-
groepen. ATP-infuus leidde tot een dosis-afhankelijke stijging van de glucose-
ornzettingssnelheid. Een hoge ATP-dosis (75 fIg/kg per minuut) bleek bij 
longkankerpatienten een stijging van de glucose-omzettingssnelheid van 50% en een 
tendens tot stijging van de gluconeogenese uit alanine van 40% te veroorzaken. Lagere 
doses ATP (37 tot 50 flg/kg per minuut) bereikten dit effect niet. Hoewel tijdens hoog 
gedoseerde ATP-infusies de glucose-omzettingssnelheid gestimuleerd werd, zan deze op 
langere temtijnjuist venninderd kunnen zijn. Tussen de ATP-infusies werd namelijk een 
lage waarde gemeten, vergelijkbaar met die bij gezonde vrijwilligers. 
Hoofdstuk 4.4 laat zien dat ATP de groei van longkankercellen remt. In kleincellige, 
grootcellige, plaveiselcelcarcinoom en mesothelioom cellijnen is de mate van 
groeirenuning gerelateerd aan de ATP-dosis (0,5 tot 3 lllluollliter). Hoe hoger de ATP-
dosis, des te meer groeiremming er optreedt. Adenocarcinoomcellen laten daarentegen 
reeds een maximale groeiremming zien bij de laagste ATP-dosis (0,5 uunoilliter). 
In hoofdstuk 4.5 wordt de waarde aangetoond van een metllOde om de 
lichaamssamenstell\ng (=onderverdeling in vetmassa en vetvrije massa) bij een groep 
kankerpatienten op leen eenvoudige wijze te bepalen: namelijk door het meten van de dikte 
van enkele huidplooien. Ais referentiemetllOde werd de deuterium-verdnnningsmetllOde 
gebruikt. Metingen van de verandering van vetmassa en vetvrije massa in 2 maanden bij 
25 longkankerpatienten laten vergelijkbare uitkomsten zien tussen beide metllOden. De 
huidplooi-meetmetllOde geef! met 0, I kg verschil slechts een minimale overschatting van 
het verlies van vetmassa en onderschatting van het verlies van vetvrije massa. 
In hoofdstuk 5 wordt de rol van ATP in patienten met niet-kleincellige longkanker 
bediscussieerd. In het hierboven beschreven gerandomiseerde klinische onderzoek naar 
het effect van ATP bij patienten met progressieve longkanker die slechts een korte 
levensverwachting van drie tot zes maanden hebben, is om etltische redenen een 
placebobehandeling in de controlegroep achterwege gelaten. Desondanks kan 
geconcludeerd worden dat de resultaten van deze studie voldoende betrouwbaar zijn. 
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Op grond van de resultaten in dit proefschrift zijn de volgende conclusies te trekken: 
1. ATP-behandeling bij patienten met niet-kleincellige longkanker (stadium lIIB of IV) 
leidt tot relmning van verlies van: 
a. lichaamsgewicht; 
h. vetmassa, vetvrije massa, spiermassa en celruassa; 
c. spierkracht; 
d. kwaliteit van leven. 
2. ATP-behandeling bij patienten met dit eindstadium van niet-kleincellige longkanker 
(stadium lIIB of IV) heeft geen invloed op de: 
a. nlmorrespons; 
b. overlevingsduur. 
3. Adenosine-behandeling bij kankerpatienten kan leiden tot vennindering van 
pijnbeleving. 
4. ATP remt de groei van longkankercellijnen. 
Bovengenoemde effecten worden onder andere bereikt via: 
I. Aanvulling van aanwezige ATP-tekorten in de lever bij gewichtsverliezende 
patienten; 
2. Stimulering van de eellust; 
3. Onderdrukking van ontstekingsprocessen. 
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Dankwoord 
Het is altijd een goede gewoonte om in het meest gelezen deel van een proefschrift de 
collega's te bedanken die hebben bijgedragen tot voltooiing hiervan. Graag wil ik dit 
ookdoen. 
" 
Allereerst mijn begeleider en co-promoter Pieter Dagnelie. Pieter, je werkkracht, 
doorzettingsvermogen, snelle en grondige correctie van de manuscripten zal ik niet 
snel vergeten. 
Mijn promotor, professor Wilson, was het die reeds in de collegezaal de 
inwendige geneeskunde als een fascinerend yak wist over te dragen. Hartelijk dank 
voor het vertrouwen in mij gesteld om als artsonderzoeker in dit vakgebied werkzaam 
te mogen zijn en de opleiding tot internist te mogen volgen. 
Ik kreeg een kamer in het laboratorium van de afdeling Inwendige Geneeskunde 
II, Hier werd een goede tijd doorgebracht. Het person eel gaat op een open en elkaar 
respecterende manier met elkaar om, wat ik altijd zeer gewaardeerd heb. Wim van den 
Berg, als het moeilijk was om analyses op te zetten of te interpreteren wist je vaak tot 
een oplossing te komen, mede door je praktische kijk op het tweetal vakgebieden 
biochemie en interne geneeskunde, die elkaar in mijn onderzoek raakten. Trinet 
Rietveld, wat heb je veel uren doorgebracht in je labhoekje! De verzamelde 
bloedmonsters moesten geanalyseerd worden. Maar hoe? Met een groot 
doorzettingsvermogen en een zelfde mate van precisie -waar dokters alleen maar naar 
mogen kijken- wist je getallen te produceren waar je uiteindelijk gelllkkig ook nog 
achter stond. 
Mijn kamergenoot en mede-promovenda Sonja Zuijdgeest-van Leeuwen droeg er 
in grote mate aan bij dat de afgelopen periode ook gezellig was. Verder deed ik nooit 
tevergeefs een beroep op je als er weer eens iets niet lukte met m'n computer. Met 
Susanne Leij-Halfwerk, de andere mede-promovenda bestond ook een harmonieuze 
samenwerking. We hadden het voorrecht onderzoeken te kunnen koppelen wat 
resulteerde in een tweetal gezamenlijke artikelen. Mijn andere kamergenoot Anne 
Marie Petersen-Westerman, bijzonder voor jou was het een tijd waarin blijdschap en 
verdriet elkaar afwisselden. We kunnen ervan leren dat er in een mensenleven meer is 
dan alleen maar werken. Toch mogen we terugzien op een goede periode in onze 
kamer, waar soms op maandag al een 'vrijdagmiddagsfeer' heerste. 
Ellen van Rooijen heeft tijdens een onderzoekstage in het kader van haar 
biologiestudie een enorme inzet bewezen met de llitvoering van de celstudie, daarbij 
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geholpen door Gardi, Rita, Ellen, Patrick en Felix. Er moesten vele hobbels geslecht 
worden, wat uiteindelijk toch is gelukt. Aardig dat ik op deze manier ook kon 'ruiken' 
aan dit toch heel andere onderzoeksgebied. Dan een aantal collega's waar ik nooit 
tevergeefs aailklopte voor hulp: Annie, de beide Jannen en zeker ook Dareos. Weer 
andere eollega's droegen ook bij aan de prettige werksfeer op het lab, wat onder 
andere tot uiting kwam in de kofflepauzes. Deze blijven trouwens trekken. 
De bereiding van de infuusvloeistof kwam voor de rekening van de medewerkers 
van de apotheek van het Dijkzigt Ziekenhuis. Versehillende apothekers hebben er 
mede voor gezorgd dat de praktische uitvoering van het onderzoek goed kon verlopen. 
Diverse internisten, iongartsen, radiotherapeuten en arts-assistenten in het 
Academiseh Ziekenhuis Rotterdam en perifere ziekenhuizen waren bereid om 
patienten voor deelname aan de ATP-studie te vragen. 
Het belangrijkste deel van het onderzoek yond plaats op de Clinical Research Unit 
in het Dijkzigt Ziekenhuis. Hier kwamen de patienten voor een polibezoek of opname. 
De verpleegkundigen Ana, Christie, Hannie, Hans, Jacqueline, Jeanne, Juul, Karin, 
Leo, Marijke en Titia hielpen bij de patientenverzorging, ATP-toediening en 
bloedmonsterverzameling. Co, je bureallstoel en weegsehaaltje kwamen goed van pas. 
Op de verpleegafdelingen B-O en de Palliatieve Unit in de Daniel den 
Hoedkliniek werden ook patienten opgenomen en behandeld. De neuro-oneologen 
Veeht en Sillevis Smitt in de Daniel den Hoed K1iniek hielpen bij het opzetten en 
uitvoeren van de pijnstudie. 
Op de zaterdagochtenden vonden metingen plaats m.b. v. de magnetische 
resonantie scan in de Daniel den Hoed Kliniek. Kwart over zeven beginnen was best 
weI vroeg. Peter, Christien en Paul waren hierbij bereid tot hulp. 
De beide supervisoren van afdeling 4-noord, Gerard de Jong en Roel Swart 
hebben tijdens bijeenkomsten van de seetie 'voeding en metabnlisme' meegedaeht 
over de interpretatie van de resultaten van het ATP-onderzoek. Ik waardeer verder de 
vrijheid die jullie gaven om tussen de klinisehe bezigheden door m'n onderzoek te 
mogen afronden. 
Mijn zus Jacobine en eollega-vriend Jaap zijn bereid om als paranimfen op te 
treden. Bijvoorbaat dank voor jullie steUlI bij de verdediging van dit proefschrift. 
Door dit proefschrift aan mijn ouders op te dragen wil ik mijn waardering tonen 
voor wat zij voor mij betekenen. 
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Lieve Mariska, de rust en evenwichtigheid die je weet uit te dragen in ons 
gezinnetje hebhen er zeker toe bijgedragen dat ik vaak laat thuis kon komen en dat 
hier ook doorgewerkt mocht worden. Bert jan en Caroline, jullie vrolijkheid en 
spontaniteit gaven telkens een welkome a!leiding. Wat hebhen juHie veel gaatjes met 
de perforator en tekeningen gemaakt op papa's kamer! Gerdine, je ontwapenende 
glimlach gar telkens weer nieuwe stimulans voor de laatste loodjes. 
Boven aHes pas erkenning aan God, Die de kracht en lust gaf am dit werk te 
mogen doen. "Zo de HEERE het huis niet bouwt, tevergeefs arheiden deszelfs 
bouwlieden daaraan" (De Bijhel, Psalm 127 vers I). 
Vaak wordt in de laatste zin de wens uitgesproken dat er meer tijd zal zijn voor 
nieuwe dingen. Laat ik het maar niet doen. 
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LIST OF ABBREVIATIONS 
IJC 
'H 
3H 
"P 
ADP 
AMP 
ATP 
BCM 
BW 
Ca2+ 
CLR 
CRP 
ECW 
FFM 
FM 
HPLC 
IL 
IP, 
MRS 
MTD 
NRS 
NSCLC 
PME 
PDE 
p, 
QOL 
TNF 
r 
Ra 
REE 
RSCL 
SD 
SEM 
tlh 
TBW 
TR 
VRS 
UTP 
carbon-13 
deuterium 
tritium 
phosphorus-31 
adenosine 5'~diphosphate 
adenosine 5'-monophosphate 
adenosine 5' -triphosphate 
body ceIl mass 
body weight 
calcium 
renal clearance 
C-reactive protein 
extracellular water 
fat-free mass 
fat mass 
high-performance liquid chromatograph 
interleukin 
inositol 1,4,5-triphosphate 
magnetic resonance spectroscopy 
maximally tolerated dose 
numerical rating scale 
non-small-cell lung cancer 
phosphomonoester 
phosphodiester 
inorganic phosphate 
quality of life 
tumor necrosis factor 
correlation coefficient 
rate of appearance 
resting energy expenditure 
Rotterdam Symptom Checklist 
standard deviation 
standard error of the mean 
half-time 
total body water 
repetition time 
verbal rating scale 
uridine 5' -triphosphate 
List of abbreviations 
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